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Abstract	
Introduction	and	Aims	Despite	the	availability	of	evidence-based	guidelines,	blood	transfusion,	one	of	the	commonest	procedures	in	health	care,	manifests	significant	variation	across	different	countries	that	appear	to	have	comparable	health	systems.	This	is	corroborated	by	extensive	data	on	blood	usage	in	coronary	artery	bypass	graft	surgery,	a	sentinel	procedure,	which	also	suggests	that	the	variation	may	be	related	to	institutional	practice.	Regional	use	of	red	cells	within	the	same	country,	data	for	which	had	not	yet	been	collated	to	date,	was	elicited,	and	it	confirmed	the	same	pattern	of	variation	where	the	highest-using	regions	tend	to	transfuse	double	the	red	cells	transfused	in	the	lowest-using	ones.	
Methods	Since	the	reasons	for	it	are	largely	unknown,	analyses	of	available	data	from	Australia,	New	Zealand,	Canada,	the	USA,	and	24	countries	in	Europe,	were	performed	using	linear	correlation	and	regression	analysis,	to	identify	potential	predictors	and	possible	effectors	of	this	variation.			
Results	Apart	from	confirming	a	known	demographic	predictor,	proportion	of	the	population	over	65	years	(p	=	0.01),	another	4	predictors	were	identified	including	clinical	activity	as	represented	by	coronary	artery	bypass	graft	surgery	(p	=	0.001)	and	health	funding	(p	=	0.007),	which	together	explained	70%	of	the	variation	in	red	cell	usage.	Similar	regression	models	for	platelets	and	plasma	showed	an	R	square	value	of	0.31	and	0.247	respectively.		The	variation	in	blood	product	use	did	not	correlate	at	all	with	health	service	outcomes	and	performance,	but	correlated	quite	tightly	with	markers	of	supply	sensitive	care	making	a	strong	case	for	unwarranted	variation	in	blood	transfusion.	Red	cell	use,	for	example,	correlated	with	the	availability	of	diagnostic	technology	as	represented,	amongst	others,	by	the	number	of	MRI	units	(r	=	0.665,	p	=	0.001).	Moreover,	it	was	shown	that	countries	that	use	more	of	one	product	use	more	of	the	others.	A	relationship	was	also	found	between	blood	product	usage	and	cultural	constructs	capturing	the	notions	of	professional	uncertainty	and	difficulty	with	accepting	new	evidence.	
Conclusions	Irrational	and	evidence-denying	variation	in	blood	transfusion	practice	exists	and	can	be	measured	relatively	easily.	Comparison	of	clinical	use	of	blood	in	discrete	geographical	regions	may	be	useful	as	a	general	measure	of	the	effectiveness	of	the	implementation	of	different	tools	to	improve	practice,	not	just	within	the	context	of	blood	transfusion	but	in	clinical	practice	in	general.	 	
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1.	Introduction		
1.1	Background		As	a	result	of	the	civil	disasters	of	HIV	and	hepatitis	C,	transfusion	medicine	in	Europe	and	elsewhere	has	led	in	the	fields	of	governance	and	risk	management	in	health	care	during	the	last	15	years.	As	a	direct	outcome	of	the	tragedies	of	the	70’s	and	80’s,	the	international	community	has	brought	to	bear	considerable	pressure	on	Blood	Establishments,	the	institutions	responsible	for	the	production	of	blood	components	for	transfusion.	This	drive	has	effectively	forced	a	total	re-organisation	of	the	service	provided	by	these	institutions.	In	Europe	this	led	to	the	enactment	of	4	European	Union	(EU)	Directives	in	the	field	of	blood	transfusion	(European	Union,	2003;	European	Union,	2004;	European	Union,	2005a;	European	Union,	2005b).	Consequently,	large	amounts	of	money	have	been	spent	on	blood	safety,	and	quality	systems	have	been	introduced	in	the	vast	majority	of	blood	services.	Moreover,	haemovigilance,	a	system	of	nation-wide	surveillance	for	complications	associated	with	transfusion,	an	initiative	taken	by	a	number	of	countries	on	a	voluntary	basis,	was	also	taken	up	by	the	EU	Commission	and	transformed	into	a	mandatory	process.	All	this	activity	has	therefore	ensured	that	the	blood	products	reaching	hospitals	are	at	a	level	of	safety	never	present	before.		Once	the	products	reach	hospital	blood	banks	they	are	transfused	to	patients.	This	part	of	the	process	has	undergone	much	less	scrutiny	and	is	very	physician-dependent.	Through	the	data	generated	by	haemovigilance	systems	(Department	of	Health	and	Human	Services,	2011;	Japanese	Red	Cross	Society,	2010;	National	Blood	Authority,	2011;	Williamson,	1998)	the	medical	community	has	become	even	more	aware	that	despite	all	the	efforts	to	minimise	risk,	blood	transfusion	still	carries	a	very	specific	known	
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complication	rate,	which	does	not	even	take	into	consideration	other	possible	difficult-to-measure	hazards	such	as	transmission	of	novel	infective	agents	like	variant	Creudtzfeldt	Jacob	Disease	(vCJD).			All	the	Blood	Services	in	Europe	subscribe	to	best	practice	in	Transfusion	Medicine	and	to	evidence-based	use	of	blood	products.	Testament	to	this	is	the	Manual	of	Optimal	Blood	Use	(McClelland	et	al.,	2010),	the	main	deliverable	of	a	health-related	project	funded	by	the	EU	Commission.	It	is	a	resource	containing	information	and	practical	materials	to	deliver	quality	assurance	throughout	the	clinical	transfusion	process;	to	promote	best	practice	in	blood	transfusion;	and	to	guide	with	compliance	with	relevant	EU	directives.	It	was	written	by	a	group	of	experts	from	the	European	Blood	Alliance	(EBA),	an	association	of	not-for-profit	Blood	Establishments,	with	25	members	from	within	the	European	Union	and	2	members	from	European	Free	Trade	Association	(EFTA)	states.	The	board	of	the	EBA	meets	twice	a	year	and	is	composed	of	the	national	medical	director	and	the	chief	executive	of	every	Blood	Establishment	represented.	The	author	is	one	of	the	two	members	representing	Malta	on	the	Board.	This	manual	is	complemented	by	a	large	number	of	guidelines	on	blood	component	use	that	have	been	published	in	most	developed	countries.	All	this	has	been	put	in	place	in	an	effort	to	guarantee	standard	practice.		Establishing	uniform	best	practice	has	however	been	quite	difficult.	A	cursory	look	at	a	simple	statistic	such	as	the	number	of	red	cells	transfused	per	thousand	inhabitants	across	European	countries,	shows	that	there	is	an	extensive	variation	(Janssen	et	al.,	2011).	A	number	of	studies	on	sentinel	surgical	procedures	such	as	coronary	artery	bypass	graft	surgery	have	also	shown	striking	differences	in	blood	product	use	even	between	institutions	within	the	same	country	(Surgenor	et	al.,	1998).	The	nature	of	this	variation	is	mostly	unknown	bar	a	couple	of	papers	whose	authors	have	argued	that	it	may	be	dependent	on	demographic	differences	(Ali	et	al.,	2010;	Seifried	et	al.,	2011).	The	thesis	will	probe	this	variation	extensively	in	order	to	better	
18	
define	the	true	core	issues,	as	any	variation	in	practice,	especially	as	apparently	extensive	as	this,	is	bound	to	have	a	significant	impact	on	the	appropriateness	of	blood	product	use.		Conclusions	may	be	drawn	to	the	effect	that	local	tradition	in	the	practice	of	transfusion	medicine	is	most	likely	the	one	single	factor	that	mostly	contributes	to	the	variation	in	blood	component	use	(Jin	et	al.,	2013).	In	many	hospitals,	it	is	left	to	the	individual	clinicians	and	their	teams	to	adopt	or	discard	practice	based	on	guidelines	as	they	please.	In	many	other	hospitals,	it	is	the	remit	of	the	transfusion	laboratory	to	be	the	gatekeeper	for	these	blood	products	(Pena	&	Dzik,	2014).	Within	yet	other	systems,	what	started	off	as	a	haemovigilance	exercise,	i.e.	a	process	for	collating	and	analysing	transfusion	reactions,	has	slowly	transformed	itself	into	a	surrogate	system	for	optimisation	of	the	use	of	blood	components.	As	part	of	this	haemovigilance	drive,	nurses	were	recruited	to	posts	to	perform	the	associated	tasks.	These	members	of	staff	have	gone	on,	in	some	cases,	to	take	on	the	mantle	of	educationists	/	trainers	in	the	use	of	blood	products	(Freedman	et	al.,	2008).	Also,	mainly	in	hospitals	in	the	United	Kingdom	(UK)	and	Ireland,	due	to	the	National	Health	Service	(NHS)	Better	Blood	Transfusion	Initiative,	it	became	common	to	have	a	Hospital	Transfusion	Committee	involved	in	the	governance	of	blood	product	utilisation	(UK	Department	of	Health,	2007).	This	latter	practice	was	also	adopted	by	the	World	Health	Organisation	(WHO)	in	its	guidance	on	blood	transfusion	as	a	specific	recommendation	(World	Health	Organisation,	2010).			Anecdotally,	change	in	practice	in	Transfusion	Medicine	has	been	mostly	effective	in	hospitals	where	Transfusion	Medicine	‘champions’	have	emerged.	These	leaders,	mainly	clinicians,	mostly	Transfusion	Medicine	Specialists	/	Haematologists	or	Anaesthetists,	have	made	a	difference	within	their	hospital	and	even	abroad,	as	they	have	pioneered	systems	within	their	hospitals	which	went	on	to	be	used	internationally	(Murphy,	2012a;	Rehm	et	al.,	1998).	This	set	of	events	over	the	past	20	years	has	presented	both	the	opportunity	
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and	the	need	to	test	the	hypothesis	that	a	champion	or	leader	in	a	hospital	setting	can	or	must	be	engaged	to	ensure	that	internationally	established	norms	of	best	practice	are	employed,	and	that	without	such,	money,	time	and	opportunities	are	wasted.		In	other	words,	that	in	order	to	complete	the	‘Vein	to	Vein’	process	in	Transfusion	Medicine	and	to	complement	the	huge	efforts	made	by	the	blood	establishments,	a	Transfusion	Medicine	leader	/	champion	must	be	engaged	by	hospitals	where	blood	products	are	used	with	the	specific	role	of	implementing	Patient	Blood	Management	(PBM)	strategies.		
1.2	Scope	of	Thesis		The	scope	of	the	project	has	been	to	use	transfusion	medicine	practice,	where	motive	(history	of	previous	disasters	from	HIV	and	hepatitis	C	among	other	problems),	opportunity	(differences	in	current	practices	across	Europe	within	a	fairly	small	professional	community)	and	means	(excellent	history	of	collaboration	and	high	quality	information	sharing	within	the	European	and	indeed	the	global	transfusion	community)	exist,	to	explore	the	nature	of	international	and	local	variation	in	practice	in	blood	product	usage	and	to	try	to	understand	the	different	parameters	contributing	to	the	significant	variation	therein.	It	is	probably	pertinent	to	mention	that	the	spirit	of	collaboration	on	an	international	level	between	Blood	Transfusion	Services	is	really	quite	significant	and	possibly	unique	within	the	different	disciplines	in	medicine.			More	specifically	the	project	will	look	at		
• The	historical	context	to	this	variation	and	the	continued	threats	to	the	blood	supply	
• A	review	of	the	literature	and	of	available	data	sources	highlighting	variation	in	blood	product	usage		
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• Securing	and	analysing	additional	data	that	confirms	this	variation	in	practice	
• The	relationship	between	this	variation	and	other	measures	of	health	care	
• Effectors	of	variation	in	different	countries		In	summary,	the	Doctoral	thesis	will	seek	to	unravel	the	reasons	behind	the	variation	in	practice	in	blood	product	usage	and	to	confirm	the	necessity	of	the	implementation	of	Patient	Blood	Management	strategies	within	hospitals	to	ensure	the	achievement	of	appropriate	blood	use.		 	
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2.	Context	and	Threats	
2.1	Historical	Context		Blood	has	been	surrounded	by	a	mystical	aura	since	the	time	of	antiquity	(Greenwalt,	1997).	This	sentiment	persevered	through	the	ages	and,	though	its	history	is	also	associated	with	tragedy,	there	still	lingers	a	strong	belief	in	its	inherent	power	to	do	good.	Despite	the	soaring	levels	of	modern	research	activity	and	the	strong	shift	to	evidence	based	practice,	the	use	of	blood	components	still	seems	to	be	resistant	to	recommendations	on	appropriate	use	as	evidenced	by	the	apparent	large	differences	in	practice	across	countries	(Cobain	et	al.,	2006)	and	even	across	institutions	within	the	same	country	(Stover	et	al.,	1998).	The	modern	history	of	blood	transfusion	owes	its	origin	to	three	important	developments	at	the	turn	of	the	previous	century.		
2.1.1	Developments	that	allowed	safe	practice	of	blood	transfusion	1. The	erstwhile	extremely	complicated	and	dangerous	transfusion	procedure,	which	required	that	the	radial	artery	of	the	person	donating	blood,	and	the	proximal	end	of	a	large	superficial	vein	of	the	person	receiving	the	blood,	were	dissected	out	and	attached	to	each	other	over	a	canula	as	the	arms	lay	parallel	to	each	other,	was	simplified	by	the	design	of	specific	apparatus.	In	1913,	Dr	Edward	Lindeman	in	New	York	thought	of	using	paraffin-lined	syringes	containing	anticoagulant	and	paraffin-lined	jars	and	needles	obviating	the	need	to	cut	open	the	patients’	and	donors’	arms	(Pair,	1929).	This	strategy	was	further	improved	upon	by	Dr	Lester	J	Unger,	who	
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designed	a	stopcock,	and	connected	the	two	needles	with	rubber	tubing	and	a	four-way	valve,	thus	enabling	the	drawing	of	blood	from	the	donor	and	its	re-direction	into	the	recipient	to	occur	uninterruptedly.		 2. The	second	development	was	the	determination	of	the	appropriate	concentration	of	anticoagulant	that	would	allow	physicians	enough	time	to	perform	the	transfusion	process,	beyond	the	three	to	five	minutes	it	took	for	the	blood	to	clot	and	block	their	needles	and	tubes.	Citrate	had	a	long-standing	history	as	a	superior	anticoagulant	used	in	laboratories	but	the	1%	concentration	at	which	it	was	used	was	extremely	toxic.	Dr	Richard	Lewisohn,	a	physician	in	Mount	Sinai	Hospital	in	New	York,	showed	that	a	concentration	of	0.1%	was	perfectly	adequate	to	maintain	anticoagulation	but	low	enough	not	to	precipitate	any	harmful	events	(Lewisohn,	1916).		 3. Karl	Landsteiner,	a	German	physician,	made	the	third	and	most	significant	contribution	for	which	he	won	the	Nobel	Prize	in	1930	(www.nobelprize.org/nobel_prizes/medicine/laureates/1930/).	In	his	haemagglutinin	experiments	performed	in	his	laboratory	in	1900	using	blood	from	6	individuals	including	his	own,	he	showed	that	antibodies	present	in	serum	combined	to	the	homologous	antigen	(Landsteiner	&	van	der	Scheer,	1924).	On	the	basis	of	his	results	he	deduced	three	blood	groups	which	he	designated	A,	B	and	C	(later	changed	to	O).	The	fourth	group,	AB,	was	discovered	by	his	colleagues	some	time	later.	This	allowed	for	the	performance	of	crossmatch	tests	that	reduced	the	occurrence	of	acute	haemolytic	post-transfusion	reactions	from	35%	to	zero.				
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2.1.2	Universal	availability	Though	during	the	First	World	War	there	was	some	use	of	blood,	albeit	in	a	limited	way,	it	was	the	Second	World	War	that	really	gave	the	necessary	impetus	for	the	development	of	the	logistical	operations	of	blood	collection,	storage	and	transport	with	ad	hoc	blood	banks	being	established	in	close	proximity	to	the	battle	front	(Maycock,	1940).	Inevitably,	its	use	in	these	circumstances	endowed	blood	with	an	almost	supernatural	aura	as	the	article	written	in	the	New	York	Times	by	Marine	Corps	correspondent	Ralph	W	Myers	attests:	“The	primary	item	in	each	Medical	Corps	man’s	front	line	survival	kit,	whole	blood	….	brought	a	new	smile	to	the	lips	and	blood	shot	eyes	of	overworked	Navy	Doctors	in	the	forward	areas.	In	a	few	minutes	the	wine-colored	bottles	were	held	aloft	above	the	prone	bodies	and	the	stuff	was	doing	its	miraculous	work”	(Myers,	1945).	Brigadier	General	Doug	B	Kendrick,	the	US	army’s	transfusion	chief	in	his	book	Blood	Program	in	World	War	2	highlights	a	comment	made	by	Carl	Mydans	in	his	book	‘More	Than	Meets	The	Eye’,	on	“combat	medics	on	bouncing	jeeps	who	…	kneeling	and	balancing	and	clinging	miraculously	with	one	arm,	raised	the	other	higher,	as	one	would	a	torch,	holding	a	bottle	of	plasma,	pouring	life	into	a	broken	body.	I	think	I	have	never	seen	a	soldier	kneeling	thus	who	was	not	in	some	way	shrouded	with	a	god-like	grace	and	who	did	not	seem	sculptured	and	destined	for	immortality”	(Kendrick,	1964).		
2.1.3	Serious	set-back	A	very	powerful	symbolism	became	attached	to	the	use	of	blood	and	its	products	and	this	persevered	well	into	the	unfortunate	subsequent	era	of	hepatitis	and	HIV	transmission.	The	fault	for	these	tragic	developments,	mainly	associated	with	infusion	of	fractionated	blood	products,	as	starkly	exemplified	by	one	particular	group	of	patients	–	people	with	haemophilia,	was	laid	squarely	at	the	door	of	transfusion	services.		
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Cryoprecipitate,	a	white	residue	that	forms	in	a	blood	bag	after	frozen	plasma	is	thawed	slowly	at	4oC,	was	discovered	in	1965	in	Stanford	University	(Pool	&	Shannon,	1965).	This	was	used	as	treatment	for	people	with	haemophilia	on	account	of	its	concentration	of	coagulation	Factor	8.	A	further	development	in	the	late	60’s	saw	thousands	of	units	of	plasma	being	pooled	to	make	large	amounts	of	cryoprecipitate	which	was	then	further	processed	to	make	highly	concentrated	Factor	8	(Brinkhous	et	al.,	1968)	which	could	be	carried	around	easily	and	injected	using	a	syringe,	a	change	that	liberated	people	with	haemophilia	from	their	total	dependence	on	hospitals.	In	order	to	satisfy	the	consequent	high	requirement	for	this	product,	paid	donations	were	resorted	to	by	companies	in	the	United	States	of	America	(USA).	Low	income	and	marginalized	groups	were	highly	represented	in	this	particular	donor	population	(Seeff,	1988).	Homosexual	men	also	became	an	important	source	since	drug	companies	valued	their	plasma	for	hepatitis	antibodies	and	were	thus	unconsciously	selectively	including	plasma	from	high-risk	groups	(McHenry	&	Khoshnood,	2014).		Though	originally	most	blood	services	in	Europe	were	self-sufficient,	once	the	demand	for	these	products	exploded	in	the	late	1970’s,	many	nations	imported	these	plasma	derivatives	from	the	USA,	as	did	countries	from	the	rest	of	the	world,	including	Japan.		In	the	first	half	of	1982,	three	men	with	haemophilia	contracted	Pneumocystis	
carinii	pneumonia.	This	condition	had	recently	become	prevalent	in	previously	healthy	homosexual	men.	Specialists	within	the	Centers	for	Disease	Control	and	Prevention	(CDC)	in	the	USA	became	suspicious	that	some	novel	causative	virus	was	being	transmitted	by	blood	(Centers	for	Disease	Control	and	Prevention,	1982).	However,	it	was	only	in	March	1983	that	the	Public	Health	Service	of	the	USA	issued	recommendations	related	to	AIDS	and	blood	donation	(Centers	for	Disease	Control	and	Prevention,	1983).	Significantly,	a	resolution	voted	on	by	the	World	Haemophilia	Federation	in	June	1983	stated	that	‘There	is	insufficient	evidence	to	recommend,	at	this	time,	any	changes	in	the	treatment	of	haemophilia,	therefore	present	
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treatment	should	continue	with	whatever	products	are	available’	(Starr,	1998).	Many	countries	took	this	to	mean	unlimited	use	of	Factor	8!		Though	evidence	showing	that	heat	treatment	inactivated	the	virus	was	reported	in	August	1984	(Evatt,	2006),	and	a	new	screening	test	for	what	was	then	known	as	HTLV	III	became	available	in	the	USA	in	spring	1985	(Centers	for	Disease	Control	and	Prevention,	1986),	these	precautions	were	not	universally	applied.	A	number	of	patients,	both	ones	with	haemophilia	and	whole	blood	recipients,	were	infected	due	to	the	inertia	of	governments	/	transfusion	services	which	failed	to	adopt	these	measures,	and	other	simple	interventions	such	as	questionnaires	delving	into	donor	behaviour.	Lawsuits	were	instituted	in	a	number	of	countries	claiming	negligence	and	a	small	number	of	blood	service	medical	personnel	were	very	publicly	indicted	for	crimes	related	to	HIV	contamination.	Some	were	convicted	and	jailed.	Twenty-two	countries	including	most	of	Europe,	Canada	and	Japan	established	funds	to	compensate	infected	recipients.		The	result	of	all	this	in	the	subsequent	years	has	been	a	concerted	effort	by	the	medical	and	pharmaceutical	communities	to	totally	sanitise	blood	products.	No	expense	was	spared	to	institute	very	robust	testing	for	known	infectious	diseases	with	some	authors	claiming	that,	with	the	ever-decreasing	potential	risk	for	transmission	through	transfusion,	this	has	gone	well	beyond	reasonable	proportions	(Davidson	et	al.,	2011;	Marshall	et	al.,	2004),	an	opinion	not	necessarily	universally	endorsed	(Murphy,	2012c).		
2.2	Continued	Threats	to	Supply	of	Blood	
2.2.1	Novel	transmissible	agents	Variant	Creutzfeldt-Jakob	Disease,	a	new	form	of	transmissible	encephalopathy	was	first	described	in	1996	(Will	et	al.,	1996).	All	6	patients	
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affected	had	a	specific	neuropathological	profile	that	was	distinct	from	classical	CJD.	Studies	showed	that	these	features	were	similar	to	those	produced	in	macaques	inoculated	by	bovine	spongiform	encephalopathy	(BSE)	(Lasmezas	et	al.,	1996),	an	epidemic	condition	that	had	peaked	in	UK	cattle	in	the	early	1990’s.	In	1998	an	independent	risk	assessment	was	commissioned	by	the	UK	Health	Department	to	assess	the	risk	of	transmission	of	vCJD	through	transfusion	and	to	make	recommendations	to	mitigate	this	risk	(Comer	&	Huntly,	2003).	Testing	for	this	potentially	transmissible	agent	was	not	an	option.	On	the	basis	of	the	precautionary	principle	a	number	of	measures	were	adopted	primarily	by	the	UK	and	Ireland	(Murphy,	2013;	Thomas	et	al.,	2013);	but	also	by	most	other	countries	where	a	ban	was	introduced	on	blood	donors	who	had	resided	in	the	UK	for	a	cumulative	period	of	more	than	six	months	between	the	years	1980	and	1996.	Despite	these	measures,	in	2004	the	first	case	of	transfusion	transmitted	vCJD	was	reported	in	the	UK	(Llewellyn	et	al.,	2004).	vCJD	has	not	turned	out	to	be	of	the	epidemic	proportions	originally	feared	(Ghani	et	
al.,	2000);	178	cases	in	the	UK	and	53	in	the	rest	of	the	world	(The	National	CJD	Research	&	Surveillance	Unit,	2017)	and	only	4	cases	have	been	transmitted	through	transfusion.	However	at	the	time	of	discovery	and	immediately	subsequent	to	that,	it	inevitably	raised	past	spectres	and	spurred	much	activity	that	was	specifically	targeted.	A	realization	did	however	start	to	set	in	that	the	greatest	protection	from	this	and	from	any	future	threats	from	novel	transmissible	agents	was	in	fact	one	of	the	least	expounded	upon	strategies	-	that	of	optimizing	blood	use	i.e.	only	appropriate	transfusions	should	be	administered	(Ludlam	&	Turner,	2005).		
2.2.2	Cost	issues	In	this	context	it	would	also	be	appropriate	to	highlight	the	issue	of	cost,	a	major	concern	of	hospital	administrators	who	are	constantly	in	search	of	additional	savings	in	an	effort	to	satisfy	budgetary	demands.	Blood	product	
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usage	like	every	other	in-patient	treatment	modality	has	come	under	scrutiny,	and	focus	has	been	strongly	re-oriented	towards	appropriate	use.			The	cost	of	healthcare	has	continued	to	spiral	upwards	in	the	last	few	years.	The	2011	edition	of	the	Organisation	for	Economic	Co-operation	and	Development	(OECD)	publication	‘Health	at	a	Glance’	reports	that,	on	average,	per	capita	health	spending	has	risen	in	real	terms	by	four	percentage	points	annually	between	2000	and	2009	(Lafortune	&	de	Looper,	2011).	The	United	States	continues	to	outspend	all	other	countries	by	a	wide	margin	with	health	care	spending	having	increased	from	$1.8	trillion	in	2004	to	$2.6	trillion	in	2010	and	is	projected	to	grow	to	$4.6	trillion	in	2020,	comprising	19.8%	of	GDP	(Centers	for	Medicare	and	Medicaid	Services,	2009).	These	figures	have,	of	necessity,	forced	governments	to	rethink	the	way	health	care	provision	is	delivered.	In	the	UK	for	example,	the	structure	of	the	NHS	will	be	altered	by	the	setting	up	of	an	independent	commissioning	board	and	the	abolition	of	strategic	health	authorities	and	primary	care	trusts,	and	by	the	use	of	markets	instead	of	targets	to	drive	improvements	in	performance	(Ham,	2010).	The	price	of	blood	products	has	also	followed	the	same	trend.	According	to	a	recent	trans-national	appraisal,	the	population	weighted	mean	cost	of	transfusing	2	units	of	red	cells	in	Western	Europe	was	estimated	at	around	€900,	a	significant	burden	(Abraham	&	Sun,	2012).	An	analysis	of	the	transfusion	process	in	the	United	States	wherein	each	step	was	mapped	out,	has	shown	that	the	full	cost	of	a	red	cell	transfusion	to	a	surgical	patient	is	$1148	and	each	transfusion	episode	costs	$3433	when	one	takes	into	consideration	also	the	indirect	costs	(Shander	et	al.,	2009).	Though	not	necessarily	a	universally	held	view,	some	recent	publications	have	repeatedly	argued	that	further	application	of	testing	procedures	to	continue	to	improve	blood	safety	have	gone	far	beyond	what	would	rationally	be	expected	in	cost-effectiveness	terms	(Davidson	et	al.,	2011).	Given	the	already	increasing	pressures	on	hospitals	to	maintain	their	spending	within	budgets	and	the	evident	financial	burden	that	can	be	attributed	to	transfusion,	it	is	understandable	that	cost	and	the	savings	that	can	be	made	
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through	eliminating	unnecessary	transfusions	have	become	an	issue	requiring	attention.		
2.2.3	Decrease	in	blood	supply	A	number	of	publications	have	alerted	the	transfusion	community	to	the	effect	of	changing	society	demographics	on	the	blood	supply.	Shortages	have	been	forecast	and	potential	remedies,	some	quite	drastic,	have	been	suggested.	Ali	et	al,	in	an	analysis	of	the	Finnish	Red	Cross	Blood	Service	national	database,	suggested	that	in	the	future	unprecedented	measures,	such	as	reversing	some	donor	deferrals,	and	hence	altering	the	safety	profile	of	the	transfused	blood,	or	else	shifting	blood	around	from	country	to	country,	therefore	risking	higher	rates	of	transfusion	transmissible	diseases	in	some	countries	on	account	of	different	epidemiological	backgrounds,	should	be	taken	to	meet	the	growing	requirement	(Ali	et	al.,	2010).	They	came	to	this	conclusion	after	simulating	the	red	cell	usage	in	different	age	groups	in	Finland	upon	the	population	demographics	of	other	countries	and	projected	that	into	the	future	on	the	assumption	that	Finish	practice	in	transfusion	medicine	was	entirely	appropriate.	According	to	their	projection,	by	2015	all	countries	would	have	been	using	more	than	40	units	per	1,000	population	and	by	2025	that	would	have	climbed	to	above	50	per	1,000	population	in	most	countries	evaluated.	This	prediction	came	on	foot	of	an	earlier	publication	from	Germany	that	studied	Mecklenburg-West	Pomerania	as	a	model	region	for	the	rest	of	Europe	(Greinacher	et	al.,	2007).	The	authors	concluded	that	a	shortfall	of	a	little	more	than	30%	in	red	cell	provision	would	occur	and	this	was	primarily	due	to	changes	in	demographics.	This	projected	trend	seems	to	have	been	acknowledged	in	different	countries	(Currie	et	al.,	2004;	Seifried	et	al.,	2011;	Vamvakas	&	Taswell,	1994).	These	projections	were	based	entirely	on	the	transfusion	medicine	practice	current	at	the	time	of	publication.	The	whole	argument	about	appropriateness	of	use	was	not	discussed.	Though,	soon	enough,	a	few	dissenters	did	voice	their	doubts	about	this	trend	as	they	started	bringing	into	play	other	
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considerations	apart	from	the	aging	population	and	the	disproportionate	use	of	blood	in	this	fraction	of	the	population	(Benjamin	&	Whitaker,	2011).	A	publication	from	the	Netherlands	highlighted	that	more	variables	need	to	be	taken	into	account,	such	as	potential	changes	in	clinical	use,	apart	from	population	demographics	(Borkent-Raven	et	al.,	2010).	Neither	has	the	trend	in	Meckleberg-West	Pomerania	been	borne	out	as	predicted	(Greinacher	et	
al.,	2016).	
2.3	Conclusion	It	is	evident	from	the	above	that	unnecessary	transfusions,	carrying	risk	without	benefit,	must	be	avoided.	Tailoring	the	use	of	blood	components	to	the	patient’s	specific	requirements	is	the	single	most	effective	method	of	ensuring	optimal	treatment	while	eliminating	the	risk	associated	with	undue	use	and	at	the	same	time	improving	equity	of	access	to	a	limited	blood	supply	whilst	reducing	the	cost	footprint	of	this	treatment	modality	(Murphy	et	al.,	2011;	Seifried	et	al.,	2011).	A	large	effort	to	address	this	began	in	the	1980’s	and	continues	up	to	the	present.	Large	differences	in	usage	of	blood	transfusion	have	evolved	in	different	countries	with	similar	economies	and	levels	of	health	care.	Germany	uses	twice	as	many	red	blood	cells	per	capita	as	the	Netherlands	(Janssen	et	al.,	2011),	for	example,	without	clear	benefit	or	disadvantage;	the	United	States	transfuses	30%	more	red	cells	as	Canada	in	very	similar	clinical	systems	(Canadian	Blood	Services,	2010;	Department	of	Health	and	Human	Services,	2011;	Hema-Quebec,	2010).	This	phenomenon	–	variations	in	practice	where	no	clear	reasons	exist	to	account	for	the	variations	-	provides	an	opportunity	to	explore	the	underlying	forces	at	work	in	apparently	geographically	defined	irrational	clinician	behaviour	in	the	presence	of	clear	evidence	of	risk	and	benefit,	and	to	develop	a	measure	to	analyse	the	effects	of	measures	to	change	such	behaviours.		 	
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3.	The	Evidence	for	Variation	in	Blood	Transfusion	Practice	
3.1	Evidence	in	the	Literature		As	explained	in	the	previous	chapter,	since	its	inception,	blood	transfusion,	has	been	largely	considered	a	benign	form	of	treatment.	Trials	to	establish	appropriate	blood	product	usage	under	different	clinical	scenarios	were	not	performed	at	the	outset	as	would	normally	happen	with	more	modern	new	treatment	modalities.	In	many	circumstances,	blood	was	considered	to	be	a	lifesaver	and	therefore,	most	naturally,	more	became	better.	Patients	would	be	transfused	to	as	close	to	a	normal	range	as	possible.	It	was	in	fact	commonplace	for	physicians	to	use	a	transfusion	trigger	for	red	cells	of	10mg/dL.	In	the	same	way	patients	were	transfused	platelets	to	counts	well	beyond	50x109/L	or	100x109/L,	and	plasma	was	often	used	as	a	volume	expander,	all	practices	now	labelled	as	inappropriate.	It	was	only	in	1999	that	the	first	seminal	trial	held	by	Hebert	and	co	showed	unequivocally	that	
more	is	in	fact	worse,	with	regard	to	red	cell	transfusion	in	patients	in	an	Intensive	Care	Unit	(ICU)	setting	(Hebert	et	al.,	1999).	Since	then,	other	publications	have	shown	this	in	a	number	of	different	scenarios	(Table	3.1)	(Carson	et	al.,	2011;	Cooper	et	al.,	2011).	Parallel	publications	could	be	highlighted	with	regards	to	platelet	and	plasma	use	(Slichter	et	al.,	2010;	Williamson	et	al.,	1999),	even	though	less	comprehensively	than	has	been	the	case	for	red	cells.							
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							Table	3.1:	Randomised	control	trials	involving	a	variety	of	patient	and	clinical	settings,	studying	transfusion	triggers.	Adapted	from	(Pena	&	Dzik,	2014)		A	number	of	evidence-based	guidelines	on	appropriate	use	of	blood	components	were	also	published	in	various	countries	and	were	widely	disseminated	for	local	adoption	within	hospitals	(Australasian	Society	of	Blood	Transfusion,	2001;	Crosby	et	al.,	1997;	Murphy	et	al.,	2001).	Despite	this	wave	of	mostly	similar	guidelines	with	almost	identical	recommendations,	the	usage	of	all	three	blood	components	still	continued	to	vary	widely	(Gombotz	et	al.,	2014;	Jin	et	al.,	2013;	Likosky	et	al.,	2014;	McQuilten	et	al.,	2014;	Mitra	et	al.,	2015;	Norgaard	et	al.,	2014).			These	differences	may	be	analysed	by	looking	at	transfusion	practices	surrounding	a	very	well	defined	sentinel	surgical	procedure	that	is	highly	standardised	across	health	care	systems,	such	as	coronary	artery	bypass	graft	(CABG)	surgery.	CABG	continues	to	be	a	procedure	with	one	of	the	heaviest	usage	of	blood	products.	Around	20%	of	blood	transfusions	in	the	United	States	are	associated	with	this	type	of	surgery	(Snyder-Ramos	et	al.,	2008;	Stover	et	al.,	1998).			
3.1.1	Variation	in	blood	usage	in	coronary	artery	bypass	grafting	In	the	last	25	years	a	number	of	studies	evaluating	blood	use	in	CABG	surgery	have	shown	a	significant	variation	of	blood	product	use	both	within	and	across	a	number	of	countries	(Andreasen	et	al.,	2007;	Bennett-Guerrero	et	al.,	2010;	Gombotz	et	al.,	2014;	Goodnough	et	al.,	1991;	Jin	et	al.,	2013;	Likosky	et	
First	Author	/	
Year	
Name	of	
Trial	
Clinical	Setting	 Transfusion	
Trigger	(mg/dL)	
No	of	Patients	Hebert	1999	 TRIC	 Adult	ICU	 7	vs	9	 838	Kirpalani	2006	 PINT	 Infants	<	1Kg	 10	vs	12	 457	Lacroix	2007	 -	 Paediatric	ICU	 7	vs	9.5	 637	Hajjar	2010	 TRAC	 Cardiac	Surgery	 8	vs	10	 502	Cooper	2011	 CRIT	 Acute	MI	 8	vs	10	 45	Carson	2011	 FOCUS	 Hip	Surgery	 8	vs	10	 2,016	Villaneuva	2013	 -	 UGI	bleed	 7	vs	9	 921	
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al.,	2014;	McQuilten	et	al.,	2014;	Snyder-Ramos	et	al.,	2008;	Stover	et	al.,	1998).			In	1991	Goodnough	et	al	performed	a	study	reviewing	blood	use	in	30	consecutive	adult	patients	undergoing	first-time	elective	CABG	surgery,	in	18	institutions	in	the	USA.	They	found	that	the	number	of	patients	transfused	varied	between	17%	and	100%	(Goodnough	et	al.,	1991)	in	different	institutions.	A	further	study	involving	24	academic	institutions,	each	reviewing	between	100	and	108	randomly	selected	patients	who	underwent	CABG	surgery,	concluded	that	blood	use	in	713	low-risk	patients	varied	between	27%	and	92%	(Stover	et	al.,	1998).	A	large	review	of	blood	product	use	involved	82,446	patients	undergoing	isolated	primary	CABG	operations	using	a	cardiopulmonary	bypass	machine,	performed	between	January	1st	2008	and	December	31st	2008,	in	408	hospitals	performing	at	least	100	eligible	on	pump	CABG	operations	per	year.	This	study	showed	a	frequency	of	blood	transfusion	rates	ranging	from	7.8%	to	92.8%	for	red	cells,	0%	to	97.5%	for	fresh	frozen	plasma	and	0.4%	to	90.4%	for	platelets	(Bennett-Guerrero	et	al.,	2010).	A	more	recent	study	also	showed	significant	variability	in	red	cell	usage	(7%	-	77%)	and	in	usage	of	fresh	frozen	plasma	(1%	-	31%)	and	platelets	(1%	-	38%)	(Jin	et	al.,	2013).	Likosky	et	al	studied	11,200	patients	undergoing	CABG	who	received	2	or	less	red	cell	units	(low-volume	transfusion).	The	hypothesis	was	that	in	this	group,	since	no	emergency	was	involved,	decisions	could	be	made	in	a	more	calculated	fashion	and	consistency	was	more	likely.	However	usage	varied	between	9.1%	and	31.7%	across	56	centres	(Likosky	et	al.,	2014).	A	study	in	Australia	which	recruited	24,222	patients	across	25	centres	showed	similar	variation	(McQuilten	et	al.,	2014).			In	Europe	this	has	been	echoed	by	similar	studies,	including	one	in	Denmark	in	four	public,	university-affiliated	hospitals	that	between	them	perform	77%	of	all	CABG	operations	in	that	country.	This	showed	a	more	modest	2-fold	variation	in	the	percentage	of	patients	transfused	with	allogeneic	red	blood	
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cells	ranging	from	30.0%	to	64.2%	(Andreasen	et	al.,	2007).	Similar	variation	in	usage	of	red	cells	(30%	-	49%)	in	6	centres	in	Austria	(Gombotz	et	al.,	2014)	was	reported	in	a	follow-up	study	to	an	original	similar	study	4	years	previously	(Gombotz	et	al.,	2007).	Despite	having	communicated	the	findings	of	the	original	study	to	the	individual	centres,	presumably	to	raise	awareness	and	prompt	a	change	in	behaviour,	transfusion	rates	in	CABG	procedures	in	the	second	study	remained	the	same.			An	international	study	performed	in	69	medical	institutions	across	16	countries	on	5065	patients	scheduled	to	undergo	CABG	surgery	showed	similar	variation.	Two	thirds	of	the	patients	enrolled	received	red	cell	transfusions.	The	rate	varied	from	100%	in	Thailand	to	8.7%	in	the	two	study	centres	in	France,	which	had	the	lowest	transfusion	rate	per	country.	Similar	variation	was	observed	in	the	transfusion	of	fresh	frozen	plasma	(0%	to	98.3%)	and	platelets	(0%	to	50.5%)	(Snyder-Ramos	et	al.,	2008).				
Study	 Year	of	
enrolment	
No.	of	
Patients	
No.	of	
Institutions	
Country/ies	 Range	of	Use	
(%)	Goodnough	LT	 1991	 540	 18	 USA	 RC:	17-100	Stover	EP	 1991-1993	 714	 24	 USA	 RC:	27-92	Bennett	Guerrero	E	 2008	 82,446	 408	 USA	 RC:	7.8-92.8	FFP:	0-97.5	Plt:	0.4-90.4	Andreasen	JJ	 2004	 571	 4	 Denmark	 RC:	30-64.2	Snyder-Ramos	S	 1996-2000	 5065	 69	 USA,	Germany,	UK,	Canada,	India,	France,	Hungary,	Thailand,	Colombia,	Romania,	Austria,	Netherlands,	Italy,	Israel,	Mexico,	Poland	
RC:	8.7-100	FFP:	0-98.3	Plt:	0-50.5	
Jin	R	 2008-2011	 5744	 12	 USA	 RC:	7-77	FFP:	1-31	Plt:	1-38	McQuilten	ZK	 2005-2011	 24,222	 25	 Australia	 RC:	16-66	FFP:	4-34	Plt:	6-32	Likosky	DS	(LV)	 2009-2012	 11,200	 56	 USA	 RC:	9.1-31.7	Gombotz	H	 2009-2010	 714	 6	 Austria	 RC:	30-49	Table	3.2:	CABG	studies	showing	variation	(LV	=	low	volume;	RC	=	red	cells;	FFP	=	fresh	frozen	plasma;	Plt	=	platelets)		
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3.1.1.1	Some	causes	for	variation	in	blood	usage	in	CABG	Use	of	blood	products	during	CABG	depends	on	a	number	of	different	factors.	Pre-operative	factors	including	haematocrit,	age,	gender,	previous	CABG	procedure,	active	cigarette	smoking,	catheterisation	on	the	same	admission,	coagulation	defects,	insulin-dependent	diabetes,	associated	transmural	myocardial	infarction	and	severe	complications	such	as	cardiogenic	shock	or	renal	failure	have	all	been	associated	with	a	higher	likelihood	of	transfusion	(Surgenor	et	al.,	1998).	Preoperative	medication	with	anti-platelet	therapy	and	anticoagulants	as	well	as	pre-operative	transfusion	of	blood	products	may	impact	intra-	and	post-operative	transfusion	needs	(Picker	et	al.,	2007).	Perioperative	variables	such	as	red	cell	volume	lost	(Stover	et	al.,	1998),	whether	the	surgery	is	performed	on-pump	or	off-pump,	duration,	urgency	and	additional	procedures	such	as	mitral	valve	replacement,	also	contribute	strongly	to	the	risk	of	transfusion	(Slight	et	al.,	2006).	A	critical	issue	is	the	skill	of	the	operating	surgeon,	which	is	highly	variable,	as	is	the	decision	to	adopt	specific	techniques	that	can	have	a	profound	effect	on	bleeding	(Bracey,	2008).	The	use	of	cell	saver	devices	and	antifibrinolytics	are	also	relevant	factors	(Brown	et	al.,	2007;	Niranjan	et	al.,	2006).	Other	issues	such	as	priming	volumes	and	fluid	management	can	also	influence	the	necessity	for	transfusion	(Slight	et	al.,	2006).	Despite	the	fact	that	these	variables	will	certainly	impact	the	extent	of	blood	usage,	they	cannot	explain	away	the	sheer	inconsistency	highlighted	in	the	quoted	studies.		A	central	determinant	is	the	transfusion	trigger	the	anaesthetist	/	surgeon	subscribes	to,	if	at	all.	Traditionally	a	Haemoglobin	value	of	8	–	10	g/dL	was	considered	a	suitable	threshold	for	transfusion.	A	recent	prospective,	randomised,	noninferiority	controlled	trial	of	502	patients	scheduled	for	CABG	elective	surgery	comparing	a	restrictive	transfusion	strategy	to	a	liberal	one	suggested	that	the	former,	targeting	a	haematocrit	of	24%,	was	as	safe	as	the	latter	(Haematocrit	=	30%),	with	respect	to	a	composite	end-point	of	30-day	mortality	and	inpatient	clinical	complications	(Hajjar	et	al.,	2010).	
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Though	indicative,	the	transfusion	trigger	cannot	be	isolated	from	the	contextual	setting	and	a	number	of	additional	considerations	need	to	be	reviewed	in	order	to	ensure	that	blood	is	used	optimally,	a	point	eloquently	made	in	a	thorough	review	(Slight	et	al.,	2009).		
3.1.1.2	Effect	of	the	institution	on	variation	in	blood	usage	in	CABG	Throughout	the	various	studies	on	variation	in	blood	product	use,	the	institution	itself	was	found	to	be	a	significant	variable	in	its	own	right.	Early	studies	showed	that	after	patient	related	factors	and	surgical	factors	were	controlled	for,	red	cell	transfusions	still	varied	significantly	among	institutions.	This	difference	was	thought	to	be	associated	with	transfusion	practice-related	factors	(Goodnough	et	al.,	1991).	A	study	performed	in	5	separate	hospitals	in	the	United	States	performed	a	two-step	logistic	regression	analysis	of	the	enrolled	cases.	Factors	that	had	previously	been	found	to	significantly	influence	the	likelihood	of	red	cell	transfusion	were	entered	as	a	first	step,	with	the	specific	hospital	entered	as	the	second	step.	This	revealed	that	the	hospital	was	also	a	significant	factor	for	red	cell	transfusion.	This	study	concluded	that	the	effects	of	the	specific	hospital	on	blood	transfusion	practice	was	the	result	of	deeply	ingrained	institutional	differences	in	training	and	hierarchical	practices	within	the	hospitals	(Surgenor	et	al.,	1998).			Some	studies	correlated	some	institutional	characteristics	to	blood	use.	Patients	in	hospitals	with	higher	volumes	of	surgery	tend	to	be	transfused	less,	and	patients	in	hospitals	with	residency	/	academic	programmes	tend	to	receive	more	red	cells	(Bennett-Guerrero	et	al.,	2010;	Maddux	et	al.,	2009).	In	a	single	country	based	study,	after	adjusting	for	patient-,	drug-,	and	procedure-related	risk	factors,	in	what	were	already	comparable	patient	populations,	the	institutional	effect	was	thought	to	be	notable	(Andreasen	et	
al.,	2007).		
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3.2	Data	Sources	Highlighting	Variation	in	Practice		
3.2.1	Haemovigilance	programmes	Haemovigilance	is	defined	as	a	set	of	surveillance	procedures	covering	the	whole	transfusion	chain	from	the	donation	of	blood	and	its	components	to	the	follow-up	of	its	recipients.	It	is	intended	to	collect	and	assess	information	on	unexpected	or	undesirable	effects	resulting	from	the	therapeutic	use	of	labile	blood	products	and	to	prevent	the	occurrence	and	recurrence.	Haemovigilance	was	taken	up	in	many	countries	mainly	as	a	voluntary	initiative	of	the	Transfusion	Services;	although	some	schemes	also	had	a	basis	in	national	law,	as	was	the	case	in	France	where	a	database	of	Transfusion	Incident	Reports	(TIR)	was	set	up	in	1994	under	the	responsibility	of	the	French	Blood	Agency	(Andreu,	2002).	The	first	report	of	the	Haemovigilance	scheme	in	the	UK,	Serious	Hazards	of	Transfusion	(SHOT)	was	published	in	1998	(Williamson,	1998).	By	1999,	ten	countries	out	of	the	then	fifteen	EU	member	states	had	put	in	place	a	structure	for	haemovigilance	and	most	came	together	as	a	single	forum	–	the	European	Haemovigilance	Network	(Faber,	2002)	which	has	since	(in	2010)	become	the	International	Haemovigilance	Network	also	encompassing	countries	outside	Europe.	In	2003	the	European	Union	published	binding	directives	which	mandated	reporting	of	serious	adverse	events	and	reactions	associated	with	transfusion,	thus	enshrining	haemovigilance	in	the	member	states’	legislative	framework	(European	Union,	2003;	European	Union,	2005a).			Comparison	of	data	arising	from	these	haemovigilance	schemes	has	been	somewhat	hampered	by	a	lack	of	standardised	definitions.	However	the	risk	of	occurrence	of	the	better-characterised	adverse	events	and	reactions	associated	with	blood	component	transfusion	has	been	reported	for	various	
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countries.	Table	3.3	shows	an	example	of	the	data	collated	from	different	sources,	indicated	in	the	table	itself,	for	2009/2010.			
Country	
Total	
number	of	
components	
transfused	
Overall	
incidence	of	
adverse	
reactions	
per	100,000	
components	
Events	per	100,000	components	transfused	
		 		 		 Anaphylaxis	 TACO	 TRALI	 ABO	Haemolysis	Australia1	 1,157,394	 25.40	 0.70	 0.50	 0.30	 N/A	Belgium2	 678,627	 9.30	 0.90	 0.30	 0.30	 0.70	Brazil3	 3,387,984	 77.00	 0.50	 2.20	 0.60	 0.20	Czech	Republic2	 640,833	 4.20	 1.40	 0	 0.90	 0.30	Finland2	 342,083	 3.80	 0.60	 0.30	 0	 0.30	France2	 2,928,807	 6.40	 2.00	 3.00	 0.80	 0.10	Germany2	 6,421,480	 0.40	 0.10	 0	 0.06	 0.10	Ireland2	 173,393	 36.90	 12.70	 8.60	 0	 0	Italy2	 3,214,887	 9.10	 7.60	 0.40	 0.10	 0.40	Japan4	 4,903,649	 35.00	 8.60	 N/A	 0.70	 0.04	Malta2	 22,537	 17.70	 4.40	 0	 4.40	 0	Switzerland2	 414,084	 8.20	 4.30	 1.40	 0	 0.50	UK2	 2,810,673	 6.40	 2.70	 0.60	 0.20	 0.10	USA5	 23,669,000	 0.70	 N/A	 6.00	 1.90	 0.20	Table	3.3:	Haemovigilance	data	for	2009/2010	[1	-	(National	Blood	Authority,	2011);	2	-	(Janssen	et	al.,	2011);	3	-	(Agencia	Nacional	de	Vigilancia	Sanitaria,	2010);	4	-	(Japanese	Red	Cross	Society,	2010);	5	-	(Department	of	Health	and	Human	Services,	2011);	TACO	=	Transfusion	Associated	Circulatory	Overload;	TRALI	=	Transfusion	Related	Acute	Lung	Injury]		In	order	to	be	able	to	compare	rates	of	complications,	authors	of	national	haemovigilance	reports	started	to	include,	as	a	denominator,	the	amount	of	blood	products	distributed	to	hospitals	or	transfused.	This	allowed	them	to	calculate	the	incidence	of	adverse	reactions.	The	inadvertent	outcome	was	the	potential	to	start	comparing	the	number	of	blood	components	distributed	to	hospitals	or	transfused	in	the	different	countries	publishing	reports.			
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3.2.2	International	benchmarking	The	Council	of	Europe	has	been	involved	in	the	field	of	blood	transfusion	since	the	1950s.	It	has	been	active	in	promoting	optimal	use	of	blood	and	blood	products,	and	is	responsible	for	a	major	publication	called	the	Guide	to	
the	preparation,	use	and	quality	assurance	of	blood	components	now	in	its	20th	edition.	In	2007,	the	scientific	secretariat	with	responsibility	for	blood	transfusion	was	transferred	to	the	European	Directorate	for	the	Quality	of	Medicines	and	Healthcare	(EDQM).			Since	2001,	a	sub-committee	of	the	European	Committee	on	Blood	Transfusion	(CD-P-TS)	has	been	responsible	for	the	collation	of	an	Annual	
report	on	the	collection,	testing	and	use	of	blood	and	blood	components	in	
Europe.	According	to	the	2009	report	(Janssen	et	al.,	2011),	red	cell	use	per	thousand	population	in	Europe	varies	significantly	(Figure	3.1).			
	Figure	3.1:	Red	cell	use:	compiled	from	data	in	the	Annual	Report	on	The	
Collection,	Testing	and	Use	of	Blood	and	Blood	Products	in	Europe	in	2009	(Janssen	et	al.,	2011).	
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3.2.2.1	Data	The	data	in	Table	3.4	on	blood	product	usage	in	2009/2010	have	been	compiled	from	a	number	of	sources:	annual	reports	published	by	the	Australian	National	Blood	Authority	(National	Blood	Authority,	2011),	the	American	Department	of	Health	and	Human	Services	(Department	of	Health	and	Human	Services,	2011),	the	Canadian	Blood	Service	(Canadian	Blood	Services,	2010),	Hema-Quebec	(Hema-Quebec,	2010),	the	New	Zealand	Blood	Service	Haemovigilance	Report	(NZBLOOD,	2010)	and	the	2009	and	2010	EDQM	reports	(Janssen	et	al.,	2011;	Janssen	et	al.,	2014).	Data	from	two	years	were	used	to	populate	as	much	of	the	table	as	possible	and	as	realistically	as	possible.	Where	possible,	these	figures	were	discussed	with	colleagues	in	the	European	Blood	Alliance	(EBA),	as	a	means	of	validation,	ensuring	their	faithfulness	to	the	actual	state	of	affairs.	Importantly,	though	they	are	labelled	as	blood	component	usage,	the	figures	presented	in	the	reports	by	a	number	of	countries	for	the	various	components,	refer	to	the	number	of	units	distributed	by	the	transfusion	services,	a	closely	related	but	slightly	inflated	value	that	also	incorporates	a	relatively	minor	amount	of	components	that	are	eventually	not	transfused.															
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 Blood Component Usage - Per 1000 Population 
Countries Red Cells Platelets Plasma 
Australia 36.8 5.9 7.4 
Austria 50.9 4.4 8.9 
Belgium 48.4 6.4 8.1 
Canada 31.2 4.3 8.7 
Croatia 39.1 NA 15.7 
Czech Republic 39.6 3.1 19.0 
Denmark 59.8 5.9 12.6 
Estonia1 39.8 4.5 5.3 
Finland 47.0 7.5 9.4 
France1 36.3 4.2 5.3 
Germany 57.8 5.7 15.0 
Greece 55.5 11.9 19.7 
Hungary 36.1 1.4 9.4 
Iceland 42.6 6.2 14.0 
Ireland1 32.9 5.8 5.2 
Italy 41.6 3.5 8.7 
Luxembourg 41.1 4.7 8.9 
Malta1 35.0 4.1 18.0 
Netherlands 34.0 3.3 5.5 
New Zealand 28.5 3.1 4.8 
Norway 40.1 4.2 9.4 
Slovakia 34.4 5.2 14.7 
Slovenia 43.5 4.6 15.3 
Spain1 36.0 4.1 4.3 
Sweden 53.0 4.7 11.3 
Switzerland 40.8 3.8 9.1 
United Kingdom 36.2 4.5 5.1 
United States 48.8 6.6 14.6 Table	3.4:	Blood	component	usage	per	1000	population	for	2009/2010	(1	–	Part	or	all	from	2010	report;	NA	=	not	available)		A	subset	of	these	figures	prompted	a	survey	where	respondents	in	15	countries,	all	with	higher	Human	Development	Indices	(HDI),	were	asked	to	fill	out	an	in-depth	questionnaire.	It	sought	to	explore	whether	differing	features	of	the	organisation	of	health	care	systems	or	even	the	blood	supply	system	could	be	correlated	in	some	way	with	the	practice	of	blood	banking	and	transfusion	medicine	(Aubuchon	et	al.,	2010).	The	authors	concluded	that	there	seemed	to	be	no	apparent	relationship	between	the	structures	and	organisations,	or	the	financing	arrangements	and	the	propensity	to	implement	new	technologies,	with	the	diversity	of	practice	in	transfusion	
43	
medicine	evident	across	these	same	countries.	They	surveyed	a	number	of	qualitative	issues,	including	the	political	system	with	respect	to	healthcare,	hospital	ownership,	hospital	governance	and	regulation,	and	the	source	of	resource	provision	for	blood	collection.	They	additionally	looked	at	control	of	new	initiatives	within	the	blood	collection	centres	and	medical	indemnification	for	blood	collectors,	the	structure	of	the	blood	collecting	institutions,	their	independence,	reporting	relationships,	and	identity	of	decision	makers.	They	also	examined	some	quantitative	data	including	Health	Care	Expenditure,	HDI,	number	of	blood	components	collected,	the	population	of	the	surveyed	countries,	and	the	cost	of	the	various	products.	The	authors	found	no	apparent	correlation	with	the	variation	in	practice	but	commented	that	they	had	not	explored	the	effect	of	clinical	demand	on	the	collection	rates	and	they	speculated	that	this	and	other	factors	including	the	age	distribution	of	the	population	may	be	important	determinants.		
3.2.2.2	Analysis	An	initial	analysis	of	the	data	collated	in	Table	3.4	was	performed.	The	distributions	of	the	three	dependent	variables,	Red	Cell,	Platelet	and	Plasma	Usage	per	1000	population	(Table	3.4),	were	analysed	using	the	Kolmogorov-Smirnov	test	(Figure	3.2)	using	IBM®	SPSS®	Statistics	Ver	20	to	ensure	that	their	distribution	was	normal	(p-values	=	0.584,	0.435	and	0.215	respectively).	In	order	to	explore	the	relationship	between	the	three	variables,	‘Red	Cell	Usage	per	1,000	Population’,	‘Platelet	Usage	per	1,000	Population’	and	‘Plasma	Usage	per	1,000	Population’	were	first	plotted	on	a	linear	graph	on	Microsoft®	Excel® for	Mac	2011	(Figure	3.3).	The	data	were	also	subjected	to	a	Pearson	Coefficient	analysis	using	IBM®	SPSS®	Statistics	Ver	20	using	each	variable	as	the	dependent	variable	in	turn	to	examine	the	relationship	between	the	three	variables	(Table	3.5).				
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	Figure	3.2:	Distribution	curves	for	the	three	dependent	variables			
Figure	3.3:	Plot	of	usage	of	red	cells,	platelets	and	plasma	
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Significant	Relationships	 Pearson	Correlation	 P-value	
Red	Cell	Usage	per	1,000	Population	-	Platelet	Usage	per	1,000	Population	 0.538	 0.005	
Plasma	Usage	per	1,000	Population	–	Red	Cell	Usage	per	1,000	Population	 0.559	 0.003	
Platelet	Usage	per	1,000	Population	–	Plasma	Usage	per	1,000	Population	 0.475	 0.014	Table	3.5:	Significant	correlations	between	usage	of	red	cells,	platelets	and	plasma		The	plot	(Fig.	3.3)	shows	a	significant	correlation	between	the	usages	of	the	three	blood	products.	This	relationship	is	confirmed	through	the	Pearson	correlation	shown	in	Table	3.5.	It	appears	that,	in	general,	countries	that	use	higher	amounts	of	red	cells	would	also	use	higher	amounts	of	plasma	and	platelets	with	the	converse	also	being	true.			
3.2.3	Variation	by	geographical	region	There	are	no	compiled	data	available	on	regional	usage	of	blood	products	based	on	discrete	geographical	regions	across	different	countries.	This	is	in	contrast	to	the	prevailing	situation	with	regard	to	other	therapeutic	modalities	(Public	Health	England,	2015).	Such	regional	information	would	help	continue	to	explore	the	extent	of	variation	in	blood	product	usage,	and	to	determine	whether	the	variation	evident	across	countries	on	a	national	level,	is	also	prevalent	on	a	regional	level	within	countries.	Through	the	EBA	network,	correspondence	was	sent	to	the	Chief	Executives	and	the	National	Medical	Directors	of	Transfusion	Services	(Blood	Establishments)	in	Europe	asking	for	regional	data,	if	available,	on	blood	component	usage	for	a	minimum	of	3	consecutive	years.	The	years	were	not	specified	so	as	not	to	limit	the	outcome	of	the	request.			Data	were	received	from	a	relatively	small	number	of	countries.	In	many	countries,	including	the	UK,	the	Netherlands,	Estonia,	Belgium,	Hungary,	and	Slovakia,	for	example,	this	data	is	simply	not	available.	The	replies	received	
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from	Germany	and	Spain	indicated	that	there	was	a	possibility	of	perhaps	retrieving	the	data	from	the	Paul	Elrich	Institute	in	Germany	and	the	Federal	Department	of	Health	in	Spain.	Communications	with	the	individuals	indicated	in	these	two	institutions	did	not	yield	any	additional	information.	Data	for	regional	usage	in	2010/11,	2011/12,	and	2012/13	in	Australia	were	collated	from	the	Australian	Haemovigilance	Report	(National	Blood	Authority,	2015)	and	population	data	were	collated	from	the	Australian	Bureau	of	Statistics	(Australian	Bureau	of	Statistics,	2015).	Data	for	Denmark	were	collated	from	two	sources;	blood	product	data	for	2007	and	2008	from	the	most	recent	Danish	Transfusion	Database	Annual	Report	2009	(Danish	Transfusion	Database,	2009)	and	population	data	were	collated	from	Statistics	Denmark	(Statistics	Denmark,	2009);	data	for	2015	were	made	available	directly	through	the	correspondence	mentioned	above.	One	year’s	worth	of	data	each	for	Finland	(2014)	and	Switzerland	(2012)	were	received	as	a	result	of	the	above-mentioned	correspondence.	Correspondence	with	Austria,	Italy	and	France	yielded	data	across	3	years	for	each	country.	The	data	received	for	Austria	were	complete	and	included	both	the	data	on	red	cells	and	the	population	of	each	region	for	2013,	2014	and	2015.	The	data	for	France	for	the	years	2012,	2013	and	2014	were	provided	in	the	form	of	three	reports	in	French	(Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance,	2013;	Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance,	2014;	Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance,	2015)	and	population	data	extracted	from	the	Institut	Nationale	de	la	Statistique	et	des	Etudes	Economiques	(Institut	Nationale	de	la	Statistique	et	des	Etudes	Economiques,	2015).	This	data	however	encompassed	all	three	products	i.e.	red	cells	+	platelets	+	plasma.	It	was	not	possible	to	extract	the	data	for	red	cells	only.	The	data	for	Italy	for	the	years	2013,	2014	and	2015	were	presented	in	the	form	of	three	reports	in	Italian	(Ministero	della	Salute,	2014;	Ministero	della	Salute,	2015;	Ministero	della	Salute,	2016)	and	population	data	extracted	from	I.Stat	the	Italian	database	for	population	statistics	(I.Stat,	2016).	The	UK	was	only	able	to	supply	the	data	for	the	four	countries	i.e.	England,	Wales,	
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Scotland	and	Northern	Ireland,	for	three	consecutive	years	(2012,	2013	and	2014).	Belgium	supplied	four	years	worth	of	data	(2012,	2013,	2014	and	2015),	split	into	two	regions	–	Flanders	and	‘Other’.	All	the	data	collected	were	for	red	cells	(apart	from	the	composite	data	made	available	for	France).	There	were	no	data	on	Platelet	usage	and	Plasma	usage	on	a	regional	basis.	The	data	are	displayed	in	Tables	3.6	–	3.14.		
3.2.3.1	Data				
	Table	3.6:	Regional	data	for	Australia				
	Table	3.7:	Regional	data	for	Austria				
Region Units	used Population
Units	per	
1000	
population Units	used Population
Units	per	
1000	
population Units	used Population
Units	per	
1000	
population
New	South	Wales 241982 7358791 32.9 256926 7262856 35.4 252792 7181410 35.2
Victoria 203374 5685931 35.8 207225 5585169 37.1 207828 5499459 37.8
Queensland 155301 4612504 33.7 166235 4522491 36.8 167051 4440761 37.6
West	Australia 64064 2478657 25.8 65742 2395701 27.4 66012 2322127 28.4
South	Australia 66311 1663431 39.9 69500 1647824 42.2 71782 1633468 43.9
Tasmania 14478 512632 28.2 15370 511794 30.0 15715 510165 30.8
Australian	Capital	Territory 12839 378335 33.9 13965 371584 37.6 13346 364875 36.6
Northern	Territory 5194 238320 21.8 6333 233586 27.1 6047 230535 26.2
National 763542 22928602 33.3 801295 22531007 35.6 800571 22182801 36.1
2012/2013 2011/2012 2010/2011
Region
Red	Cells	
Distributed Population
Units	per	
1000	
population
Red	Cells	
Distributed Population
Units	per	
1000	
population
Red	Cells	
Distributed Population
Units	per	
1000	
population
Region	1 142297.0 3650000.0 39.0 138254.0 3680000.0 37.6 136075.0 3720000.0 36.6
Region	2 43902.0 1430000.0 30.7 40175.0 1430000.0 28.1 39582.0 1440000.0 27.5
Region	3 12802.0 370000.0 34.6 13320.0 380000.0 35.1 13065.0 380000.0 34.4
Region	4 22193.0 550000.0 40.4 22510.0 560000.0 40.2 21345.0 560000.0 38.1
National 221400 6000000.0 36.9 214170 6050000.0 35.4 209840 6100000.0 34.4
2013 2014 2015
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	Table	3.8:	Regional	data	for	Denmark			
	Table	3.9:	Regional	data	for	Finland			
	Table	3.10:	Regional	data	for	France		
Region
Red	Cells	
Transfused Population
Transfused	
per	1000	
population
Red	Cells	
Transfused Population
Transfused	
per	1000	
population
Red	Cells	
Transfused Population
Transfused	
per	1000	
population
Hovedstaden 119192 1636744 72.8 112118 1645825 68.1 74046 1789174 41.4
Sjaelland 53425 816116 65.5 43063 819427 52.6 31254 827499 37.8
Syddanmark 76749 1189813 64.5 73842 1194659 61.8 47702 12111770 39.4
Midtylland 70128 1227424 57.1 63613 1237041 51.4 45307 1293309 35
Nordjylland 34575 576970 59.9 35400 578839 61.2 20825 585499 35.6
National 354069 5447067 65.0 328036 5475791 59.9 219134 5707251 38.4
2007 2008 2015
Region Units	Used Population
Units	per	
1000	
population
Ahvenanmaa-Islands	(South-West	from	Finland) 1260 28791 43.8
South	Finland 68457 1895814 36.1
East	Finland 29775 816786 36.5
North	Finland 27677 741515 37.3
Middle	Finland 41348 1110137 37.2
West	Finland 34418 868470 39.6
National 202935 5461512 37.2
2014
Region
Products	
transfused Population
Units	per	
1000	
population
Products	
transfused Population
Units	per	
1000	
population
Products	
transfused Population
Units	per	
1000	
population
Alsace-Champagne-Ardenne-Lorraine 307493.0 5550672.0 55.4 306879.0 5554151.0 55.3 301078.0 5558160.0 54.2
Aquitaine-Limousin-Poitou-Charentes 288115.0 5826386.0 49.5 288017.0 5859024.0 49.2 273630.0 5889357.0 46.5
Auvergne-Rhones-Alpes 354944.0 7726430.0 45.9 351558.0 7768302.0 45.3 343466.0 7844798.0 43.8
Bourgogne-Franche-Comte 145954.0 2818299.0 51.8 146133.0 2820044.0 51.8 142873.0 2820673.0 50.7
Bretagne 153172.0 3247902.0 47.2 151945.0 3267551.0 46.5 149572.0 3285349.0 45.5
Centre 101623.0 2567067.0 39.6 103647.0 2573372.0 40.3 88278.0 2579285.0 34.2
Corse 15834.0 318233.0 49.8 11469.0 321865.0 35.6 10447.0 325210.0 32.1
Ile-de-France 601053.0 11929155.0 50.4 641893.0 11987311.0 53.5 583318.0 12044364.0 48.4
Languedoc-Roussillon-Midi-Pyrenees 286377.0 5655368.0 50.6 288610.0 5710759.0 50.5 282045.0 5764753.0 48.9
Nord-Pas-de-Calais-Picardie 268413.0 5980491.0 44.9 262168.0 5992338.0 43.8 260174.0 6001823.0 43.3
Normandie 150302.0 3325560.0 45.2 148342.0 3329982.0 44.5 137029.0 3333128.0 41.1
Pays	de	la	Loire 163635.0 3646733.0 44.9 161658.0 3674627.0 44.0 158420.0 3702235.0 42.8
Provences-Alpes-Cote	d	Azur 236321.0 4944626.0 47.8 235891.0 4962649.0 47.5 234679.0 4980529.0 47.1
France	Metropolitaine 3073236.0 63536918.0 48.4 3098210.0 63839972.0 48.5 2965009.0 64129660.0 46.2
2012 2013 2014
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	Table	3.11:	Regional	data	for	Italy			
	Table	3.12:	Regional	data	for	Switzerland		
Region
Red	Cells	
Distributed Population
Units	per	
1000	
population
Red	Cells	
Distributed Population
Units	per	
1000	
population
Red	Cells	
Distributed Population
Units	per	
1000	
population
Valle	d'Aosta 4900.0 127844.0 38.3 4782.0 128591.0 37.2 4772.0 128298.0 37.2
Piemonte 197761.0 4374052.0 45.2 188917.0 4436798.0 42.6 187100.0 4424467.0 42.3
Liguria 73023.0 1565127.0 46.7 71000.0 1591939.0 44.6 72903.0 1583263.0 46.0
Lombardia 466480.0 9794525.0 47.6 457428.0 9973397.0 45.9 464078.0 10002615.0 46.4
PA	di	Trento 22098.0 530308.0 41.7 21314.0 536237.0 39.7 20605.0 537416.0 38.3
PA	di	Bolzano 22486.0 509626.0 44.1 21511.0 515714.0 41.7 20316.0 518518.0 39.2
Friuli	Venezia	Giulia 61398.0 1221860.0 50.2 56104.0 1229363.0 45.6 54757.0 1227122.0 44.6
Veneto 242254.0 4881756.0 49.6 239293.0 4926818.0 48.6 242527.0 4927596.0 49.2
Emilio	Romagna 230128.0 4377487.0 52.6 217981.0 4446354.0 49.0 212905.0 4450508.0 47.8
Toscana 174643.0 3692828.0 47.3 169630.0 3750511.0 45.2 164153.0 3752654.0 43.7
Umbria 43520.0 886239.0 49.1 44046.0 896742.0 49.1 44099.0 894762.0 49.3
Marche 75003.0 1545155.0 48.5 74163.0 1553138.0 47.8 74499.0 1550796.0 48.0
Lazio 218856.0 5557276.0 39.4 213323.0 5870451.0 36.3 211633.0 5892425.0 35.9
Sardegna 114478.0 1640379.0 69.8 110805.0 1663859.0 66.6 111416.0 1663286.0 67.0
Abruzzo 54206.0 1312507.0 41.3 54726.0 1333939.0 41.0 54500.0 1331574.0 40.9
Campania 156111.0 5769750.0 27.1 158710.0 5869965.0 27.0 165633.0 5861529.0 28.3
Molise 15093.0 313341.0 48.2 16329.0 314725.0 51.9 15788.0 313348.0 50.4
Puglia 153566.0 4050803.0 37.9 152600.0 4090266.0 37.3 153969.0 4090105.0 37.6
Basilicata 24008.0 576194.0 41.7 25222.0 578391.0 43.6 24185.0 576619.0 41.9
Calabria 67442.0 1958238.0 34.4 66512.0 1980533.0 33.6 68089.0 1976631.0 34.4
Sicilia 202732.0 4999932.0 40.5 200177.0 5094937.0 39.3 200423.0 5092080.0 39.4
National 2621060.0 59685227.0 43.9 2565552.0 60782668.0 42.2 2568975.0 60795612.0 42.3
2013 2014 2015
region
Units	
Distributed Population
Units	per	
1,000	
Population
Aargau-Solothurn 20202 886623 22.8
Basel 24996 463962 53.9
Bern 49185 992617 49.6
Fribourg 8499 291395 29.2
Geneva 22174 463101 47.9
Grisons 6617 233289 28.4
Neuchâtel-Jura 6521 245496 26.6
Eastern	Switzerland 19081 666310 28.6
Svizzera	Italiana 12174 341652 35.6
Valais 13461 321732 41.8
Vaud 31179 734356 42.5
Central	Switzerland 17910 690964 25.9
Zurich 65583 1707563 38.4
National 297582 8039060 37.0
2012
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	Table	3.13:	Data	for	Belgium	(split	into	Flanders	and	‘Other’)			
	Table	3.14:	Data	for	UK	(Split	by	country;	NI	=	Northern	Ireland)		
Region Year Total	Units Population
Units	per	
1000	
population
Flanders 2012 302544 6835577 44.26
Other 2012 206055 4200371 49.06
National 2012 508599 11035948 46.09
Flanders 2013 280727 6896445 40.71
Other 2013 195818 4235824 46.23
National 2013 476545 11132269 42.81
Flanders 2014 261561 6911226 37.85
Other 2014 190322 4244910 44.84
National 2014 451883 11156136 40.51
Flanders 2015 254839 6944003 36.7
Other 2015 186020 4265041 43.62
National 2015 440859 11209044 39.33
Country Year Population
Units	per	
1000	
population
England 2012 53,493,729 32.86
Scotland 2012 5,313,600 34.9
Wales 2012 3,074,067 36.62
NI 2012 1,823,634 29.05
England 2013 53,865,800 31.63
Scotland 2013 5,327,700 33.85
Wales 2013 3,082,400 31.73
NI 2013 1,829,700 26.4
England 2014 54,316,600 30.62
Scotland 2014 5,347,600 31.55
Wales 2014 3,092,000 31.41
NI 2014 1,840,500 26
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3.2.3.2	Analysis	The	figures	depict	a	wide	range	of	variation	with	some	countries	having	wider	amplitudes.	Using	each	country’s	average	red	cell	usage	as	a	reference	(100%),	it	is	possible	to	assess	the	variation	across	regions	within	the	same	country.	The	regions	in	Austria	range	between	81%	and	111%	(30	percentage	points).	Australian	regions	vary	between	72%	and	120%	(48	percentage	points).	In	Italy,	the	country	with	the	highest	variation,	the	range	is	between	64%	and	158%	(96	percentage	points).	French	regions	varied	between	82%	and	115%	(33	percentage	points).	The	regions	in	Denmark	ranged	between	87%	and	113%	(26	percentage	points).	In	Finland,	the	country	with	the	lowest	variation,	the	range	was	between	97%	and	118%	(21	percentage	points).	Swiss	regions	also	varied	significantly	demonstrating	a	range	between	62%	and	146%	(84	percentage	points).	Figure	3.4	illustrates	the	distribution	of	variation	in	the	different	regions	in	the	countries	reviewed.		
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Figure	3.4:	Distribution	of	blood	product	usage	variation	amongst	the	geographical	regions	in	the	different	countries			Scatter	plots	performed	using	IBM®	SPSS®	Statistics	Ver	20	with	‘Population	Size	of	Region’	plotted	on	the	X-axis	and	‘Red	Cell	Usage	per	1,000	Population’	plotted	on	the	Y-axis	were	used	to	depict	and	analyse	the	regional	data.	The	same	data	were	subjected	to	a	Pearson	Correlation	Coefficient	analysis	performed	using	IBM®	SPSS®	Statistics	Ver	20	using	‘Red	Cell	Usage	per	1,000	Population’	as	the	dependent	variable	and	‘Population	Size	of	Region’	as	the	predictor.	
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	Figure	3.5:	Scatterplot	showing	correlation	of	population	size	of	region	and	regional	red	cell	usage	per	1,000	population				 Red	Cell	Use	per	1000	population	Population	size	of	region	 Pearson	Correlation	 0.217	P-value	 0.004	Sample	Size	 171	Table	3.15:	Table	showing	Pearson	correlation	and	P-value	for	the	relationship	between	population	size	of	region	and	regional	red	cell	usage	per	1,000	population.		
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	Figure	3.6:	Scatter	plot	showing	the	relationship	between	regional	red	cell	usage	per	1,000	population	and	population	size	of	region	by	individual	country			 Relationship	between	Regional	‘Red	Cell	Use	per	1000	Population’	and	Population	Size	of	Region	clustered	by	country	 Pearson	Correlation	Austria	 0.107	Belgium	 -0.781	UK	 0.675	Australia	 0.329	Italy	 -0.160	France	 0.446	Denmark	 0.386	Finland	 -0.792	Switzerland	 0.124	Table	3.16:	Correlation	between	regional	red	cell	usage	per	1,000	population	and	regional	population,	country	by	country		
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The	scatter	plot	in	Figure	3.5,	depicting	a	plot	of	all	regions	from	all	countries	pooled	together,	shows	that	regions	with	larger	populations	tend	to	have	higher	red	cell	usage	than	regions	with	lower	populations.	When	plotted	country	by	country	however,	the	scatter	plot	(Figure	3.6)	and	the	subsequent	correlation	(Table	3.16)	tell	a	slightly	different	story.	The	relationship	between	‘Red	Cell	Usage	per	1,000	Population’	and	‘Population	Size	of	Region’	is	positive	in	the	case	of	Australia,	Austria,	France,	Denmark,	and	Switzerland	i.e.	the	larger	the	population	the	larger	the	‘Red	Cell	Usage	per	1,000	Population’.	In	the	case	of	Italy	and	Finland,	however,	the	relationship	is	negative	i.e.	the	smaller	the	population,	the	larger	the	‘Red	Cell	Usage	per	1,000	Population’	tends	to	be.			
	Table	3.17:	Corrected	data	for	Switzerland		Regional	variation	was	explored	further	in	Switzerland	with	the	help	of	Swiss	colleagues	who	provided	more	detailed	information	(Table	3.17).	Regional	red	cell	usage	was	corrected	for	the	presence	of	university	hospitals	in	5	regions.	For	the	purposes	of	the	analysis,	it	was	assumed	that	15%	of	blood	used	in	a	region	with	a	university	hospital	was	transfused	to	patients	migrating	into	the	region	for	medical	specialist	help.	The	blood	usage	for	these	regions	was	therefore	revised	downwards	to	85%	of	the	original	figure.	The	residual	15%	was	then	distributed	across	the	regions	without	university	hospitals	according	to	a	formula	that	took	into	consideration	the	individual	regions’	proportion	of	the	population	that	was	over	65	years.	Despite	these	corrections	there	was	still	considerable	variation	across	the	regions.	If	the	average	use	were	to	be	taken	as	100%,	the	variation	ranged	from	85%	to	
region cantons
University	
Hospital
Units	
Distributed
Units	
Distributed	
(corrected) Population
Population	
>	65	Years
Units	per	
1000	
Population
Units	per	
1000	
Population	
(corrected)
Aargau-Solothurn Aargau,	Solothurn 20202 27891 886623 148501 22.8 31.5
Basel Basel-Stadt,	Basel-Land yes 24996 21247 463962 95021 53.9 45.8
Bern Bern yes 49185 41807 992617 192915 49.6 42.1
Fribourg Fribourg 8499 10674 291395 42007 29.2 36.6
Geneva Geneva yes 22174 18848 463101 75727 47.9 40.7
Grisons Grisons,	Glarus 6617 8871 233289 43531 28.4 38.0
Neuchâtel-Jura Neuchâtel,	Jura 6521 8859 245496 45156 26.6 36.1
Eastern	SwitzerlandSt.	Gall	(70%),	Thurgau,	Appenzell	Inner-/Ausserrhoden 19081 24774 666310 109950 28.6 37.2
Svizzera	Italiana Ticino 12174 12174 341652 71889 35.6 35.6
Valais Valais 13461 16424 321732 57234 41.8 51.0
Vaud Vaud yes 31179 26502 734356 117744 42.5 36.1
Central	SwitzerlandLucerne,	Zug,	Obwalden,	Nidwalden,	Uri,	Schwyz	(50%) 17910 23765 690964 113091 25.9 34.4
Zurich Zurich,	Schaffhausen,	St.	Gall	(30%),	Schwyz	(50%) yes 65583 55746 1707563 285852 38.4 32.6
National 297582 297582 8039060 1398618 37.0 37.0
56	
138%	(53	percentage	points)	which	is	less	than	the	variation	using	the	crude	unaltered	data	(84	percentage	points)	but	still	quite	significant.		
3.3	Discussion		The	literature	review	examining	blood	product	usage	in	CABG	highlights	an	inconsistency	in	practice,	that	continues	to	be	of	concern	(Magruder	et	al.,	2017).	Significant	variation	in	transfusion	practice	still	exists	across	cardiac	surgery	centres	even	after	adjustment	of	the	data	to	correct	for	different	variables.	Additionally,	it	has	been	shown	that	hospitals	that	tend	to	use	a	lot	of	red	cells	also	use	more	plasma	and	platelets	(McQuilten	et	al.,	2014).	Evidence-based	assertions	have	been	made	to	the	effect	that	this	inconsistency	in	transfusion	practice	may	be	due,	at	least	partially,	to	institutional	based	protocols	(Snyder-Ramos	et	al.,	2008).	It	has	in	fact	been	argued,	in	relation	to	transfusion	of	blood	products,	that	in	the	absence	of	professional	consensus,	institutional	culture	assumes	an	important	role	(Jin	
et	al.,	2013).	An	interesting	suggestion	made	by	Likosky	et	al	is	the	possibility	that	geographical	regions	may	have	their	own	transfusion	signature	(Likosky	
et	al.,	2014).	They	found	that	the	rate	of	1-unit	as	well	as	2-unit	transfusions	varied	more	than	2-fold	across	regions.		Figure	3.1	on	page	40	and	Table	3.4	on	page	42	give	a	very	clear	picture	of	the	variation	in	red	cell,	plasma	and	platelet	usage	across	a	number	of	countries.	It	is	worth	noting	that	in	countries	with	less	developed	health	systems,	inefficient	practices	and	the	lack	of	a	modern	transfusion	service	set-up	contribute	to	a	situation	of	chronic	blood	component	shortages	that	lead	to	low	levels	of	transfusion.	Unlike	the	rest	of	the	countries	listed,	which	are	ranked	in	the	very	high	HDI	group	in	the	2011	Human	Development	Ranking	Report	(United	Nations	Development	Programme,	2011),	Moldova	and	Romania	are	ranked	in	lower	groups	and	they	also	have	the	lowest	
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figures	for	red	cell	use	per	1000	population	[13.4/1000	and	17.4/1000	respectively].	This	is	a	reflection	of	the	inadequacy	of	the	local	system	which	likely	translates	into	under-transfusion	(Murphy,	2012b).	However,	even	if	one	were	to	disregard	the	countries	with	levels	of	use	that	hover	around	the	20-mark,	there	still	is	a	2-fold	difference	between	the	lowest	using	country	–	Ireland	at	33	units	per	1000	population	and	the	highest	using	one	–	Denmark	at	60	units	per	1000	population.	Attempts	have	been	made	to	explain	this	difference	by	a	demographic	argument	(Ali	et	al.,	2010;	Seifried	et	al.,	2011),	but	the	sheer	difference	prompts	one	to	speculate	that	additional	issues	are	at	play.		The	analysis	performed	comparing	the	three	variables	“Red	Cell	Usage	per	1,000	Population’,	Platelet	Usage	per	1,000	Population’	and	‘Plasma	Usage	per	1,000	Population’	(Figure	3.3;	Table	3.5)	on	pages	44	and	45	showed	that	countries	using	high	amounts	of	one	product	seem	also	to	use	higher	amounts	of	the	other	products.	It	is	certainly	the	case	that	in	a	few	indications	for	blood	product	use	e.g.	haemhorrage	and	disseminated	intravascular	coagulation	the	concomitant	transfusion	of	all	three	products	occurs,	and	in	haematological	malignancies	the	use	of	both	red	cells	and	platelets	is	common.	However,	in	many	indications	blood	products	are	used	individually	and	therefore,	the	correlation	is	surprising	though	similar	to	the	reported	finding	that	hospitals	which	use	more	of	one	tend	to	use	more	of	the	others	(McQuilten	et	al.,	2014).	This	correlation	is	likely	indicative	of	a	pattern	where	low	or	high	usage	is	also	country	specific.		Unlike	in	many	other	therapeutic	modalities,	there	appears	to	be	a	dearth	of	information	surrounding	the	use	of	blood	products	at	a	regional	level.	Though	much	evidence	is	found	in	the	literature	documenting	the	varying	use	of	blood	products	in	specific	interventions	across	countries	or	institutions,	as	described,	no	publication	has	shown	regional	variation	across	different	countries	based	on	real	regional	data	as	has	been	shown	in	this	
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chapter.	The	figures	acquired	related	only	to	red	cell	usage	as	unfortunately	data	were	not	forthcoming	on	plasma	and	platelet	usage.			The	anlaysis	performed	on	the	crude	data	acquired	was	actually	quite	revealing.	It	is	clear	that	even	at	regional	level	the	variation	in	red	cell	usage	is	quite	significant,	in	Italy	the	highest-using	region	transfuses	more	than	double	the	red	cells	transfused	in	the	lowest-using	region.	The	level	of	variation	differs	and	there	does	not	seem	to	be	any	association	between	the	national	average	of	red	cell	usage	of	a	country	and	its	range	of	regional	variation.	It	may	be	argued	that	the	variation	may	be	due	to	the	fact	that	some	regions	within	a	country,	normally	the	ones	with	big	urban	centres	and	higher	population	sizes,	would	have	large	university	hospitals	with	much	higher	clinical	activity	and	therefore,	of	necessity,	higher	blood	use.	Though	analysis	of	all	the	regions	together	did	show	an	association	between	population	size	and	‘Red	Cell	Usage	per	1,000	Population’,	when	the	analysis	was	performed	on	a	country	by	country	basis,	it	was	found	that	this	association	was	reversed	in	Italy	and	Finland.	Additionally,	the	more	in-depth	analysis	of	Switzerland	showed	that	there	was	still	considerable	variation	when	corrections	were	made	for	medical	migration	into	regions	where	university	hospitals	were	situated,	and	allowance	was	made	for	demographic	differences	between	regions.		
3.4	Conclusion	1. A	literature	review	exploring	transfusion	practices	surrounding	a	sentinel	surgical	procedure	in	which	a	significant	quantity	of	blood	is	transfused	showed	that	the	sheer	inconsistency	in	practice	could	not	be	explained	solely	by	clinical	imperatives.	Moreover	there	is	evidence	to	suggest	an	effect	of	the	individual	institution	(hospital)	on	the	variation	in	blood	usage,	in	other	words	local	traditions	appear	to	influence	blood	transfusion	practice.	
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2. Multiple	data	sources	including	haemovigilance	programmes	and	data	collated	from	the	Council	of	Europe	and	national	blood	transfusion	reports	show	a	consistent	variation	in	blood	usage	across	a	number	of	countries.	3. Analysis	of	the	usage	figures	for	the	three	blood	products	shows	that	countries	that	use	more	of	one	tend	to	use	more	of	another.	4. The	sheer	inconsistency	of	the	variation	found	in	red	cell	usage	across	regions	within	the	same	country,	lack	of	association	of	the	range	of	variation	with	the	national	average	and	the	findings	related	to	the	inverse	relationship	between	regional	population	size	and	red	cell	usage	all	militate	in	favour	of	the	argument	that	a	significant	part	of	the	variation	in	red	cell	usage	seems	to	be	without	an	as	yet	known	basis.	This	continues	to	be	confirmed	by	a	more	detailed	analysis	of	variation	in	one	specific	country.		The	literature	reviewed	and	the	data	collated	and	analysed	in	this	chapter	therefore	demonstrate	very	clearly	that	variation	in	blood	product	usage	is	a	real	phenomenon.	At	its	widest	range,	when	comparing	usage	both	at	a	national	level	and	at	a	regional	level	the	higher-using	regions	/	countries	appear	to	use	twice	as	much	blood	as	the	lowest-using	regions	/	countries.	This	significant	variation	in	practice	in	a	therapeutic	modality	governed	by	very	similar	guidelines	in	all	the	countries	reviewed	deserves	further	exploration	to	tease	out	and	to	understand	the	contributing	factors.	Unless	these	are	identified,	one	cannot	start	to	address	this	seemingly	inconsistent	practice.		 	
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4.	Relationships	between	variation	in	blood	product	usage	
and	other	variables	
	Having	both	reviewed	the	literature	and	examined	national	figures	for	blood	product	usage,	and	compared	regional	data	for	a	number	of	countries	which	were	analysed	here	for	the	first	time,	it	is	opportune	to	look	closer	at	what	lies	behind	the	variation.	Though	it	is	of	concern,	very	little	has	been	published	to	date	on	possible	explanations.	This	chapter	attempts	an	initial	understanding	of	the	reasons	for	this	variation.	It	explores	the	potential	relationships	blood	product	variation	may	have	with	plausible	predictors.	It	also	probes	the	relationship	between	blood	product	usage	and	overall	health	system	performance	to	identify	any	dependencies.			
4.1	Plausible	Predictors		
4.1.1	Population	demographics	As	early	as	1994	in	the	United	States,	a	survey	on	blood	transfusion	had	shown	that	53.3%	of	red	cells	are	transfused	to	patients	who	are	more	than	65years	old	(Vamvakas	&	Taswell,	1994).	A	more	recent	survey	of	the	demographics	of	blood	used	in	2006	across	four	countries	–	USA,	England,	Austria	and	Denmark	–	showed	that	50%	of	red	cell	units	were	transfused	to	patients	over	65	years	(Cobain	et	al.,	2006).			Comparing	the	figures	provided	by	Eurostat,	the	European	Commission’s	statistical	database,	on	population	age	structure	demonstrates	significant	
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differences	in	the	percentages	of	the	population	over	65	years	of	age	among	different	countries	(Eurostat,	2011).	Since	a	relatively	high	proportion	of	blood	used	is	transfused	to	the	elderly	it	is	plausible	to	assume	that	any	major	difference	in	the	proportion	of	the	population	over	65	years	among	different	countries	will	impact	blood	usage	and	will	therefore	give	rise	to	variation.	This	association	has	already	been	examined.	Ali	et	al	reported	that	‘…	the	variation	in	RBC	use	per	capita	can	be	explained	by	the	age	distribution	
of	the	different	populations	and	not	by	the	different	national	and	regional	
treatment	policies	and	protocols	used’	(Ali	et	al.,	2010).		
4.1.2	Clinical	drivers	of	blood	product	use	A	small	number	of	pathologies/procedures	have	been	shown	to	consistently	account	for	a	significant	proportion	of	blood	component	use.	In	Northern	Ireland	for	example,	a	third	of	surgical	patients	receiving	red	cell	transfusions	would	have	had	an	orthopaedic	procedure,	and	a	further	12%	undergo	cardiac	surgery.	In	the	same	country,	of	the	transfused	medical	patients,	34%	have	an	oncology-related	condition,	around	a	third	of	which	are	haematological	(Barr	et	al.,	2010).	This	pattern	is	reflected	in	England	and	Wales	where	two	of	the	top	three	Case-mix	Groups	receiving	red	cell	transfusion	are	‘Musculoskeletal’	and	‘Haematology’	(15%	and	13%	respectively)	(Wells	et	al.,	2009).	In	addition,	cardiac	pathologies	are	responsible	for	12%	of	plasma	transfusion	and	haematological	malignancies	are	responsible	for	20%	of	platelet	use	while	a	further	11%	of	platelets	are	transfused	to	patients	who	undergo	coronary	artery	bypass	surgery.	These	patterns	are	also	reflected	in	the	States	(Anderson	et	al.,	2007)	and	other	countries	(Cobain	et	al.,	2006).	Plasma	use	is	mostly	associated	with	massive	haemorrhage	(Duguid	et	al.,	2004),	including	post-partum	haemorrhage.			Thus	cardiac	surgery,	hip	replacement	surgery	(as	a	marker	of	orthopaedic	surgery),	maternal	mortality	(as	a	surrogate	marker	for	severe	post-partum	haemorrhage),	and	malignancies	more	specifically	haematological	
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malignancies	would	seem	to	be	powerful	drivers	of	blood	component	use	in	developed	countries	and	significant	differences	in	their	prevalence	may	therefore	also	contribute	partially	to	the	difference	in	blood	use	across	countries.			
4.1.3	Other	variables	
4.1.3.1	Funding	It	is	plausible	to	examine	whether	a	genuine	interdependence	exists	between	the	degree	of	funding	available	to	a	health	service	and	the	amount	of	blood	transfused	in	that	service.	This	can	be	explored	by	determining	the	relationship	between	blood	component	use	and	health-related	or	development	economic	markers.	Three	commonly	used	markers	would	be:	a. Health	Care	Expenditure	per	Capita	which	reflects	funding	that	countries	make	available	for	their	populations’	health	b. Human	Development	Index	(HDI)	which	captures	the	level	of	development	within	a	country.	It	is	made	up	of	a	composite	of	4	indicators	within	3	dimensions	–	‘Life-expectancy	at	Birth’	within	the	dimension	of	‘Health’;	‘Mean	Years	of	Schooling’	and	‘Expected	Years	of	Schooling’	within	the	dimension	of	‘Education’;	and	‘Gross	National	Income	per	Capita’	within	the	dimension	of	‘Living	Standards’.	c. Gross	Domestic	Product	which	reflects	the	economy	of	the	country.		
4.1.3.2	Population	Density	Transfusion	Services	in	countries	that	are	more	sparsely	populated	may	have	to	carry	a	higher	amount	of	red	cells	and	platelets	in	stock	in	their	remoter	hubs	in	order	to	minimise	the	risk	of	supply	failure	to	areas	that	are	far	from	the	large	urban	centres.	This	may	to	some	degree	impact	the	variation	in	the	number	of	blood	components	issued	by	transfusion	services,	depending	upon	the	remoteness	of	some	areas	that	are	serviced	by	the	same	Blood	Centres.	
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As	stated	previously	this	value	may	be	reported	instead	of	the	actual	figure	for	blood	component	transfusion.		
4.2	Overall	Health	Service	Performance	and	Blood	Product	Variation		It	would	be	interesting	to	see	whether	the	level	of	blood	product	usage	correlated	in	any	way	with	the	general	performance	of	the	health	care	systems	in	the	individual	countries.			Overall	rankings	for	the	delivery	of	health	services	in	a	country	can	be	established	through	health	service	assessments.	Various	purposes	have	been	attributed	to	the	performance	of	health	service	assessments.	The	primary	ones	would	include	the	motivation	of	health	system	reforms;	the	promotion	of	alignment	and	harmony	amongst	diverse	players	in	individual	health	systems;	the	evaluation	and	tracking	of	system	performance;	and	the	facilitation	of	learning	from	comparisons	across	different	countries	(Bennett	&	Peters,	2015).	There	is	a	persistent	interest	particularly	among	international	institutions	in	comparative	analyses	of	health	systems	investigating	the	differences	in	delivery,	governance	and	financing	of	health	services	across	countries	probing	their	relative	effectiveness	and	equity.	Two	such	institutions	are	the	Organisation	for	Economic	Cooperation	and	Development	(OECD)	and	the	World	Health	Organisation	(WHO)	who	have	led	in	this	respect	(Tchouaket	et	al.,	2012;	World	Health	Organisation,	2016).	This	practice	has	not	been	without	its	controversy	spanning	from	the	whole	philosophy	of	the	idea,	to	the	choice	of	indicators,	to	reliability	of	data	(Coyne	&	Hilsenrath,	2002),	(Navarro,	2002),	(Musgrove,	2010).		There	is	no	doubt	that	measurement	of	countries’	status	and	progress	towards	meeting	targets	is	a	substantial	task	which	would	normally	require	action	across	a	range	of	national	and	international	organisations,	both	
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governmental	and	non-governmental.	The	difficulties	of	measurement	are	also	further	compounded	by	persistent	problems	of	data	availability,	quality	and	comparability	across	a	host	of	indicators	(World	Health	Organisation,	2016).			Having	said	that,	a	ranking	of	the	health	services	of	the	different	countries,	whose	variation	of	blood	usage	is	being	explored,	has	been	computed	using	key	performance	indicators	collated	from	the	OECD	database	(Organisation	for	Economic	Co-operation	and	Development,	2016b),	and	validated	against	the	Health	Sustainable	Goal	Index	(GBD	2015	SDG	Collaborators,	2016).		This	ranking	was	used	in	the	analysis	performed	in	the	next	section		
4.3	Analysis	of	the	Effect	of	the	Underpinning	Contributors	on	the	
Variation	in	Blood	Product	Usage		Table	4.1	on	page	69	lists	the	values	for	the	factors	identified	as	plausible	predictors	of	the	variation	in	blood	component	usage	discussed	in	section	4.1	(page	61)	for	a	number	of	developed	countries	for	which	red	cell,	platelet	and	plasma	usage	are	available.	2009	was	chosen	as	the	index	year	as	that	seemed	to	be	the	year	with	the	more	complete	data	sets.	The	data	are	extracted	from	a	number	of	online	databases	that	are	publically	accessible	including	ones	from	the	OECD,	the	World	Bank	Group,	the	Heal	the	World	Foundation	(Nation	Master)	and	the	United	Nations	Development	Programme.	The	data	retrieved	relate	to	2009	or	the	nearest	available	year.	The	individual	factors	identified	are	listed	below	with	their	relevant	reference.		
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1. Per	Cent	Population	above	65	years	(Organisation	for	Economic	Co-operation	and	Development,	2009b)	2. Human	Development	Index	(HDI)	(United	Nations	Development	Programme,	2011)	3. Gross	Domestic	Product	(GDP)	per	Capita	US$	(World	Bank,	2009c)	4. Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity	(World	Bank,	2009b)	5. Population	Density	–	Persons	per	Square	Kilometre	(Heal	The	World	Foundation,	2012)	6. Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population	(Organisation	for	Economic	Co-operation	and	Development,	2009a)	7. Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population	(Organisation	for	Economic	Co-operation	and	Development,	2009a)	8. Age	Standardised	rate	per	100,000	population	for	all	cancers	excluding	non-melanoma	skin	cancers	(International	Agency	for	Research	on	Cancer,	2008)	9. Age	Standardised	rate	per	100,000	population	for	HL,	NHL,	Leukaemia	&	MM	(International	Agency	for	Research	on	Cancer,	2008)	10. Maternal	Mortality	Ratio	per	100,000	Live	Births	(World	Bank,	2009a)		Table	4.2	on	page	70	lists	the	values	for	the	key	performance	indicators	used	in	the	country	health	service	system	ranking	exercise	discussed	in	Section	4.2	(page	64).	The	individual	indicators	were	extracted	from	the	OECD	database	(Organisation	for	Economic	Co-operation	and	Development,	2016a)	and	are	listed	below.	All	indicators	relate	to	2009	or	the	nearest	year	and	all	have	the	specific	web	address	indicated,	or	their	digital	object	identifier	(DOI)	number,	for	ease	of	reference.	Indicators	1	through	to	7	were	extracted	from	the	Health	Care	Quality	Indicators	and	indicators	8	to	10	were	extracted	from	the	Cancer	Care	sub-set	of	the	Health	Care	Quality	Indicators.		
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1. Asthma	and	Chronic	Obstructive	Pulmonary	Disease	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	2. Congestive	Heart	Failure	and	Hypertension	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	3. Diabetes	hospital	admissions	in	total	population	aged	15	years	and	over	-	Age-standardised	rate	per	100,000	population	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	4. 30-day	mortality	after	hospital	admission	for	Myocardial	Infarction	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	5. 30-day	mortality	after	hospital	admission	for	Haemorrhagic	Stroke	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	6. 30-day	mortality	after	hospital	admission	for	Ischaemic	Stroke	in	total	population	aged	45	years	and	over	-	Age	and	sex	standardised	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	7. Hip	fracture	surgery	initiated	within	2	days	after	admission	to	hospital	in	total	population	aged	65	years	and	over	-	Crude	rate	per	100	patients	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	8. Breast	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	-	Age	standardised	survival	-	%	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	9. Cervical	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	-	Age	standardised	survival	-	%	(http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT)	
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4.3.1	Analyses	Statistical	analyses	in	this	section	were	performed	using	IBM©	SPSS©	Statistics	for	Macintosh©	Version	20.0.			
4.3.1.1	Linear	correlation	All	the	identified	factors	(predictors)	were	subjected	to	a	Pearson	Correlation	Coefficient	analysis	using	the	Red	Cell,	Platelet	and	Plasma	Usage	per	1000	Population	in	turn	as	the	dependent	variables	(Table	3.4,	page	42)	to	measure	the	linear	correlation	between	each	dependent	variable	and	each	factor.	Using	this	tool,	‘Percent	Population	over	65	Years’,	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’	and	‘Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population’	were	individually	found	to	be	significantly	positively	correlated	to	‘Red	Cell	Usage	per	1000	Population’.	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	related	negatively	to	the	dependent	variable	and	was	only	marginally	above	the	0.05	criterion	for	significance	(Table	4.3).															
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Relationship 
Pearson 
Correlation 
 
P-value 
Red Cell Usage per 1000 Population – Per Cent Population 
above 65 years 
0.556 0.002 
Red Cell Usage per 1000 Population – Human 
Development Index (HDI) 	 0.128 0.517 
Red Cell Usage per 1000 Population – Gross Domestic 
Product (GDP) per Capita US$	 0.194 0.324 
Red Cell Usage per 1000 Population – Health Care 
Expenditure per Capita US$ Purchasing Power Parity	 0.308 0.110 
Red Cell Usage per 1000 Population – Population Density 
– Persons per Square Kilometre	 -0.107 0.588 
Red Cell Usage per 1000 Population – Prevalence of 
Coronary Artery Bypass Surgery per 100,000 Population	 0.483 0.014 
Red Cell Usage per 1000 Population – Prevalence of Hip 
Replacement Surgery per 100,000 Population	 0.612 0.001 
Red Cell Usage per 1000 Population – Age Standardised 
rate per 100,000 population for all cancers excluding non-
melanoma skin cancers	 -0.208 0.288 
Red Cell Usage per 1000 Population – Age Standardised 
rate per 100,000 population for HL, NHL, Leukaemia & MM	 -0.347 0.070 
Red Cell Usage per 1000 Population – Maternal Mortality 
Ratio per 100,000 Live Births	 -0.220 0.262 Table	4.3:	Pearson	correlation	coefficient	for	variables	in	relation	to	red	cell	usage	per	1000	population		In	order	to	further	tease	out	the	relationship	between	‘Red	Cell	Usage	per	1000	Population’	and	‘Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity’,	a	partial	correlation	was	performed.	This	was	corrected	for	the	variation	in	‘Percent	Population	over	65	Years’	since	this	latter	factor	has	been	shown	to	be	one	of	the	major	determinants	of	the	variation	in	international	usage.	Table	4.4	demonstrates	clearly	that	once	this	factor	is	corrected	for,	there	is	a	significant	correlation	between	‘Red	Cell	Usage	per	1000	Population’	and	‘Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity’	confirming	the	relationship	between	the	dependent	and	the	predictor.	
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Control	Variables	 	 Total	Health	Expenditure	$	per	Capita	Elderly	population	(over	65	y)	as	percent	of	population	
Red	Cell	Usage	per	1000	population	
Correlation	 0.430	
P-Value	 0.032	Table	4.4:	Partial	correlation	of	red	cell	usage	per	1000	population	with	total	health	expenditure	per	capita	US$	purchasing	power	parity	(corrected	for	percent	population	over	65	years’)		A	similar	analysis	using	‘Platelet	Usage	per	1000	Population’	as	the	dependent	variable	yielded	a	significant	negative	correlation	with	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	Excluding	Non-melanoma	Skin	Cancers’	(Pearson	Correlation	=	-0.471;	P-value	=	0.013).	There	also	appears	to	be	marginal	correlation	with	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’	(Pearson	Correlation	=	0.392;	P-value	=	0.052)		‘Plasma	Usage	per	1000	Population’	was	significantly	negatively	correlated	with	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	(Pearson	Correlation	=	-0.489;	P-value	=	0.008)	and	possibly	marginally	negatively	correlated	with	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	Excluding	Non-melanoma	Skin	Cancers’	(Pearson	Correlation	=	-0.352;	P-value	=	0.066).		There	was	a	significant	amount	of	correlation	amongst	the	predictors	themselves.	Most	notably,	‘Gross	Domestic	Product	(GDP)	per	Capita	(Current	US$)’	and	‘Health	Care	Expenditure	per	Capita	(current	US$	purchasing	power	parity)’	were	very	highly	correlated	almost	reaching	a	level	of	1	(Pearson	Correlation	=	0.922).	It	was	subsequently	decided	to	eliminate	GDP	from	any	further	analyses.			
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Not	unexpectedly,	‘Health	Care	Spending	per	Capita	(current	US$	purchasing	power	parity)’	was	also	correlated	with	‘Human	Development	Index’.	Both	these	predictors	also	positively	correlated	with	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	and	with	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	Excluding	Non-melanoma	Skin	Cancers’,	an	understandable	phenomenon	in	view	of	the	fact	that	the	diagnosed	incidence	of	malignancy	is	higher	in	well-developed	countries.		‘Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population’	was	found	to	be	significantly	positively	correlated	with	6	out	of	the	9	predictors	-	‘Percent	Population	over	65	Years’;	‘Human	Development	Index’;	‘Gross	Domestic	Product	per	Capita	(Current	US$)’;	‘Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity’;	‘Population	Density	–	Persons	per	Square	Kilometre’;	and	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’.	Most	of	these	correlations	are	intuitively	explained.	Hip	replacement	is	a	procedure	that	tends	to	be	performed	on	the	elderly,	similarly	to	coronary	artery	bypass	surgery,	in	countries	with	high	levels	of	development	that	can	afford	to	have	it	performed.	The	correlation	with	population	density	is	likely	explained	by	the	positive	correlation	of	population	density	with	population	over	65	years.		In	order	to	continue	to	understand	the	relationship	between	blood	product	usage	and	cancer,	a	correlation	was	performed	between	data	for	cancer	survival	and	mortality	(extracted	from	Table	4.2,	page	70)	and	red	cell,	platelet,	and	plasma	use	per	1,000	population.	The	data	categories	identified	were	the	following:	1. Breast	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	(age	standardised	survival	-	%)	2. Cervical	cancer	5-year	relative	survival	in	the	female	population	aged	15	years	and	over	(age	standardised	survival	-	%)	
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3. Colorectal	cancer	5-year	relative	survival	in	the	total	population	aged	15	years	and	over	(age	standardised	survival	-	%)	4. Deaths	from	cancer	(per	100,000	inhabitants)		The	identified	factors	(predictors)	were	subjected	to	a	Pearson	Correlation	Coefficient	analysis	using	the	Red	Cell,	Platelet	and	Plasma	Usage	per	1000	Population	in	turn	as	the	dependent	variables	to	measure	the	linear	correlation	between	each	dependent	variable	and	each	factor.		
 
Relationship 
Pearson 
Correlation 
 
P-value 
Platelet Usage per 1000 Population – Colorectal	cancer	5-year	relative	survival	in	the	total	population	aged	15	years	and	over	(age	standardised	survival	-	%)	 0.473 0.047 
Platelet Usage per 1000 Population – Deaths	from	cancer	(per	100,000	inhabitants)	 -0.472 0.020 Table	4.5:	Correlation	between	blood	products	and	cancer	survival	and	mortality		
4.3.1.2	Regression	analysis	The	major	limitation	of	the	Pearson	Correlation	Coefficient	Test	is	that	it	investigates	solely	the	relationship	between	a	dependent	variable	and	a	single	predictor	(explanatory	variable).	However,	the	goal	of	this	exercise	was	to	estimate	collectively	the	quantitative	effect	of	all	the	predictors	upon	the	dependent	variable	that	they	influence.		It	is	well	known	that	a	lone	predictor	could	be	rendered	a	very	important	contributor	in	explaining	variations	in	the	responses,	but	would	be	rendered	unimportant	in	the	presence	of	other	predictors.		In	other	words,	the	suitability	of	a	predictor	in	a	model	fit	often	depends	on	what	other	predictors	are	included	with	it.		As	pointed	out	previously,	the	Pearson	correlation	analysis	showed	significant	correlation	amongst	the	predictors	themselves,	a	condition	which	is	described	as	multicollinearity	in	regression	analysis.	This	poses	a	problem	because	it	prohibits	precise	statistical	inference.	In	other	words,	small	
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changes	in	the	data	values	may	lead	to	large	changes	in	the	parameter	estimates	and	this	severely	prohibits	quality	prediction	therefore	the	results	of	the	regression	analyses	were	evaluated	also	in	the	light	of	the	outcome	from	the	Pearson	Correlation.		A	Regression	Analysis	using	a	backward	procedure	was	used	to	identify	the	predictors	that	contribute	significantly	in	explaining	the	variation	in	the	responses	(Red	Cell	/	Platelet	/	Plasma	Usage	per	1000	Population).			The	model	used	to	analyse	the	data	with	‘Red	Cell	Usage	per	1000	Population’	as	the	dependent	variable	showed	that	the	nine	predictors	together	contributed	to	73.5%	of	the	variance.			The	parsimonious	regression	model	that	related	the	dependent	variable	‘Red	Cell	Usage	per	1000	Population’	to	the	explanatory	variables	identified	5	significant	predictors,	3	of	them	positively	correlated	and	2	of	them	negatively	correlated:	Per	Cent	Population	over	65	Years;	Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity;	Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population;	Population	Density	–	Persons	per	Square	Kilometre;	and	Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM	(Table	4.6).	This	five-	predictor	model	explained	70.5%	of	the	total	variance	(Table	4.7).											
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Table 4.6: Coefficients for red cell usage as dependent variable 
 
 		Table	4.7:	Model	summary	–	red	cells 	The	parsimonious	regression	model	that	related	the	dependent	variable	‘Platelet	Usage	per	1000	Population’	to	the	explanatory	variables	displayed	one	significant	predictor	–	Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population	and	two	marginally	negatively	correlated	ones	–	‘Per	Cent	Population	over	65	Years’	and	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	Excluding	Non-melanoma	Skin	Cancers’	(Table	4.8).	This	model	explained	31%	of	the	total	variance	(Table	4.9).					
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
t 
P-
value B Std. Error Beta 
 
(Constant) 28.979 11.047  2.623 0.017 
Per Cent population over 65 Years 1.377 0.479 0.414 2.873 0.010 
Health Care Expenditure per Capita 
US$ Purchasing Power Parity 
0.002 0.001 0.410 3.031 0.007 
Population Density - Persons per 
Square Kilometre 
-0.022 0.010 -0.292 -2.098 0.050 
Prevalence of Coronary Artery 
Bypass Surgery per 100,000 
Population 
0.151 0.040 0.515 3.755 0.001 
Age-standardised Rate per 100,000 
Population for HL, NHL, Leukaemia & 
MM 
-0.960 0.308 -0.458 -3.117 0.006 
R R Square Adjusted R Square Std. Error of the Estimate 
0.840 0.705 0.627 4.91643 
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Table	4.8: Coefficients for platelet usage as dependent variable 
 			Table	4.9:	Model	summary	-	platelets		The	parsimonious	regression	model	that	related	the	dependent	variable	‘Plasma	Usage	per	1000	Population’	to	the	explanatory	variables	identified	2	predictors	using	a	backward	procedure	(Table	4.10).	One	of	them	is	marginally	positively	correlated	and	the	other	is	negatively	correlated:	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’	(P-value	=	0.053);	and	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	(P-value=	0.038).	However,	this	two-	predictor	model	explained	only	24.7%	of	the	total	variance	(Table	4.11).		
Table 4.10: Coefficients for plasma usage as dependent variable 
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
t P-value B Std. Error Beta 
(Constant) 11.877 3.923  3.028 0.006 
Per Cent Pop over 65 -0.201 0.110 -0.362 -1.832 0.081 
Prev CABS per 100,000 Pop 0.026 0.009 0.527 2.743 0.012 
All Cancers exc Non-melanoma Skin 
Cancers – Age Std Rate per 
100,000 Pop 
-0.017 0.010 -0.359 -1.777 0.090 
R R Square Adjusted R Square Std. Error of the Estimate 
0.556 0.310 0.211 1.19381 
Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
t P-value B Std. Error Beta 
 
(Constant) 16.357 4.447  3.678 0.001 
Prevalence of Coronary Artery 
Bypass Surgery per 100,000 
Population 
0.057 0.028 0.393 2.049 0.053 
Age Standardised rate per 100,000 
population for HL, NHL, Leukaemia 
& MM 
-0.442 0.200 -0.423 -2.208 0.038 
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		Table	4.11:	Model	summary	–	plasma		
4.3.1.3	Country	ranking		The	22	KPIs	(predictors),	in	Table	4.2	page	70,	for	each	country	were	combined	together	to	rank	the	individual	country’s	health	system	performance.	Using	IBM©	SPSS©	Statistics	for	Macintosh©	Version	20.0	each	variable	was	standardised	to	have	a	mean	of	0	and	a	standard	deviation	of	1.	The	missing	values	were	then	replaced	by	0.	A	number	of	clinical	outcomes,	more	specifically	1	–	6	and	15	–	19,	may	be	termed	negative	statements	since	larger	values	in	the	variable	column	signify	poorer	performance	as	opposed	to	the	rest	of	the	variables	where	larger	values	in	the	variable	column	correspond	to	better	performance.	In	the	case	of	the	former	variables,	the	standardised	score	obtained	was	multiplied	by	-1	such	that	the	larger	values	in	the	variable	column	would	have	a	negative	score	and	the	smaller	values	in	the	column	would	have	a	positive	score.	This	computation	was	performed	to	correct	for	the	directionality	of	the	negative	statements	to	enable	a	summation	of	the	scores	pertaining	to	each	country	with	a	view	to	ranking	the	health	system	performance	of	each	country	(Table	4.12).		
R R Square Adjusted R Square Std. Error of the Estimate 
0.497 0.247 0.178 3.640 
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In	order	to	validate	the	ranking	exercise,	the	scores	obtained	through	this	analyses	were	compared	to	the	Health	Related	sustainable	Development	Goals	Index	published	in	the	Lancet	last	year	(GBD	2015	SDG	Collaborators,	2016)	(Table	4.13).		
	Table	4.13:	Health	system	performance	ranking:	comparison	between	score	based	on	clinical	outcomes	and	the	health	related	sustainable	development	goal	index		The	Pearson	Correlation	between	the	two	groups	of	values	showed	quite	significant	correlation	with	a	Pearson	Correlation	Coefficient	of	0.756	with	a	
Countries Total	Score Health	Related	
Sustainable	
Development	
Goals	Index	
(Lancet	2016)
Iceland 15.24 85
Sweden 14.59 85
Norway 13.50 81
Switzerland 13.44 78
Italy 9.57 78
Finland 9.31 82
Spain 8.11 82
Australia 7.57 81
Netherlands 7.43 82
France 7.04 77
Canada 6.25 81
Germany 4.25 80
Belgium 3.98 79
New	Zealand -0.43 74
United	States -3.85 75
Denmark -5.27 79
United	Kingdom -5.87 82
Ireland -6.30 81
Slovenia -8.19 76
Austria -10.92 74
Czech	Republic -11.10 74
Slovakia -18.25 73
Hungary -24.58 73
Estonia -25.52 74
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P-value	of	0.000019.	This	demonstrated	strong	concordance	between	the	two	sets	of	values.		A	Pearson	Correlation	was	computed	to	measure	the	strength	of	the	relationship	between	‘Red	Cell	Usage	per	1,000	Population’,	‘Platelet	Usage	per	1,000	Population’	and	‘Plasma	Usage	per	1,000	Population’	(Table	3.4,	page	42)	on	the	one	hand	and	the	standardised	score	(Table	4.12)	obtained	through	the	previous	analysis	(Table	4.14).		Pearson	Correlation	 Standardised	Score	Red	Cell	Usage	per	1000	population	 Correlation	Coefficient	 0.107	P-value	 0.620	Platelet	Usage	per	1000	population	 Correlation	Coefficient	 0.258	P-value	 0.223	Plasma	Usage	per	1000	population	 Correlation	Coefficient	 -0.122	P-value	 0.569	Table	4.14:	Correlation	analysis	between	blood	product	usage	and	the	standardised	score		All	Pearson	correlations	(0.107,	0.258	and	-0.122)	are	close	to	0	indicating	that	each	relationship	is	rather	weak.	Moreover,	the	p-values	(0.620,	0.223	and	0.569)	all	exceed	the	0.05	level	of	significance	indicating	that	each	pairwise	relationship	is	not	significant.	
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4.4	Discussion		The	analyses	performed	in	the	previous	section	suggests	that	for	red	cell	transfusion	rates	per	capita,	most	(70%)	of	the	apparent	variation	in	usage	between	countries	can	be	explained	by	a	number	of	underlying	contributors	that	are	peculiar	to	each	country.	The	models	for	platelet	use	and	plasma	use,	however,	could	explain	a	lesser	amount	of	the	variation.		
4.4.1	Population	demographics	Population	demographics,	more	specifically	the	‘Per	Cent	Population	over	65	Years’	is	clearly	associated	with	the	variation	in	usage	at	least	for	red	cells.	The	extent	of	the	correlation	is	substantial	as	demonstrated	by	the	high	Pearson	Correlation	figure	of	0.556,	the	second	highest	in	the	analysis.	This	predictor	is	also	the	highest	contributor	in	the	regression	model	for	red	cells	after	the	constant.		This	is	congruent	with	data	found	in	the	literature	showing	a	disproportionate	increase	in	blood	usage	in	the	elderly	population	as	demonstrated	in	the	following	examples:	A	Belgian	study	published	in	2007,	reviewing	the	data	for	the	year	2000,	showed	that	patients	over	65	years	of	age	accounted	for	more	than	66%	of	individuals	receiving	blood	(Beguin	et	
al.,	2007).	Wells	and	co-workers,	in	a	retrospective	multi-centre	epidemiological	study	in	the	UK	showed	that	the	median	age	for	red	cell	recipients	was	69	years	and	for	FFP	recipients	it	was	64	years	while	that	for	platelet	recipients	was	59	years	(Wells	et	al.,	2009).	Also,	in	Finland	70-	to	80-year	olds	have	been	shown	to	have	an	8-fold	higher	consumption	than	20-	to	40-year	olds	(Ali	et	al.,	2010).			
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The	analyses	presented	above	partially	parallels	modelling	performed	by	Ali	et	al	in	their	2010	paper,	where	red	cell	usage	according	to	Finnish	practice	was	superimposed	on	to	the	population	demographics	of	other	countries	(Ali	
et	al.,	2010).	One	conclusion	that	this	study	makes,	that	the	increasing	population	of	elderly	patients	in	most	countries	will	have	significant	impact	on	the	demand	for	red	cells,	is	corroborated	by	the	findings	in	this	chapter.	However,	the	authors	went	on	to	comment	that	the	difference	in	usage	observed	between	the	lowest-using	country	and	the	highest-using	country	can	be	fully	explained	by	the	different	national	population	pyramids,	a	position	which	was	endorsed	also	by	Seifried	et	al	(Seifried	et	al.,	2011).	This	is	in	contrast	with	the	current	findings.	Both	the	linear	correlation	process	and	the	regression	analysis	have	shown	that	population	demographics,	more	specifically	‘Per	cent	population	over	65	Years’,	though	certainly	quite	significant,	is	only	one	of	a	number	of	factors	(some	of	which	may	not	even	have	been	addressed	in	this	particular	analysis)	that	partially	explain	the	variance.	Moreover,	even	all	together,	the	predictors	identified	by	the	regression	model	were	only	capable	of	addressing	70%	of	the	variation.		
4.4.2	Clinical	drivers	of	blood	product	use	
4.4.2.1		‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’	This	predictor	was	the	most	consistent	across	most	analyses.	Correlation	was	shown	with	red	cell	use	in	both	the	linear	correlation	and	the	regression	analysis.	The	Pearson	correlation	in	relation	to	platelet	use	demonstrated	a	marginally	significant	relationship,	as	did	the	regression	analyses	performed	with	platelet	usage	and	plasma	usage	in	turn	as	the	dependent	variables.			The	association	between	cardiac	surgery	and	high	red	cell	use	is	not	surprising	and	well	known	(Stover	et	al.,	1998)	with	20%	of	all	blood	products	transfused	worldwide	being	attributed	to	coronary	artery	bypass	graft	procedures	(Snyder-Ramos	et	al.,	2008).	The	US	2011	Nationwide	
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survey	quotes	a	figure	of	50%	of	all	platelets	transfused	being	used	in	cardiac	surgery	(Department	of	Health	and	Human	Services,	2013).	Fairly	recent	studies	have	continued	to	confirm	this,	including	a	review	of	data	on	364,532	surgical	in-hospital	stays	in	Belgium	which	showed	that	8%	of	the	surgical	transfusion	costs	were	associated	with	coronary	artery	bypass	surgery	(Beguin	et	al.,	2007)	and	in	Finland,	of	all	blood	components	used,	16%	were	transfused	for	cardiac	and	circulatory	disorders	(Ali	et	al.,	2010).	Similarly	in	Germany,	cardiac	surgery	is	responsible	for	almost	30%	of	red	cell	use,	(Greinacher	et	al.,	2010).	Increasingly,	though,	patients	with	coronary	artery	disease	are	undergoing	medical	interventions	such	as	stenting	rather	than	coronary	artery	bypass	surgery	(Fajadet	&	Chieffo,	2012).	These	non-surgical	interventions	are	associated	with	less	usage	of	blood	products	and	therefore,	in	the	future,	transfusion	in	this	category	of	patient	can	be	expected	to	decrease.			
4.4.2.2	‘Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population’	The	significantly	positive	correlations	of	‘Prevalence	of	Hip	Replacement	Surgery	per	100,000	Population’	with	a	high	number	of	other	predictors	led	to	a	dilution	of	its	effect	on	‘Red	Cell	Usage	per	1000	Population’	when	all	the	predictors	were	included	in	a	Regression	Model	and	it	lost	its	initial	significance	as	an	independent	predictor.			
4.4.2.3	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	
&	MM’;	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	
Excluding	Non-melanoma	Skin	Cancers’		Both	these	predictors	were	negatively	correlated	with	blood	product	use.	In	the	Pearson	Correlation	‘Age-standardised	Rate	per	100,000	Population	for	HL,	NHL,	Leukaemia	&	MM’	correlated	marginally	with	red	cell	use	and	
86	
significantly	with	Plasma	use.	This	correlation	was	confirmed	in	both	corresponding	regression	models.	‘Age-standardised	Rate	per	100,000	Population	for	All	Cancers	Excluding	Non-melanoma	Skin	Cancers’	was	significantly	negatively	correlated	with	platelet	use	in	the	Pearson	correlation,	however	the	significance	decreased	to	a	marginal	level	in	the	corresponding	regression	model.	This	predictor	was	also	marginally	negatively	correlated	to	plasma	use	in	the	Pearson	correlation,	a	finding	which	was	completely	absent	in	the	corresponding	regression	model.			A	number	of	studies	have	shown	that	malignancies	are	associated	with	high	blood	use.	A	review	of	data	on	589,936	medical	in-hospital	stays	in	Belgium,	showed	that	oncological	patients	including	individuals	with	haematological	malignancies	were	responsible	for	around	40	%	of	transfusion	costs	(Beguin	
et	al.,	2007).	In	Finland,	haematological	malignancies	were	responsible	for	21%	of	transfusions	(Ali	et	al.,	2010),	and	in	Germany	around	10%	(Greinacher	et	al.,	2010).			The	relationship	between	blood	product	use	and	a	country’s	burden	of	malignancy	is	a	complex	relationship.	Cancer	incidence	is	known	to	increase	with	a	country’s	wealth,	while	mortality	from	cancer	has	an	inverse	relation	with	markers	of	prosperity,	as	does	the	mortality/incidence	ratio	(Ades	et	al.,	2013).	Predictors	for	cancer	incidence	include	lifestyle,	nutrition	and	infections	(World	Health	Organisation,	2003),	all	effectors	for	other	diseases	which	would	themselves	have	an	impact	on	blood	product	use.		Further	analyses	allowed	some	more	insight	into	this	relationship.	Platelet	usage	was	found	to	correlate	significantly	with	5-year	survival	in	patients	with	colorectal	cancer	and	was	found	to	have	an	inverse	relation	with	deaths	from	cancer.	Or,	patients	with	cancer	fare	better	in	countries	where	more	platelets	are	used.	In	general,	patients	experience	better	survival	within	the	context	of	health	services	which	provide	good	access	to	care,	more	screening	for	cancer	and	better	treatment	for	cancer.	These	conditions	are	commoner	
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in	countries	with	better	funded	services.	Platelets	are	the	more	expensive	blood	product	amongst	the	three.	In	the	United	States,	a	platelet	unit	would	cost	2.5	times	the	price	of	a	red	cell	pack	and	5	times	a	plasma	pack	(Toner	et	
al.,	2011),	and	in	the	UK,	the	NHS	blood	component	price	list	indicates	prices	of	£120.00	for	standard	red	cells,	£193.15	for	platelets	and	£28.46	for	plasma	(NHS	Blood	and	Transplant,	2016).	The	point	can	perhaps	be	argued,	therefore	that	platelets,	being	the	more	expensive	product,	are	used	more	in	countries	with	better	funded	health	services.			
4.4.3	Funding	
4.4.3.1	‘Health	Care	Expenditure	per	Capita	(Current	US$	Purchasing	Power	
Parity)’;	‘Gross	Domestic	Product	per	Capita	(Current	US$)’;	‘Human	
Development	Index’		Of	these	3	predictors,	the	analysis	draws	attention	to	‘Health	Care	Expenditure	per	Capita	(Current	US$	Purchasing	Power	Parity)’.	Initially	there	appeared	to	be	no	relationship	between	this	predictor	and	‘Red	Cell	Usage	per	1000	Population’	in	the	Pearson	correlation	(Pearson	Correlation	=	0.308,	p-value	=	0.110).	However,	an	additional	analysis	correlating	red	cell	use	with	health	spending	while	controlling	for	population	over	65	showed	a	significant	relationship	(Pearson	correlation	=	0.430,	p-value	=	0.032).	The	regression	analysis	also	portrayed	a	striking	significance	between	this	predictor	and	‘Red	Cell	Usage	per	1000	Population’	(p	value	=	0.007).	A	similar	relationship	was	not	present	in	the	platelet	and	plasma	analyses.		Funding	of	Blood	Establishments	is	normally	determined	by	the	revenue	made	from	the	sale	of	blood	products.	Different	mechanisms	exist.	The	two	main	funding	models	are	(1)	actual	revenue	made	from	billing	hospitals	for	the	blood	products	provided,	or	(2)	drawing	down	a	budget	from	the	national	
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health	service	with	blood	products	being	supplied	to	hospitals	free	of	charge.	The	operating	revenue	of	these	not-for-profit	institutions	is	quite	substantial	e.g.	
• Finland	–	Finnish	Red	Cross	Blood	Service:	>€74,000,000	(Finish	Red	Cross	Blood	Service,	2010)	
• UK	–	NHS	Blood	and	Transplant:	>£550,000,000	(NHS	Blood	and	Transplant,	2010)	
• Netherlands	–	Sanquin:	>€353,000,000	(Sanquin,	2010)	
• Ireland	–	Irish	Blood	Transfusion	Service:	>€110,000,000	(Irish	Blood	Transfusion	Service,	2010)		A	case	for	supply-driven	use	may	certainly	be	argued	especially	in	countries	where	the	distinction	between	the	haematologists	working	within	the	Blood	Establishments,	who	therefore	manage	blood	collection,	and	the	haematologists	working	on	the	hospital	floor,	and	therefore	requesting	blood	components	for	their	patients,	is	blurred.		The	correlation	together	with	the	point	made	in	the	previous	section	(4.4.2.3)	suggests	the	very	real	possibility	of	a	relationship	with	supply-sensitive	care,	a	concept	that	is	described	by	Wennberg	in	his	book	Tracking	Medicine	(Wennberg,	2010),	and	that	contributes	towards	unwarranted	variation.	This	is	a	phenomenon	that	was	identified	during	the	1970’s	and	1980’s	in	the	USA	when	a	number	of	studies	showing	geographic	variation	of	care	(Wennberg	&	Gittelsohn,	1973)	concluded	that	patient	care	did	not	necessarily	depend	only	on	the	severity	of	the	condition	or	on	patient	choice	of	treatment	but	also	on	the	ease	of	availability	of	materials	and	services	to	the	caring	physician.	Significantly,	in	his	treatise	on	the	subject,	Wennberg	goes	on	to	make	the	statement	that	more	is	not	necessarily	better.	This	premise	adds	credence	to	the	fact	that	physicians’	decisions	on	transfusion	are	not	always	based	on	evidence-based	practice	but	are	also	influenced	by	increased	availability	of	
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blood	components.	This	concept	will	be	analysed	in	further	depth	in	the	next	chapter.		
4.4.4	Population	density	The	inverse	relation	to	‘Population	Density	–	Persons	per	Square	Kilometre’	may	be	a	reflection	of	the	higher	stock	of	blood	components	remote	hospitals,	in	countries	with	large	areas	which	are	sparsely	populated,	are	forced	to	carry	in	order	to	ensure	that	they	can	cover	for	all	eventualities.	Remote	hubs	have	to	carry	enough	blood	products	to	cope	with	emergencies	and	disasters,	as	one	cannot	always	afford	to	wait	long	enough	for	supplies	to	reach	these	areas.	On	the	other	hand,	hospitals	in	areas	of	countries	where	population	density	is	higher,	are	more	likely	to	be	situated	closer	to	each	other	and	therefore	may	possibly	rely	on	timely	help	from	neighbouring	depots.	A	point	that	lends	some	weight	to	this	hypothesis	is	that	when	reporting	blood	component	usage,	as	pointed	out	earlier	in	the	chapter,	some	countries	actually	use	a	surrogate	value	–	‘blood	components	distributed’,	which	though	close	enough	to	the	actual	usage,	may	be	slightly	inflated	by	the	extra	components	that	are	distributed	to	remote	hubs,	only	to	be	discarded	when	not	used.		
4.4.5	Country	ranking	The	key	performance	indicators	chosen	for	this	analysis	reflect	the	diversity	of	the	processes	occurring	all	along	the	pathway	to	health	service	delivery	including	funding,	human	resources,	equipment,	bed	availability,	ease	of	access,	policy	penetrance,	etc.	The	ranking	obtained	using	this	analysis	was	validated	by	a	comparison	to	the	Health	Sustainable	Goal	index	(GBD	2015	SDG	Collaborators,	2016),	a	tool	based	on	the	Global	Burden	of	Diseases	Project,	designed	to	provide	data	to	policymakers	helping	them	to	understand	the	nature	of	their	individual	country’s	health	challenges,	and	allowing	them	therefore	to	implement	strategies	to	improve	their	health	
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systems.	It	is	based	on	premature	death	and	disability	data,	by	age	and	sex	from	1990	to	the	present,	for	more	than	300	diseases	in	almost	200	countries,	as	collected	and	analysed	by	more	than	1800	collaborators	in	124	countries	(www.healthdata.org/gbd).	A	highly	standardised	approach	is	used	to	overcome	issues	of	inconsistent	coding	and	definitions	and	a	number	of	mechanisms	have	been	put	in	place	to	ensure	independence,	to	review	progress	and	to	provide	recommendations	(Murray	et	al.,	2013).	Very	tight	concordance	was	demonstrated	between	the	two	tools.			The	analysis	showed	that	blood	product	usage	does	not	predict	for	overall	health	system	performance	and	neither	does	better	health	system	performance	predict	for	any	particular	usage	of	any	of	the	blood	products.		
4.5	Conclusion		Up	to	this	point,	the	following	has	been	established:	1. There	is	significant	variation	between	the	rates	of	usage	of	blood	components	across	a	number	of	countries	though	this	does	not	correlate	with	overall	health	service	performance.	The	variation	therefore	cannot	be	explained	by	different	health	system	outcomes	but	must	be	related	to	other	reasons.	2. The	rate	at	which	blood	products	are	used,	seems	to	be	associated	with	a	number	of	predictors	which	can	contribute	to	a	portion	of	the	variation	in	blood	product	usage	across	different	countries.	These	predictors	include	a) The	percentage	of	the	country	population	that	is	over	65	years	of	age	b) The	population	density	within	the	specific	country	c) Clinical	activity	as	represented	by	CABG	and	the	burden	of	cancer	
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d) Amount	of	funding	within	the	individual	country’s	health	services	3. A	certain	amount	of	residual	variation	is	unexplained	by	the	predictors	identified.		It	is	certainly	clear	that	the	variation	in	blood	product	usage	across	countries	cannot	all	be	explained	away	simply	by	invoking	an	argument	centred	around	a	different	demographic,	namely	the	percentage	of	the	population	over	65	years	in	the	individual	countries,	as	others	have	done	(Ali	et	al.,	2010;	Seifried	et	al.,	2011).	Differences	in	clinical	activity,	and	the	variable	scoping	in	health	care	funding,	also	demonstrably	contribute	to	this	variation.	Out	of	all	this	arises	an	important	question	surrounding	the	relationship	of	these	variables	with	blood	product	usage,	i.e.	whether	the	variation	seen	is	representative	purely	of	a	different	burden	of	disease	in	the	different	countries	(and	regions),	and	therefore	constitutes	effective	care,	or	whether	there	may	be	an	element	of	it	that	is	supply-related	and	could	therefore	represent	unwarranted	variation.	This	query	is	the	central	topic	dealt	with	in	the	next	chapter.		 	
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5.	Effectors	of	Variation	in	Blood	Transfusion	Practices	
5.1	Unwarranted	Variation	in	Health	Care		In	2014	an	OECD	publication	looking	at	variation	in	health	care	both	across	and	within	13	countries,	focusing	on	a	selected	set	of	high	volume	and	high-cost	health	care	activities,	reported	that	there	is	substantial	evidence	to	suggest	that	large	geographic	differences	in	health	care	provision	are	not	consistent	with	disease	burden	or	indeed,	with	patient	preference.	Rather	it	appears	that	in	areas	of	high	activity,	unnecessary	care	is	being	provided.	Differences	in	supply	of	services,	and	diversity	in	medical	practices	were	cited	as	playing	significant	contributory	roles	towards	creating	this	variation	(Organisation	for	Economic	Co-operation	and	Development,	2014).	This	forms	part	of	a	body	of	literature	on	unwarranted	variation	in	healthcare	reporting	diagnostic	and	interventional	practices	that	are	dependent	on	geographic	location	on	a	country	by	country	basis	or	on	a	region	by	region	basis.	In	truth,	the	concept	that	a	number	of	medical	procedures	may	be	unnecessary,	and	may	result	in	harm	to	the	patient	rather	than	benefit,	is	an	old	one	(Glover,	1938).	Much	of	the	published	work	on	geographical	variation	in	health	care	provision	details	the	significant	difference	in	practice	across	regions.			Considered	a	seminal	paper,	John	Wennberg’s	original	publication,	in	1973,	examined	the	extent	to	which	bed	and	manpower	use,	expenditure	and	procedure	utilization	varied	among	hospital	service	areas	in	the	state	of	Vermont	(Wennberg	&	Gittelsohn,	1973).	The	authors	found	large	differences	in	neighbouring	communities	a	mere	20	miles	apart	which,	they	explained,	were	based	more	on	behavioural	and	distributional	differences	than	on	
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differences	in	illness	patterns.	Wennberg	and	his	colleagues	went	on	to	establish	the	Dartmouth	Atlas	of	Health	Care	through	which	much	of	the	notional,	methodological	and	illustrative	work	on	variation	in	health	care	provision	in	the	USA	was	performed	(www.dartmouthatlas.org).	Apart	from	consistently	showing	that	the	identified	extensive	small-area	variations	in	care	delivery	cannot	be	explained	by	illness	and	patient	behaviour,	their	work	also	highlights	the	fact	that	usage	is	influenced	by	attributes	of	the	local	physicians,	and	that	physician	opinion	acts	as	a	driver	of	demand	for	surgery.	Patterns	of	practice	variation	were	uncovered.	In	surgery,	there	was	marked	variation	for	specific	procedures	which	were	distinctive	and	persistent	over	time,	for	example	the	rate	of	tonsillectomy	in	the	highest	performing	state	was	10	times	that	of	the	lowest	performing	state.	Hospitalisation	rates	for	acute	and	chronic	medical	conditions	were	consistent	from	one	cause	of	admission	to	another.	However	a	region	tended	to	have	high	rates	or	low	rates	in	general.	A	few	conditions	stood	out,	in	that	variation	was	consistently	low	across	the	board.	This	happened	with	conditions	such	as	myocardial	infarctions,	gastro-intestinal	bleeds	and	strokes,	and	procedures	like	colectomy	for	colon	cancer,	herniorrhaphy,	and	hip	repair.			All	this	was	mirrored	by	similar	work	carried	out	in	other	countries	where	similar	initiatives	were	taken	and	atlases	documenting	geographic	variation	were	set	up.	These	resources	are	now	available	in	Canada	(www.ices.on.ca)	(Eskander	et	al.,	2015),	England	(www.fingertips.phe.org.uk)	(Public	Health	England,	2015),	Australia	(www.safetyandquality.gov.au)	(Australian	Commission	on	Safety	and	Quality	in	Health	Care,	2015),	and	Spain	(www.atlasvpm.org)	(Tebe	et	al.,	2013).	ECHO,	or	the	European	Collaboration	for	Healthcare	Optimisation	is	a	recent	initiative,	funded	through	a	European	Framework	7	grant,	led	by	a	Spanish	team	from	the	Aragon	Health	Sciences	Institute	(IACS)	in	collaboration	with	partners	from	Denmark,	Portugal,	Austria,	England	and	Slovenia	(www.echo-health.eu).	This	group	put	together	a	number	of	atlases	reporting	unwarranted	
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differences	in	health	systems	performance	across	the	various	participating	countries	(Garcia	Armesto	et	al.,	2014).			A	recent	systematic	review	of	the	literature	on	medical	practice	variations	included	836	publications	(between	2000	and	2011)	that	met	the	study	criteria.	All	showed	significant	variation	across	regions,	hospitals	and	physician	practices	in	the	treatment	of	many	conditions	and	the	supply	of	resources	both	between	and	within	OECD	countries.	Many	of	the	publications	included	in	the	review	looked	at	specific	clinical	conditions	mostly	cancer,	cardiovascular,	gynaecological,	musculoskeletal	and	respiratory	diseases.	Variation	studies	in	immunization,	screening	and	diagnostic	testing	were	very	prominent	with	the	last	category	showing,	for	example,	a	70-fold	difference	in	the	frequency	of	CT	scans	ordered	for	specific	conditions	and	a	50-fold	difference	in	diagnostic	MRI	scans	ordered	for	breast	cancer	across	hospitals	in	Ontario,	Canada.	Publications	looking	at	medical	admissions,	elective	surgical	admissions,	and	the	supply	of	health	care	resources	per	capita	such	as	physician	supply,	bed	supply	and	advanced	technology	(e.g.	mammography	units)	were	also	well	represented	(Corallo	et	al.,	2014).		This	variation	in	practice	is	echoed	by	the	variation	in	blood	product	usage	shown	earlier	on.	A	variation	that	also	appears	to	follow	higher	levels	of	activity.		
5.1.1	Sources	of	unwarranted	variation	Based	on	this	literature,	a	theoretical	model	(Figure	5.1)	has	been	proposed	mainly	by	the	Dartmouth	Atlas	researchers	identifying	three	categories	of	service	(Table	5.1)	that	helps	explain	unwarranted	variation,	which	is	defined	as	medical	practice	variation	across	regions	or	provider	groups	that	is	not	explained	on	the	basis	of	illness	or	patient	need.			
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										Figure	5.1:	Service	categories	encapsulating	unwarranted	variation	representing	underuse	of	effective	care,	misuse	of	preference	sensitive	care	and	overuse	of	supply	sensitive	care	(adapted	from	Dartmouth	Atlas	Project)			
Effective	Care1	 Effective	care	refers	to	services	that	are	of	proven	value	and	have	no	significant	tradeoffs	–	i.e.	the	benefits	of	the	services	so	far	outweigh	the	risks	that	all	patient	with	the	specific	medical	need	should	receive	them	
Preference-sensitive	Care2	
Preference-sensitive	care	comprises	treatments	that	involve	significant	tradeoffs	affecting	the	patient’s	quality	and/or	length	of	life.	Decisions	about	these	interventions	–	whether	to	have	them	or	not,	which	ones	to	have	–	ought	to	reflect	the	patients’	personal	values	and	preferences,	and	ought	to	be	made	only	after	patients	have	enough	information	to	make	an	informed	choice.	Sometimes	the	scientific	evidence	on	the	main	outcome	is	quite	good;	other	times	the	evidence	is	weaker	
Supply-sensitive	Care3	
Supply-sensitive	care	is	care	whose	frequency	of	use	is	not	determined	by	well-articulated	medical	theory,	much	less	by	scientific	evidence.	Supply-sensitive	services	include	doctor	visits,	diagnostic	tests	and	hospitalisations.	The	use	of	supply-sensitive	care	varies	widely	across	regions	within	countries	and	across	countries.	Where	there	is	greater	capacity,	more	care	is	delivered	–	whether	or	not	it	is	warranted	Table	5.1:	Definitions	of	effective	care;	preference-sensitive	care;	supply-sensitive	care	[1	-	(Dartmouth	Atlas	Project,	2007a);	2	-	(Dartmouth	Atlas	Project,	2007b);	3	-	(Dartmouth	Atlas	Project,	2007c)]		
Effective	Care	
Preference	Sensitive	Care	
Supply	Sensitive	Care	
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Part	of	this	geographic	variation	has	been	attributed	to	over-utilisation	(Emanuel	&	Fuchs,	2008).	Over	the	years	it	has	been	robustly	shown	that	due	to	a	number	of	considerations,	ranging	across	methods	of	physician	remuneration,	increased	availability	of	resources,	fear	of	litigation,	and	culture	and	physician	attitudes,	this	variation	in	practice	contributes	to	overdiagnosis	and	overtreatment	which	wastes	resources	and	may	even	effectively	lead	to	patient	harm	(Hicks,	2015;	Ralston	&	Schroeder,	2015).			Though	no	formal	definition	exists	for	over-diagnosis	(Carter	et	al.,	2015),	it	has	come	to	represent	a	state	of	affairs	where,	as	a	consequence	of	a	number	of	issues,	individuals	are	diagnosed	with	conditions	that	would	never	cause	symptoms	or	morbidity	had	they	remained	un-diagnosed	(Malhotra	et	al.,	2015).	This	can	then	lead	to	over-treatment	a	term	that	includes	(i)	treatment	of	these	over-diagnosed	conditions	and	(ii)	also	encompasses	treatment	that	has	minimal	evidence	of	benefit	or	is	excessive	relative	to	alternative	accepted	standards	(Malhotra	et	al.,	2015).	A	classic	example	of	this	is	transfusing	blood	products	to	patients	whose	clinical	circumstances	do	not	require	them,	a	common	enough	situation	in	many	hospitals.	Both	types	of	over-treatment	have	the	potential	of	causing	patient	harm.	In	the	cases	brought	about	by	over-diagnosis	harm	can	happen	either	directly	e.g.	radiation	from	unnecessary	imaging,	or	indirectly	when	it	leads	to	unnecessary	downstream	treatment.	Unnecessary	treatment	also	has	the	potential	for	both	anticipated	and	unanticipated	negative	consequences	a	significant	possibility	also	associated	with	blood	transfusion	as	evidenced	by	the	haemovigilance	data	highlighted	in	Chapter	Three.			Over-diagnosis	and	over-treatment	have	been	grouped	together	under	the	term	‘Over-use’,	a	phenomenon	that	has	been	recognized	to	contribute	to	the	projected	unsustainability	of	quality	health	care	worldwide.	In	the	USA	it	is	estimated	that	around	a	third	of	medical	practice	may	qualify	as	‘Over-use’	(Institute	of	Medicine,	2012).	Similar	findings,	though	perhaps	not	to	as	large	
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an	order,	are	also	found	in	other	countries	(Malhotra	et	al.,	2015;	Vogel,	2015).			
5.1.2	Supply	sensitive	care	as	a	source	of	unwarranted	variation	Supply	sensitive	care,	a	term	coined	by	Wennberg	in	the	seventies,	and	later	incorporated	into	the	model	of	service	proposed	by	the	Dartmouth	Atlas	refers	to	the	influence	supply	of	resources	has	on	utilisation	rates	(Wennberg	&	Gittelsohn,	1973).	Within	this	concept,	the	level	of	utilisation	of	beds,	tests	and	procedures	is	therefore	not	dependent	on	any	specific	medical	evidence	but	is	a	consequence	of	local	capacity.	Therefore	in	regions	where	more	hospital	beds	per	capita	are	available,	hospital	admissions	rates	are	higher;	in	areas	with	more	doctors	per	capita,	more	specialist	visits	occur;	and	where	more	CT	scanners	are	available,	more	CT	scans	are	performed	on	patients	(Wennberg,	2010).	These	relationships	have	been	demonstrated	quite	consistently	(www.dartmouthatlas.org).	The	converse	is	also	true	in	that	where	there	are	fewer	medical	resources	less	utilisation	occurs,	and	therefore	patients	receive	less	care.	These	latter	patients,	though,	do	not	experience	any	less	survival	or	poorer	quality	of	life	when	compared	to	their	counterparts	in	other	geographic	locations	that	have	more	resources	and	consequent	higher	health	care	spending	(Rothberg	et	al.,	2010).			The	analysis	in	the	previous	chapter	showed	a	correlation	between	the	availability	of	resources,	in	the	form	of	funding,	and	increased	transfusion	of	blood	products.	It	also	showed	a	relationship	between	high	clinical	activity	and	higher	blood	product	usage.	It	is	therefore	very	plausible	to	extrapolate	that	the	same	factors	also	influence	the	way	doctors	practice	transfusion	medicine.	Over-diagnosis	and	over-treatment	will	have	an	effect	on	blood	product	usage,	since	blood	transfusion	is	used	in	various	surgical	procedures,	in	various	medical	conditions	including	anaemia	and	thrombocytopaenia,	in	hereditary	and	acquired	coagulation	disorders	and	in	haematology	/	oncology	patients.		
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One	driver	for	supply	sensitive	care	is	thought	to	be	Fee	for	Service,	a	re-imbursement	model	where	services	provided	are	un-bundled	and	paid	for	separately.	This	has	been	blamed	for	contributing	to	over-use	as	it	is	implicated	in	incentivising	quantity	rather	than	quality.	Much	has	been	made	of	this,	especially	in	the	USA,	and	recent	legislation	has	attempted	to	re-engineer	re-imbursement	processes	into	associating	payment	with	quality	or	value	(McMahon	&	Chopra,	2012).	This	is	by	no	means	a	problem	restricted	to	the	United	States.	A	recent	broadly	inclusive	longitudinal	study	showed	that	higher	reported	achievement	incentivised	under	the	Quality	and	
Outcome	Framework	(QOF	–	a	pay	for	performance	instrument)	in	the	UK	has	not	reduced	premature	deaths	in	the	population	(Kontopantelis	et	al.,	2015).	To	date	no	link	has	been	reported	between	supply-sensitive	care,	or	the	effect	of	fee	for	service	re-imbursement	models,	and	Transfusion	Medicine	(Aubuchon	et	al.,	2010).	Whether	this	link	exists,	and	therefore	blood	product	use	is	also	a	victim	of	supply	sensitive	care,	is	discussed	below.			
5.1.3	Predictors	of	supply	sensitive	care	In	general	terms	supply	sensitive	care	constitutes	the	additional	frequency	of	clinical	activities	such	as	doctors’	visits,	diagnostic	tests	and	hospital	admissions	related	to	the	capacity	of	the	local	health	care	system	(Wallace	et	
al.,	2012).	As	far	as	diagnostic	tests	are	concerned,	it	is	well	known	that	medical	imaging	such	as	computerized	tomography	(CT),	mammography	and	magnetic	resonance	imaging	(MRI),	is	one	of	the	areas	where	over-use	is	common.	It	is	estimated	that	10	–	30%	of	imaging	is	performed	for	inappropriate	indications	(Rubin	et	al.,	2015).	CT	has	been	promoted	incorrectly	for	tumour	detection	(Djulbegovic	&	Paul,	2011),	for	example.	Though	mammography	does	have	some	benefit	in	screening	for	breast	cancer,	analyses	have	shown	that	a	very	small	percentage	of	women	are	actually	helped	by	the	test	(Welch	&	Frankel,	2011).	In	one	study	over	half	the	requests	for	a	MRI	test	were	found	to	be	inappropriate	or	of	uncertain	
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value	(Emery	et	al.,	2013).	Table	5.3,	(page	108),	lists	the	identified	predictors	for	supply	sensitive	care.		
5.1.4	Professional	uncertainty	and	difficulty	with	change	as	
effectors	of	unwarranted	variation	Within	the	context	of	unwarranted	variation,	the	professional	uncertainty	hypothesis	as	defined	by	Wennberg	and	Gittelsohn,	in	1982,	(Wennberg	et	al.,	1982)	takes	into	account	the	degree	of	uncertainty	physicians	face	in	making	decisions.	The	authors	linked	the	diversity	in	surgical	practice	to	differences	in	beliefs	among	doctors	when	it	came	to	considering	the	indication	and	efficacy	of	a	procedure	when	faced	with	circumstances	in	which	clinical	science	was	inadequate.	This	hypothesis	became	one	of	the	central	themes	employed	to	rationalise	unwarranted	variation.		It	was	proposed	that	in	general,	procedures	with	low	variation	such	as	colectomy	for	colon	cancer,	hernia	or	hip	repair,	or	treatment	for	myocardial	infarction	or	gastrointestinal	bleeds	were	ones	where	the	condition	to	be	treated	could	be	reliably	diagnosed,	and	where	there	was	significant	consensus	on	the	value	of	the	procedure.	On	the	other	hand,	high	variation	procedures	like	cardiac	surgery	would	have	the	converse	characteristics	bringing	professional	uncertainty	to	the	fore.	This	theory	has	been	expounded	upon	by	a	number	of	authors	and	has	been	central	to	the	explanations	given	for	variation	both	on	a	regional	level	and	across	countries	(Birkmeyer	et	al.,	2013;	Weeks	et	al.,	2014)	and	has	been	used	also	to	explain	away	variation	in	other	circumstances,	for	example	variation	in	primary	health	care	services	(Grytten	&	Sorensen,	2003).			Evidence	shows	that	clinicians	tend	to	regret	the	consequences	of	unnecessary	treatments,	less	than	the	consequences	of	not	administering	treatment,	especially	when	they	perceive	that	treatment	may	have	led	to	
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some	benefit	(Djulbegovic	&	Paul,	2011).	Therefore	they	tend	towards	giving	the	treatment	to	avoid	uncertainty.	The	medical	culture	of	shame	and	blame	has	been	a	fundamental	of	Western	medical	training	for	generations.	Universal	trust	in	the	limitless	capacity	of	medicine	is	ingrained	in	modern	Western	medical	culture	(Hoffman	&	Kanzaria,	2014).	This	phenomenon	predicates	an	insistence	on	perfect	results	and	a	consequent	lack	of	tolerance	for	what	in	fact	is	inevitable	morbidity	and	mortality.	An	outcome	that	is	less	than	ideal	therefore	becomes	reflective	of	a	perceived	bad	process.	This	inevitably	puts	huge	pressure	on	doctors	to	try	to	be	perfect	and	to	strive	for	‘certainty’	(Kassirer,	1989),	one	consequence	being	that	uncertainty	should	be	avoided	at	all	costs	and	that	one	should	therefore	err	in	favour	of	‘doing	more’.		Lack	or	delay	in	take-up	of	new	evidence	by	doctors	as	it	becomes	available	has	also	been	identified	as	an	issue	in	the	context	of	misuse	or	over-use	in	health	care	services	(Institute	of	Medicine,	2001).	Despite	the	wealth	of	evidence,	its	systematic	and	consistent	application	still	defies	most	institutions	(Oxman	et	al.,	1995).	Though	a	number	of	strategies	have	been	employed	to	alter	this	state	of	affairs,	there	seems	to	be	a	lack	of	effectiveness	in	translating	research	into	practice	(Bero	et	al.,	1998).	The	report	of	the	Institute	of	Medicine,	Crossing	the	Quality	Chasm,	indicates	an	average	lag	of	17	years	for	new	evidence	to	be	introduced	into	daily	practice	(Institute	of	Medicine,	2001).	Research	that	could	have	made	a	difference	has	often	been	ignored	for	a	long	time	e.g.	using	crystalloid	instead	of	colloid	for	volume	replacement	in	shock	(Perel	et	al.,	2013).	The	social	context	within	which	implementation	of	change,	on	foot	of	new	evidence,	occurs	is	of	course	a	determining	factor	and	the	culture	of	each	organisation	plays	a	significant	role	(Stetler,	2003).	Its	capacity	to	identify,	interpret,	share	and	put	new	evidence	in	use	is	critical	(Wensing	et	al.,	2006).	The	promotion	of	a	learning	culture	within	the	organisation	and	proactive	leadership	are	also	very	important	for	the	implementation	of	change	(Nelson	et	al.,	2002).		
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It	is	plausible	to	speculate	that	professional	uncertainty	and	difficulty	with	change	also	hold	true	in	the	practice	of	blood	transfusion.	As	highlighted	in	Chapter	Three,	it	was	less	than	20	years	ago	that	the	first	seminal	double	blind	randomised	trial	looking	at	transfusion	triggers	(Hebert	et	al.,	1999)	was	performed.	Prior	to	that	practice	was	based	mostly	on	tradition	and	anecdotal	experience.	Guidelines	have	incorporated	this	new	evidence	but	it	is	probably	reasonable	to	assume	that	there	is	a	delay	in	putting	this	evidence	into	use.		
5.2	Cultural	Constructs	and	Health	Care		Notions	such	as	avoiding	uncertainty	and	openness	to	change	form	part	of	organisational	culture.	Geert	Hofstede	devised	a	model	through	which	he	measured	the	strength	of	country-specific	cultural	dimensions	within	an	organisation	(Hofstede,	2001).	This	model	is	one	of	the	most	frequently	cited	in	publications	looking	at	behavioural	differences	across	different	countries	(Kirkman	et	al.,	2006).	Hofstede	in	his	model	defines	culture	as	“the	collective	programming	of	the	mind	that	distinguishes	the	members	of	one	group	or	category	of	people	from	another”	(Hofstede	et	al.,	2010).	The	model	is	based	on	systematic	analysis	of	detailed	survey	data	about	the	values	of	employees	working	in	local	subsidiaries	of	a	large	multi-national	corporation:	IBM.	This	revealed	common	problems	but	with	solutions	differing	from	country	to	country	in	specific	dimensions:	1. Social	inequality,	including	the	relationship	with	authority	2. The	relationship	between	the	individual	and	the	group	3. Concepts	of	masculinity	and	femininity	4. Ways	of	dealing	with	uncertainty	and	ambiguity		The	culture	dimensions	were	named	‘Power	Distance’,	‘Collectivism	vs	Individualism’,	‘Masculinity	vs	Femininity’	and	‘Uncertainty	Avoidance’.	Later	
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in	collaboration	with	other	individuals	an	additional	two	dimensions	were	described:	‘Long	vs	Short	Term	Orientation’	and	‘Indulgence	vs	Restraint’	(Table	5.2).																													
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Power	Distance		(pdi)	 The	extent	to	which	the	less	powerful	members	of	institutions	and	organisations	within	a	country	expect	and	accept	that	power	is	distributed	unequally	
Collectivism	vs	Individualism	(idv)	
Individualism	pertains	to	societies	in	which	the	ties	between	individuals	are	loose:	everyone	is	expected	to	look	after	him/herself	and	his	and	her	immediate	family.	Collectivism	pertains	to	societies	in	which	people	from	birth	onward	are	integrated	into	strong,	cohesive	in-groups,	which	throughout	people’s	lifetime	continue	to	protect	them	in	exchange	for	unquestioning	loyalty	
Masculinity	vs	Femininity	(mas)	
A	society	is	termed	masculine	when	emotional	gender	roles	are	clearly	distinct:	men	are	supposed	to	be	assertive,	tough	and	focussed	on	material	success,	whereas	women	are	supposed	to	be	more	modest,	tender	and	concerned	with	quality	of	life.	A	society	is	termed	feminine	when	emotional	genders	overlap:	both	men	and	women	are	supposed	to	be	modest,	tender	and	concerned	with	the	quality	of	life.	Uncertainty	Avoidance	(uai)	 The	extent	to	which	the	members	of	a	culture	feel	threatened	by	ambiguous	or	unknown	situations.	
Long	vs	Short	Term	Orientation	(ltowvs)	
Long	term	orientation	stands	for	the	fostering	of	virtues	oriented	toward	future	rewards	–	in	particular	perseverance	and	thrift.	Short	term	orientation	stands	for	the	fostering	of	virtues	related	to	the	past	and	present	–	in	particular,	respect	for	tradition,	preservation	of	face,	and	fulfilling	social	obligations.	
Indulgence	vs	Restraint	(ivr)	
Indulgence	stands	for	a	tendency	to	allow	relatively	free	gratification	of	basic	natural	human	desires	related	to	enjoying	life	and	having	fun.	Restraint	reflects	a	conviction	that	such	gratification	needs	to	be	curbed	and	regulated	by	strict	norms.	Table	5.2:	Geert	Hofstede’s	culture	dimension	definitions	adapted	from	
Culture	and	Organisations:	Software	of	the	Mind:	Intercultural	Cooperation	
and	its	Importance	for	Survival.	3rd	Edition		Professional	uncertainty	and	difficulty	with	change	are	best	represented	by	3	of	the	dimensions;	the	Uncertainty	Avoidance	Index	(UAI),	the	Power	
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Distance	Index	(PDI),	and	the	Individualism	vs	Collectivism	construct,	since	they	capture	notions	such	as	the	ability	to	cope	with	new	situations,	conformity	with	the	status	quo,	and	dealing	with	uncertainty.	In	this	culture	model,	for	every	country,	each	dimension	is	assigned	a	discrete	value	depending	on	the	positioning	of	the	particular	country	within	the	spectrum	of	the	individual	cultural	dimension.			These	constructs	are	used	below	to	explore	the	extent	blood	transfusion	practice	is	influenced	by	professional	uncertainty	and	difficulty	with	change.	
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5.3	Analyses		
5.3.1	Supply	sensitive	care	A	representative	dataset	(Table	5.3)	comprising	markers	whose	variation	is	associated	with	supply	sensitive	care	has	been	compiled	using	information	from	the	OECD	database	(Organisation	for	Economic	Co-operation	and	Development,	2016a).	The	table	was	populated	with	data	for	2009/2010	or	the	nearest	year.	Data	that	were	missing	were	tabled	as	N/A	or	not	available.	The	markers	are	listed	below	together	with	their	unique	digital	object	identifier	(DOI)	numbers	for	ease	of	reference.		‘Hospital	Beds	Per	1,000	Inhabitants’	(https//doi.org/10.1787/0191328e-en)	and	‘Hospital	Discharges	Per	100,000	Inhabitants’	(https//doi.org/	10.1787/5880c955-en)	are	included	as	markers	for	hospital	activity.	The	markers	representing	diagnostic	tests	and	hospital	equipment	include	‘CT	Scanners	Per	1,000,000	Inhabitants’	(https//doi.org/10.1787/bedece12-en),	‘MRI	Units	Per	1,000,000	Inhabitants’	(https//doi.org/10.1787/1a72e7d1-en),	Mammography	Machines	Per	1,000,000	Inhabitants’	(https//doi.org/10.1787/685c9c5e-en),	‘Radiotherapy	Equipment	Per	1,000,000	Inhabitants’	(https//doi.org/10.1787/47a5492f-en),	‘CT	Exams	Per	1,000	Inhabitants’	(https//doi.org/10.1787/3c994537-en)	and	‘MRI	Exams	Per	1,000	Inhabitants’	(https//doi.org/10.1787/1d89353f-en).	‘Doctors	Consultations	Per	Capita’	(https//doi.org/10.1787/173dcf26-en),	‘Medical	Doctors	Per	1,000	Inhabitants’	(https//doi.org/10.1787/4355e1ec-en),	‘Nurses	Per	1,000	Inhabitants’	(https//doi.org/10.1787/283e64de-en),	‘Medical	Graduates	Per	100,000	Inhabitants’	(https//doi.org/10.1787/ac5bd5d3-en)	and	‘Nurse	Graduates	Per	100,000	Inhabitants’	(https//doi.org/10.1787/c54611e3-en)	represent	professional	staffing	and	clinical	activity.		
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	Statistical	analysis	was	performed	using	IBM®	SPSS®	Statistics	for	Mackintosh	Ver	20.	The	data	in	Table	5	were	used	as	predictors	in	this	analysis	and	the	data	in	Table	3.4	(page	42)	for	blood	product	usage	were	used	as	the	independent	variables.		
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Table	5.3:	Predictors	used	in	analyses	(NA	=	not	available)
	
H
ealth	Activity	and	Resource	Predictors	
Countries	Hospital	Beds	
(Per	1,000	
Inhabitants)	 CT	Scanners	
(Per	1,000,000	
Inhabitants)	 MRI	Units	(Per	
1,000,000	
Inhabitants)	 Mammography	
Machines	(Per	
1,000,000	
Inhabitants)	
Radiotherapy	
Equipment	(Per	
1,000,000	
Inhabitants)	
Doctor	
Consultations	
(Per	Capita)	
Hospital	
Discharges	(Per	
100,000	
Inhabitants)	 CT	Exams	(Per	
1,000	
Inhabitants)	 MRI	Exams	
(Per	1,000	
Inhabitants)	
Medical	
Doctors	(Per	
1,000	
Inhabitants)	 Nurses	(Per	
1,000	
Inhabitants)	
Medical	
Graduates	(Per	
100,000	
Inhabitants)	
Nurse	
Graduates	(Per	
100,000	
Inhabitants)	
Australia	
3.77	
39.14	
5.72	
24.62	
8.90	
6.60	
16593.90	
92.60	
21.20	
3.12	
10.18	
10.88	
63.54	
Austria	
7.68	
29.36	
18.46	
22.29	
5.03	
6.90	
27912.90	
NA	
NA	
4.69	
7.63	
20.69	
48.01	
Belgium	
6.51	
NA	
NA	
NA	
NA	
7.60	
17057.90	
187.10	
65.30	
2.92	
9.42	
7.88	
37.25	
Canada	
2.80	
13.80	
7.91	
16.23	
NA	
7.60	
8282.90	
122.60	
42.70	
2.34	
9.32	
6.95	
45.26	
Czech	Republic	
7.14	
14.17	
5.74	
12.73	
8.52	
11.20	
20899.60	
87.90	
32.30	
3.58	
8.09	
12.63	
13.95	
Denmark	
3.49	
23.72	
15.39	
17.02	
12.67	
4.60	
16031.00	
95.90	
53.50	
3.54	
15.61	
21.80	
83.23	
Estonia	
5.37	
14.99	
7.49	
9.86	
2.25	
6.30	
17566.80	
153.40	
37.40	
3.28	
6.16	
8.99	
35.37	
Finland	
6.25	
20.42	
15.73	
31.65	
8.80	
4.20	
18441.10	
23.80	
34.70	
3.09	
13.56	
9.37	
57.62	
France	
6.66	
11.08	
6.43	
NA	
NA	
6.70	
17036.70	
138.40	
55.10	
3.27	
8.19	
6.87	
34.30	
Germany	
8.24	
31.24	
25.15	
NA	
NA	
9.20	
23670.30	
114.10	
96.40	
3.62	
11.95	
12.29	
45.14	
Greece	
4.93	
34.30	
22.06	
49.88	
5.76	
4.00	
20636.40	
325.00	
99.30	
NA	
NA	
11.57	
25.78	
Hungary	
7.14	
7.18	
2.79	
14.57	
4.09	
11.90	
21189.90	
74.90	
31.50	
3.02	
6.21	
9.21	
33.61	
Iceland	
3.72	
34.54	
21.98	
15.70	
12.56	
6.40	
13936.00	
156.50	
75.70	
3.65	
15.29	
11.62	
64.68	
Ireland	
2.83	
14.99	
11.69	
13.89	
8.38	
3.80	
13024.20	
NA	
NA	
3.01	
12.50	
15.92	
31.75	
Italy	
3.69	
31.85	
21.59	
32.02	
6.33	
6.80	
14238.30	
NA	
NA	
4.17	
6.48	
11.31	
18.31	
Luxembourg	
5.47	
26.12	
14.06	
20.09	
6.03	
6.10	
16081.20	
194.30	
75.50	
2.70	
11.12	
NA	
17.88	
Netherlands	
4.66	
11.25	
10.95	
NA	
NA	
5.70	
11583.80	
65.20	
43.60	
2.92	
11.66	
12.55	
38.24	
New	Zealand	
2.41	
14.64	
9.76	
25.28	
8.37	
4.10	
14555.70	
NA	
NA	
2.58	
9.73	
7.83	
31.21	
Norway	
4.52	
NA	
NA	
NA	
NA	
4.00	
17721.10	
NA	
NA	
4.05	
15.93	
10.69	
72.23	
Slovakia	
6.54	
13.37	
6.13	
14.48	
10.77	
11.60	
18851.70	
85.90	
29.90	
3.30	
6.07	
7.82	
56.83	
Slovenia	
4.60	
11.77	
6.86	
17.16	
5.88	
6.60	
17365.40	
42.60	
20.70	
2.41	
8.03	
7.94	
80.45	
Spain	
3.16	
16.04	
12.41	
14.58	
4.49	
7.50	
10314.00	
85.70	
59.60	
3.60	
4.95	
8.37	
20.43	
Sweden	
2.76	
NA	
NA	
NA	
NA	
2.90	
16245.40	
NA	
NA	
3.82	
11.03	
10.68	
NA	
Switzerland	
5.10	
32.80	
NA	
33.19	
16.92	
4.00	
16873.00	
NA	
NA	
3.83	
15.20	
9.41	
74.10	
United	Kingdom	
3.26	
6.68	
5.51	
8.80	
5.10	
5.00	
13231.70	
NA	
NA	
2.65	
9.75	
13.18	
29.41	
United	States	
3.08	
40.87	
31.52	
41.77	
11.30	
4.10	
13090.70	
252.60	
95.80	
2.44	
10.80	
6.70	
63.43	
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5.3.1.1	Linear	correlation	All	the	markers	were	subjected	to	a	Pearson	Correlation	Coefficient	analysis	using	red	cell,	platelet	and	plasma	usage	per	1000	population	in	turn	as	the	dependent	variables	to	measure	the	linear	correlation	between	each	dependent	variable	and	each	supply	sensitive	care	indicator	identified.	Using	this	tool	a	number	of	health	resources,	hospital	activity,	and	diagnostic	test	markers	were	found	to	correlate	significantly	with	each	of	the	3	dependent	variables	as	tabulated	in	Tables	5.4,	5.5	and	5.6	respectively.			
Significant	Relationships	 Pearson	Correlation	 P-value	
Red	Cell	Usage	per	1,000	Population	-	CT	Scanners	(Per	1,000,000	Inhabitants)	 0.561	 0.005	
Red	Cell	Usage	per	1,000	Population	-	MRI	Units	(Per	1,000,000	Inhabitants)	 0.665	 0.001	
Red	Cell	Usage	per	1,000	Population	-	Mammography	Machines	(Per	1,000,000	Inhabitants)	 0.476	 0.034	
Red	Cell	Usage	per	1,000	Population	-	Hospital	Discharges	(Per	100,000	Inhabitants)	 0.491	 0.011	
Red	Cell	Usage	per	1,000	Population	-	MRI	Exams	(Per	1,000	Inhabitants)	 0.593	 0.009	
Red	Cell	Usage	per	1,000	Population	-	Medical	Doctors	(Per	1,000	Inhabitants)	 0.386	 0.057	
Red	Cell	Usage	per	1,000	Population	-	Medical	Graduates	(Per	100,000	Inhabitants)	 0.425	 0.034	Table	5.4:	Significant	correlations	between	red	cell	use	and	supply	sensitive	care	predictors						
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Table	5.5:	Significant	correlations	between	platelet	use	and	supply	sensitive	care	predictors	
	
	
Significant	Relationships	 Pearson	Correlation	 P-value	
Plasma	Usage	per	1,000	Population	-	Hospital	Discharges	(Per	100,000	Inhabitants)	 0.418	 0.034	
Plasma	Usage	per	1,000	Population	–	CT	Scanners	(Per	1,000,000	Inhabitants)	 0.361	 0.091	
Plasma	Usage	per	1,000	Population	–	MRI	Units	(Per	1,000,000	Inhabitants)	 0.372	 0.088	Table	5.6:	Significant	correlations	between	plasma	use	and	supply	sensitive	care	predictors	
	Supply	sensitive	care	markers	for	diagnostic	tests	were	correlated	with	the	usage	of	all	three	blood	products,	albeit	marginally	so	with	Plasma.		‘CT	Scanners	(Per	1,000,000	Inhabitants)’	and	‘MRI	Units	(Per	1,000,000	Inhabitants)’	correlated	with	all	three	dependent	variables.	P-values	were	<	
Significant	Relationships	 Pearson	Correlation	 P-value	
Platelet	Usage	per	1,000	Population	-	CT	Scanners	(Per	1,000,000	Inhabitants)	 0.524	 0.010	
Platelet	Usage	per	1,000	Population	-	MRI	Units	(Per	1,000,000	Inhabitants)	 0.537	 0.010	
Platelet	Usage	per	1,000	Population	-	Mammography	Machines	(Per	1,000,000	Inhabitants)	
0.633	 0.003	
Platelet	Usage	per	1,000	Population	-	CT	Exams	(Per	1,000	Inhabitants)	 0.570	 0.013	
Platelet	Usage	per	1,000	Population	-	MRI	Exams	(Per	1,000	Inhabitants)	 0.556	 0.017	
Platelet	Usage	per	1,000	Population	-	Nurses	(Per	1,000	Inhabitants)	 0.486	 0.014	
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0.05	level	of	significance	with	‘Red	Cell	Usage	per	1000	population’	and	‘Platelet	usage	per	1000	population’	and	>0.05	<0.1for	‘Plasma	usage	per	1000	population’.	‘Mammography	Machines	(Per	1,000,000	Inhabitants)’	correlated	both	with	‘Red	Cell	usage	per	1000	population’	and	with	‘Platelet	usage	per	1000	population’	as	did	‘MRI	Exams	(Per	1,000	Inhabitants).	‘CT	Exams	(Per	1,000	Inhabitants)’	correlated	with	‘Platelet	Usage	per	1000	population’.		‘Hospital	Discharges	(Per	100,000	Inhabitants)’,	a	marker	of	hospital	activity,	correlated	significantly	with	both	‘Red	Cell	Usage	per	1000	population’	and	with	‘Plasma	Usage	per	1000	population’.		Markers	for	professional	staffing	also	correlated	with	blood	product	usage:	‘Medical	Doctors	(Per	1,000	Inhabitants)’	and	‘Medical	Graduates	(Per	100,000	Inhabitants)’	with	‘Red	Cell	Usage	per	1000	population’;	and	‘Nurses	(Per	1,000	Inhabitants)’	with	‘Platelet	Usage	per	1000	population’.			There	was	also	correlation	amongst	the	diagnostic	test	predictors	themselves.	The	equipment	markers	‘CT	Scanners	(Per	1,000,000	Inhabitants)’,	‘MRI	Units	(Per	1,000,000	Inhabitants)’	and	‘Mammography	Machines	(Per	1,000,000	Inhabitants)’	correlated	significantly	with	one	another	as	they	also	did	with	‘CT	Exams	(Per	1,000	Inhabitants)’	and	‘MRI	Exams	(Per	1,000	Inhabitants)’.	There	was	no	significant	correlation,	however,	between	the	latter	two	predictors.		‘Hospital	Discharges	(Per	100,000	Inhabitants)’	was	significantly	associated	with	‘Medical	Doctors	(Per	1,000	Inhabitants).		The	markers	for	professional	staffing	also	correlated	amongst	themselves:	‘Medical	Doctors	(Per	1,000	Inhabitants)’	with	Medical	Graduates	(Per	100,000	Inhabitants)’	and	‘Nurses	(Per	1,000	Inhabitants)’	with	‘Nurse	Graduates	(Per	100,000	Inhabitants)’.		
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5.3.2	Professional	uncertainty	and	difficulty	with	change	Table	5.7	represents	the	values	assigned	to	each	cultural	construct	in	Hofstede’s	cultural	dimensions	model	for	the	countries	used	in	the	analysis	(Hofstede	et	al.,	2010).	Croatia	and	Iceland	were	omitted	because	of	missing	values.		
Country	 pdi	 idv	 mas	 uai	 ltowvs	 ivr	
Australia	 36	 90	 61	 51	 21	 71	
Austria	 11	 55	 79	 70	 60	 63	
Belgium	 65	 75	 54	 94	 82	 57	
Canada	 39	 80	 52	 48	 36	 68	
Czech	Republic	 57	 58	 57	 74	 70	 29	
Denmark	 18	 74	 16	 23	 35	 70	
Estonia	 40	 60	 30	 60	 82	 16	
Finland	 33	 63	 26	 59	 38	 57	
France	 68	 71	 43	 86	 63	 48	
Germany	 35	 67	 66	 65	 83	 40	
Greece	 60	 35	 57	 112	 45	 50	
Hungary	 46	 80	 88	 82	 58	 31	
Ireland	 28	 70	 68	 35	 24	 65	
Italy	 50	 76	 70	 75	 61	 30	
Luxembourg	 40	 60	 50	 70	 64	 56	
Malta	 56	 59	 47	 96	 47	 66	
Netherlands	 38	 80	 14	 53	 67	 68	
New	Zealand	 22	 79	 58	 49	 33	 75	
Norway	 31	 69	 8	 50	 35	 55	
Slovakia	 104	 52	 110	 51	 77	 28	
Slovenia	 71	 27	 19	 88	 49	 48	
Spain	 57	 51	 42	 86	 48	 44	
Sweden	 31	 71	 5	 29	 53	 78	
Switzerland	 34	 68	 70	 58	 74	 66	
United	Kingdom	 35	 89	 66	 35	 51	 69	
United	States	 40	 91	 62	 46	 26	 68	Table	5.7:	Values	for	Hofstede’s	cultural	dimensions		
	113	
5.3.2.1	Linear	Correlation	The	values	assigned	to	Hofstede’s	cultural	dimensions	were	subjected	to	a	Pearson	Correlation	Coefficient	analysis	using	the	Red	Cell,	Platelet	and	Plasma	Usage	per	1000	population	in	turn	as	the	dependent	variables	to	measure	the	linear	correlation	between	each	dependent	variable	and	each	dimension.		Statistical	analysis	was	performed	using	IBM®	SPSS®	Statistics	for	Mackintosh	Ver	20.	The	data	in	Table	5.7	were	used	as	predictors	in	this	analysis	and	the	data	in	Table	3.4	(page	42)	for	blood	product	usage	were	used	as	the	independent	variables.		This	analysis	yielded	significant	results	with	the	dependent	variable	‘Plasma	Usage	per	1000	Population’.	There	appears	to	be	a	significant	negative	correlation	with	IDV	–	Collectivism	vs	Individualism.	There	is	also	a	marginal	correlation	with	PDI	–	Power	Distance	Index	(Table	4.8).		 Significant	Relationships	 Pearson	Correlation	 P-value	
Plasma	Usage	per	1,000	Population	–	PDI	(Power	Distance	Index)	 0.347	 0.082	
Plasma	Usage	per	1,000	Population	–	IDV	(Individualism	vs	Collectivism)	 -0.467	 0.016	
Plasma	Usage	per	1,000	Population	–	UAI	(Uncertainty	Avoidance	Index)	 0.320	 0.111	Table	5.8:	Correlation	between	plasma	usage	and	Hofstede’s	cultural	dimensions		The	analyses	performed	with	‘Red	Cell	Usage	per	1000	Population’	and	‘Platelet	Usage	per	1000	Population’	as	dependent	variables	did	not	yield	any	significant	correlations.		
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The	analysis	was	also	performed	while	omitting	the	Scandinavian	countries.	The	results	were	not	markedly	different,	in	that	the	dependent	variable	‘Plasma	Usage	per	1,000	Population’	showed	a	similar	correlation,	though	in	this	analysis	UAI	–	Uncertainty	Avoidance	Index	also	correlates	significantly	(Table	5.9).	There	was	a	difference	in	the	result	of	the	analysis	with	‘Red	Cell	Usage	per	1,000	Population’	as	the	dependent	variable.	This	analysis	yielded	a	marginal	correlation	of	the	variable	with	UAI	-	Uncertainty	Avoidance	Index	(Table	5.10).	There	were	still	no	correlations	in	the	analysis	performed	with	’Platelet	Usage	per	1,000	Population’.			 Significant	Relationships	 Pearson	Correlation	 P-value	
Plasma	Usage	per	1,000	Population	–	PDI	(Power	Distance	Index)	 0.409	 0.053	
Plasma	Usage	per	1,000	Population	–	IDV	(Individualism	vs	Collectivism)	 -0.485	 0.019	
Plasma	Usage	per	1,000	Population	–	UAI	(Uncertainty	Avoidance	Index)	 0.440	 0.036	Table	5.9:	Correlation	between	plasma	usage	and	power	distance	index	(PDI),	collectivism	vs	individualism	(IDV),	and	uncertainty	avoidance	index	(UAI)	
 	 			Table	5.10:	Correlation	between	red	cell	usage	and	uncertainty	avoidance	index			
Significant	Relationships	 Pearson	Correlation	 P-value	
Red	Cell	Usage	per	1,000	Population	–	UAI	(Uncertainty	Avoidance	Index)	 0.392	 0.064	
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5.4	Discussion		
5.4.1	Unwarranted	variation	The	representative	markers	listed	in	Table	5.3	were	identified	on	the	basis	of	the	frequency	with	which	they	have	been	associated	with	unwarranted	variation	or	supply	sensitive	care	(Emery	et	al.,	2013;	Rubin	et	al.,	2015;	Tasian	et	al.,	2014;	Wennberg	et	al.,	2015;	Westert	et	al.,	1993).	The	predictors	in	the	table	in	fact	correlate	among	themselves.	Countries	with	a	larger	number	of	CT	Scanners	per	capita	also	have	a	larger	amount	of	MRIs	per	capita	and	mammography	machines	per	capita.	In	countries	with	higher	numbers	of	doctors,	more	hospital	discharges	happen	signifying	a	higher	level	of	hospital	activity.	This	variation	occurs	in	countries	with	health	services	of	a	similar	level.	In	effect,	this	finding	validates	the	markers	identified	as	being	representative	of	unwarranted	variation.		
5.4.2	Unwarranted	variation	in	blood	product	usage	Various	publications	examining	blood	product	usage	in	specific	circumstances	have	shown	variation	in	use	(Gombotz	et	al.,	2014;	Mitra	et	al.,	2015).	Hospitals	using	high	volumes	of	one	product	also	use	high	volumes	of	the	other	two	products	(McQuilten	et	al.,	2014)	and	a	review	of	use	of	blood	products	among	older	adults	in	the	United	States	showed	that	one	is	more	likely	to	receive	blood	if	one	lives	in	the	Southern	region	of	the	USA	as	opposed	to	individuals	living	in	the	West	(Rogers	et	al.,	2009).	The	authors	of	one	publication	have	gone	so	far	as	to	claim	that	geographic	regions	have	their	own	transfusion	signature	(Likosky	et	al.,	2014).	Now,	in	this	thesis,	for	the	first	time,	this	variation	in	blood	products	has	been	linked	to	unwarranted	variation.		
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In	Chapter	Three,	it	was	clearly	shown	that	regional	variation,	mirroring	the	geographic	variation	shown	in	unwarranted	variation,	also	occurs	in	blood	product	usage.	Additionally,	the	analysis	performed	above	clearly	shows	that	blood	product	usage	has	a	significant	relationship	with	markers	of	supply	sensitive	care.	All	three	products	show	a	relationship	to	a	greater	or	lesser	degree	with	the	diagnostic	test	markers,	the	health	resource	markers,	and	the	hospital	activity	markers.	More	blood	products	are	used	in	countries	with	higher	levels	of	markers	associated	with	supply	sensitive	care	confirming	the	fact	that	blood	product	usage	is	also	a	victim	of	unwarranted	variation.		
5.4.3	Professional	uncertainty	and	difficulty	with	change	There	appears	to	be	some	correlation	between	blood	product	usage	and	Hofstede’s	culture	dimensions.	A	number	of	interesting	points	may	be	made	possibly	giving	further	insight	into	attitudes	surrounding	the	practice	of	blood	transfusion.		The	strongest	correlation	appears	to	be	between	‘Plasma	Usage	per	1,000	Population’	and	the	‘Individualism	vs	Collectivism	Index	(IDV)’.	The	relationship	is	an	inverse	one,	i.e.	in	countries	scoring	higher	on	the	individualism	side	of	the	spectrum,	less	blood	is	used	and	in	countries	tending	towards	Collectivsm,	more	blood	products	are	transfused.	A	number	of	observations	can	be	made.	According	to	Hofstede’s	dimensions	of	national	cultures,	there	is	a	positive	attitude	towards	what	is	new	in	countries	stronger	on	the	individualism	construct.	The	education	process	within	these	countries	tends	to	prepare	the	individual	to	cope	with	new,	unknown	and	unforeseen	situations,	and	the	purpose	of	learning	is	to	‘know	how	to	learn’.	Families	within	that	culture	encourage	children	to	develop	their	own	opinions	thereby	fostering	a	more	discerning	attitude.	Individualist	cultures	also	encourage	the	seeking	out	of	more	knowledge	and	cultivate	an	independent	self	(Hofstede	et	al.,	2010).	It	is	therefore	easy	to	conceive	that	in	these	countries	new	evidence	tends	to	be	accepted	faster.	The	new	
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evidence	in	blood	transfusion	practice	mainly	surrounds	a	more	conservative	attitude	recommending	lower	transfusion	triggers	and	therefore	less	blood	use.	Additionally,	within	individualistic	cultures,	the	patient	is	much	more	involved	in	the	decision	making	shifting	the	focus	from	Supply	Sensitive	Care	to	Preference	Sensitive	Care	and	doctors	are	more	willing	to	adopt	a	‘wait	and	see’	attitude	rather	than	rushing	in	with	some	form	of	therapy	(Meeuwesen	et	al.,	2009).	On	the	other	hand	in	countries	tending	towards	the	Collectivism	side	of	the	spectrum,	conformity	tends	to	be	a	valued	quality,	where	the	group	predetermines	opinions.	When	new	issues	crop	up,	there	needs	to	be	collective	discussion	and	change	occurs	only	when	the	collective	is	satisfied	that	it	is	the	right	way	forward.	The	institution	plays	a	very	strong	part	in	determining	behaviour	(Hofstede	et	al.,	2010).		In	these	countries	there	is	therefore	procrastination	in	the	adoption	of	new	evidence.	Practitioners	would	also	tend	to	conform	to	the	traditions	within	the	individual	institution,	which	itself	appears	to	be	a	variable	affecting	transfusion	practice	(Surgenor	et	al.,	1998).		Another	correlation	that	appears	valid	is	the	one	between	‘Plasma	Usage	per	1,000	Population’	and	the	‘Uncertainty	Avoidance	Index	(UAI)’.	This	relationship	does	not	hold	for	all	countries.	The	analysis	which	included	the	Scandinavian	countries	showed	a	lower	Pearson	correlation	and	a	P-value	>0.1.	However	when	the	Scandinavian	countries	were	omitted	from	the	analysis,	the	correlation	became	much	stronger	with	a	p-value	of	0.036.	Additionally	within	these	parameters,	there	also	appears	to	be	some	relationship,	albeit	marginal,	between	‘Red	Cell	Usage	per	1,000	Population’	and	UAI.	Within	the	model,	Hofstede	also	included	a	dimension	he	termed	Uncertainty	Avoidance	Index	(UAI).	He	borrowed	the	term	from	American	organisation	sociology.	Modern	societies	differ	on	the	way	they	cope	with	uncertainty	and	this	in	turn	brings	about	a	different	approach	to	practice	in	healthcare	in	the	different	societies.	In	uncertainty	avoiding	cultures	doctors	are	prone	to	a	higher	level	of	drug	prescription,	an	attitude	that	their	patients	expect	of	them	(Hofstede	et	al.,	2010).	It	has	been	shown,	for	example,	that	
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doctors	practicing	within	this	culture	feel	uncomfortable	with	the	diagnostic	difficulty	raised	in	relation	to	viral	and	bacterial	infections	and	tend	to	use	more	antibiotics	unnecessarily	(Borg,	2012).	It	is	therefore	likely	that	the	same	doctors	would	be	uncomfortable	tolerating	mild	deficiencies	in	haemoglobin	or	raised	PTs	and	APTTs	and	would	tend	to	transfuse	plasma	and	possibly	red	cells	earlier.	On	the	other	hand	in	uncertainty	tolerant	countries,	there	is	stronger	patient	engagement	and	doctors	tend	not	to	prescribe	medication	unnecessarily.	Additionally,	physicians	in	countries	with	a	high	UAI	are	tolerant	of	familiar	risk	(as	opposed	to	unfamiliar	risk	which	generates	uncertainty)	(Borg	et	al.,	2012),	and	are	therefore	more	likely	to	underestimate	the	potential	complications	of	blood	products,	a	therapy	they	prescribe	several	times	a	day.	This	would	tend	to	encourage	a	more	liberal	attitude	in	relation	to	their	use.		‘Power	Distance	Index	(PDI)’	was	the	third	dimension	highlighted	by	the	analysis	albeit	in	a	marginal	fashion.	‘Plasma	usage	per	1,000	Population’	was	marginally	correlated	(p-value	=	0.53)	with	‘Power	Distance	Index	(PDI)’.	The	lower	the	PDI,	the	lower	the	‘Plasma	Usage	per	1,000	Population	with	the	converse	also	being	true.	Individuals	in	countries	scoring	low	on	PDI	tend	to	be	more	adaptable,	empowered	and	less	dependent	(Hofstede	et	al.,	2010),	therefore	favouring	their	adoption	of	evidence.	The	tendency	towards	dependency	and	faithfulness	towards	institutional	norms	and	directions	is	stronger	in	countries	with	larger	power	distance	cultures	making	it	less	easy	for	individuals	to	subscribe	to	newly	emerging	evidence	as	it	becomes	available.	Additionally,	instruments	of	accountability,	such	as	audits,	are	unpopular	in	countries	with	a	high	PDI	as	they	are	perceived	to	target	the	less	powerful	(Borg,	2014).	It	is	therefore	difficult	to	establish	baselines	and	perform	gap	analyses	through	which	one	may	identify	reasons	for	change.	Power-holders	in	these	cultures	(senior	doctors)	are	often	subject	to	less	accountability,	a	situation	in	turn	used	by	the	less	powerful	(junior	doctors)	as	justification	to	ignore	guidelines	(Borg,	2014).	A	further	point	that	may	contribute	to	the	issue	is	that	in	countries	with	low	PDI	patients	are	
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empowered	and	participate	in	treatment	decisions	shifting	the	focus	towards	Preference	Sensitive	Care.	It	is	worth	noting	that	in	a	previous	publication	an	inverse	relationship	was	shown	between	PDI	and	blood	donation,	where	the	authors	postulated	that	in	high	power	distance	cultures,	people	may	be	more	inclined	to	donate	blood	only	when	told	to	do	so	explicitly	by	power-holders	(de	Kort	et	al.,	2010).		
5.5	Conclusions			A	number	of	conclusions	that	contribute	new	information	to	the	area	may	be	drawn	from	this	chapter:		Analysis	of	supply	sensitive	care	predictor	data	shows	that	high	activity	markers	tend	to	occur	together	i.e.	countries	with	higher	activity	in	one	marker	seem	to	have	higher	activities	in	many	other	markers.	This	phenomenon	occurs	on	a	background	of	well-developed	health	services	of	very	similar	levels.		Blood	product	usage	shows	significant	geographical	variation	(Chapter	Three)	mirroring	geographic	variation	in	other	modalities.	Furthermore	blood	product	usage	is	significantly	related	with	markers	of	supply	sensitive	care	making	a	very	strong	case	for	unwarranted	variation	in	blood	transfusion	practice		Increased	blood	product	usage	seems	to	occur	in	countries	with	low	scores	for	individualism,	higher	Uncertainty	Avoidance	Indices,	and	possibly	high	Power	Distance	Indices,	dimensional	constructs	that	encapsulate	the	notions	of	professional	uncertainty	and	difficulty	with	change.		 	
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6.	Conclusions,	Limitations	and	the	Future	
6.1	Introduction		Blood	transfusion	is	one	of	the	most	common	patient	treatment	procedures	in	clinical	practice	in	hospitals	in	the	developed	world	(Pfunter	&	Stocks,	2010).	It	is	complicated	by	a	number	of	well	known,	and	less	well	known	associated	hazards.	Judicious	use	based	on	evidence	is	therefore	a	highly	sensible	approach.	Unnecessary	transfusions,	carrying	risk	without	benefit,	should	be	avoided.	Ensuring	that	patients	are	only	transfused	the	blood	products	they	really	require	is	the	most	effective	way	of	providing	optimal	treatment	while	safeguarding	the	patient	from	unnecessary	risk	associated	with	unwarranted	use,	and	at	the	same	time	guaranteeing	equity	of	access	to	what	is	essentially	a	limited	resource	(Murphy	et	al.,	2011;	Seifried	et	al.,	2011).			An	examination	of	the	national	figures	for	blood	product	usage	shows	extensive	variation	with	the	highest	users	transfusing	twice	as	much	blood	products	as	the	lower	users.	Apart	from	demonstrating	an	association	with	population	demographics,	more	specifically	with	the	percent	of	population	over	65	years	of	age	(Ali	et	al.,	2010),	the	reasons	for	this	variation	are	unknown	(Aubuchon	et	al.,	2010).			This	thesis	set	about	examining	the	variation	that	was	apparent	on	a	nation-by-nation	basis.	Regional	data	on	blood	product	usage	was	collated	and	examined.	The	relationship	between	blood	product	usage	data	and	other	variables	including	measures	of	healthcare	was	explored	and	the	impact	of	a	number	of	potential	effectors	identified.	In	this	way,	the	thesis	sought	to	unravel	the	reasons	behind	the	variation	in	blood	product	usage	–	a	
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necessary	prelude	to	making	recommendations	or	taking	initiatives	to	ensure	the	achievement	of	appropriate	blood	use.	It	also	sought	to	define	a	potential	tool	that	could	be	used	to	assess	the	impact	of	measures	introduced	to	effect	change.		
6.2	Summary	of	Key	Findings		
6.2.1	Confirmation	of	variation	and	its	extent	A	literature	review	exploring	transfusion	practices	associated	with	coronary	artery	bypass	surgery,	a	procedure	that	is	responsible	for	approximately	20%	of	all	products	transfused	worldwide	(Snyder-Ramos	et	al.,	2008)	showed	an	extensive	inconsistency	in	blood	use	that	goes	much	beyond	that	related	to	clinical	issues.	Moreover	there	appears	to	be	evidence	to	suggest	an	effect	of	the	individual	institution	(hospital)	on	the	variation	in	blood	usage.			For	the	first	time,	regional	data	for	a	number	of	countries	were	compared.	The	variation	was	considerable	and	its	extent	does	not	seem	to	relate	to	the	countries’	national	averages.	It	was	also	discovered	that	though	in	general	the	number	of	red	cells	used	was	related	to	the	size	of	the	population	in	the	region,	this	did	not	hold	true	for	all	countries.	Correction	for	the	percent	of	the	population	over	65	years	and	for	migration	to	large	urban	areas	for	specialty	care	in	one	country	did	not	eliminate	the	variation.	Additionally,	an	analysis	of	the	national	usage	figures	for	red	cells,	platelets	and	plasma	shows	that	countries	that	use	more	of	one	product	tend	to	use	more	of	the	other	products.	Clearly	variation	in	blood	product	usage	in	countries	with	relatively	similar	health	systems,	and	across	regions	within	the	same	country	is	a	real	phenomenon,	mirroring	geographic	variation	seen	in	other	areas	of	health	care.	
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6.2.2	Relation	of	variation	with	overall	health	system	performance	The	variation	in	blood	product	usage	does	not	correlate	with	overall	health	performance.	There	is	no	simple	linear	relationship	between	blood	use	and	health	system	performance	indices.	Countries	with	health	care	systems	that	perform	better	do	not	seem	to	cluster	at	either	end	of	the	blood	product	usage	scale.	This	was	shown	for	the	first	time	by	correlating	blood	usage	with	a	standardised	score	based	on	a	number	of	markers	reflecting	overall	performance	of	the	health	systems	of	a	number	of	countries.	This	is	in	keeping	with	findings	that	variation	in	other	areas	of	healthcare	are	not	necessarily	related	to	overall	outcomes	(Heijink	et	al.,	2015).			
6.2.3	Correlation	of	blood	usage	variation	to	a	number	of	predictors	Up	to	now	the	only	correlation	that	had	been	associated	with	the	variation	in	blood	usage	has	been	the	percentage	of	the	population	above	65	years.	This	finding	has	been	confirmed	in	this	thesis,	but	is	by	no	means	the	sole	predictor	of	the	variation.	Additional	new	predictors	were	discovered	namely:	1. The	population	density	within	the	specific	country	2. Clinical	activity	as	represented	by	(a)	CABG	and	(b)	the	burden	of	cancer	3. Amount	of	funding	within	the	individual	country’s	health	services	Together	these	predictors	explained	approximately	70%	of	the	variation	in	red	cell	usage,	31%	of	the	variation	in	platelet	usage	and	25%	of	the	variation	in	plasma	usage.		The	percentage	of	the	population	over	65	years	cannot,	on	its	own,	explain	away	all	the	variation	in	blood	product	usage,	as	some	authors	have	claimed	(Ali	et	al.,	2010;	Seifried	et	al.,	2011).	This	thesis	has	shown	that	differences	
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in	clinical	activity,	and	issues	related	to	health	care	funding,	also	contribute	to	the	explanation.			
6.2.4	Potential	effectors	of	the	variation	A	number	of	new	findings	in	this	regard	were	made:		Analysis	of	supply	sensitive	care	predictor	data	shows	extensive	variation	in	activity	levels	in	a	number	of	specific	markers,	and	shows	that	in	general	a	country	would	have	markers	with	similar	levels	of	activity,	i.e	the	level	of	activity	is	country-dependent.	This	parallels	the	finding	mentioned	earlier	where	countries	tending	to	use	more	of	one	blood	product	use	more	of	the	others.		Furthermore	blood	product	usage	is	significantly	related	with	markers	of	supply	sensitive	care,	and	since	this	occurs	on	a	background	of	well-developed	health	services	of	similar	levels	with	broadly	similar	outcomes,	a	strong	case	for	unwarranted	variation	in	blood	transfusion	practice	can	be	made.		Using	Hofstede’s	culture	model,	it	was	discovered	that	increased	plasma	usage	mostly	seems	to	occur	in	countries	with	low	scores	for	individualism,	higher	Uncertainty	Avoidance	Indices,	and	possibly	high	Power	Distance	Indices,	and	for	red	cells	possibly	in	countries	with	higher	Uncertainty	Avoidance.	These	dimensional	constructs	encapsulate	the	notions	of	professional	uncertainty	and	difficulty	with	adopting	change.	A	case	can	certainly	be	made	for	difficulty	with	adoption	of	available	evidence-based	guidelines	as	a	reason	for	the	unwarranted	variation.	Additionally	there	also	appears	to	be	a	degree	of	professional	uncertainty	contributing	to	the	unwarranted	variation,	in	that	physicians	tend	to	‘err	on	the	side	of	caution’	and	transfuse	blood	products	even	when	this	is	not	strictly	necessary.		
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6.3	Blood	Product	Usage	as	a	Quality	Indicator		Quality	indicators	(QIs)	are	measures	that	have	been	developed	by	Health	Services	to	assess	quality	in	healthcare.	Many	examples	of	quality	indicators	exist	and	various	agencies	in	different	countries	make	use	of	a	selection	to	measure	the	status	of	their	health	system	including	the	Agency	for	Healthcare	Research	and	Quality,	The	Joint	Commission	(and	Joint	Commission	International),	Canadian	Institute	for	Health	Information,		(https://www.ahrq.gov,	https://www.jointcommission.org,	https://www.chi.ca/en).	Potential	QIs	should	be	assessed	for	feasibility	depending	on	their	practical	application	in	health	service	studies	and	on	the	quality	and	availability	of	data;	for	reliability	and	reproducibility;	for	acceptability	both	to	assessors	and	institutions	being	scrutinised;	for	sensitivity	to	change;	and	for	validity	(Otsubo	et	al.,	2016).		Blood	product	usage	is	ideally	placed	to	be	used	as	a	quality	indicator:	
	
Feasibility:	Blood	product	usage	data	can	be	very	practically	applied	in	healthcare	services	research.	It	is	a	measure	that	encapsulates	appropriateness	of	practice	in	several	clinical	sectors	simultaneously,	health	service	funding,	penetrance	of	policy	and	guidelines,	the	degree	of	unwarranted	variation,	and	medical	and	nurse	training.	The	data	are	readily	available	and	are	collected	and	published	regularly	conferring	a	huge	advantage	when	compared	to	other	indices.	The	quality	of	data	is	high	and	relatively	easily	retrieved	from	hospital	and	Blood	Establishment	databases.		
Reliability:	Traceability	of	blood	products	has	become	a	cornerstone	of	practice	over	the	years.	Legislation	within	the	European	Union	for	example	has	made	traceability	of	every	blood	product	mandatory.	The	fate	of	almost	every	
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blood	unit	is	accurately	recorded	allowing	for	extraction	of	very	precise	and	reliable	data.		
Acceptability:	There	appear	to	be	no	issues	with	acceptability.	The	values	for	national	blood	product	usage	are	already	published	in	Council	of	Europe	reports	and	in	various	national	reports	and	are	freely	available.	Many	hospitals	voluntarily	participate	in	international	quality	initiatives	that	include	collection	of	data	on	blood	usage	e.g.	the	Performance	Assessment	Tool	for	Quality	Improvement	in	Hospitals	(PATH)	(www.pathqualityproject.eu).	This	is	a	system	designed	by	the	WHO	to	support	hospitals	defining	strategies	for	improvement	in	quality	(Groene	et	al.,	2008).		
Sensitivity	to	change:	Blood	product	usage	is	very	sensitive	to	change.	The	financial	crisis	occurring	in	2008	was	followed	by	a	significant	downturn	in	the	world	economy.	This	had	an	extensive	impact	on	most	countries	with	health	spending	bearing	its	own	share	of	cutbacks.	Additionally	the	last	few	years	have	seen	an	emphasis	on	Patient	Blood	Management	(PBM)	programmes.	PBM	is	a	programme	of	initiatives	some	countries	have	adopted	or	are	in	the	process	of	adopting	to	deal	with	optimising	patient	care	in	relation	to	blood	transfusion.	It	aims	for	a	multidisciplinary	approach	that	encompasses	measures	to	avoid	unnecessary	transfusions	and	to	ensure	that	patients	receive	optimal	treatment.	Both	these	initiatives	and	the	financial	crisis	have	had	an	impact	on	blood	usage.	It	is	immediately	clear	from	the	data	in	Tables	3.6	–	3.14	that	in	most	countries	red	cell	usage	decreased	on	a	national	basis	when	compared	to	the	index	value	used	throughout	this	thesis	(Table	3.4).		
Validity:	Blood	product	usage,	as	an	index	measuring	quality	performance,	has	been	validated	by	the	analysis	performed	in	this	thesis.	It	was	clearly	shown	that	blood	product	usage	does	not	relate	to	the	overall	performance	of	health	care	
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systems.	An	index	that	moves	with	overall	performance	would	not	necessarily	be	sensitive	to	change	in	the	degree	of	unwarranted	variation.	Blood	product	usage	however	has	been	shown	to	move	with	markers	that	are	directly	related	to	supply	sensitive	care.	Moreover,	usage	seems	to	be	related	also	to	cultural	differences	that	may	affect	the	extent	of	unwarranted	variation.			This	thesis	is	therefore	a	powerful	demonstration	using	very	potent	clinical	totems	–	the	widespread	use	of	blood,	the	problems	associated	with	it,	the	costs,	the	prevalence	of	guidelines,	the	existence	of	high	grade	studies	in	high	grade	journals	–	that	irrational	and	evidence-denying	variation	in	clinical	practice	exists	and	can	be	measured	relatively	easily,	and	that	comparison	of	clinical	use	of	blood	in	health	care	in	discrete	geographical	regions	may	be	used	as	a	general	measure	of	the	effectiveness	of	different	tools	to	improve	practice	over	time	and	space,	not	just	within	the	context	of	blood	product	use,	but	possibly	in	clinical	practice	in	general.		Blood	product	usage	is	a	valid	measure	of	variation	in	practice	within	health	care	regions	that	do	not	have	a	reason	for	variation	from	other	regions	with	similar	economics	and	politics	other	than	failure	to	implement	good	practice	for	whatever	reason	or	reasons.	It	is	therefore	possible	to	envisage	that	variation	in	blood	product	usage	can	be	used	as	a	quality	performance	indicator	to	see	whether	direct	interventions	have	an	effect	on	this	poor	penetration	of	emerging	evidence	or	to	study	the	time	to	adoption	of	emerging	evidence,	and	how	that	might	be	improved	upon.		Variation	in	blood	product	usage	would	be	an	ideal	candidate	to	measure	changes	brought	about	by	the	initiatives	associated	with	transfusion	which	have	been	incorporated	in	the	Choosing	Wisely	campaign.	This	started	as	an	initiative	of	the	American	Board	of	Internal	Medicine	Foundation	in	the	United	States	in	2012	aiming	at	helping	physicians	identify	tests	and	interventions	that	were	often	unnecessary	and	therefore	potentially	harmful	
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(Hurley,	2014).	Since	then	this	initiative	has	gone	global:	Canada,	New	Zealand,	Australia,	Japan,	and	a	number	of	European	countries,	Germany,	the	Netherlands,	Italy,	Switzerland	and	England	and	Wales,	have	launched	similar	campaigns	(Vogel,	2015).	Overuse	of	blood	transfusion	is	listed	as	a	
Choosing	Wisely	recommendation	in	the	US.	Similarly	blood	transfusion	recommendations	have	been	made	with	regards	to	the	UK	Choosing	Wisely	campaign	(Murphy,	2015).	Blood	product	usage	would	be	the	ideal	indicator	to	use	to	measure	interventions	within	this	campaign	such	as	the	one	being	suggested	by	Malhotra	et	al,	where	guideline	committees	are	being	encouraged	to	produce	tools	to	help	doctors	understand	and	share	decisions	with	their	patients	based	on	best	evidence	(Malhotra	et	al.,	2015).		
6.4	Limitations		There	are	a	number	of	limitations	with	regards	to	the	work	within	this	thesis.	The	analyses	are	limited	to	one	defined	period	–	2009/2010.	This	specific	period	was	chosen	because	of	availability	of	a	majority	of	the	data	used.	Confirming	the	analyses	for	different	sets	of	years	would	have	made	the	conclusions	more	robust.	However,	though	the	data	for	blood	product	usage	are	available	for	other	years,	some	of	the	other	data	used,	especially	that	extracted	from	the	OECD	database	for	particular	markers	is	only	available	for	specific	years	and	is	often	not	available	for	subsequent	years.	Re-attempting	the	analyses	in	this	way	was	not	possible	during	the	time-frame	of	the	thesis.		It	may	have	been	useful	to	age	adjust	the	national	figures	on	blood	product	usage	to	eliminate	the	bias	in	favour	of	populations	with	a	higher	percentage	of	people	over	65	years.	This	was	not	possible	as	the	figures	for	blood	usage	for	different	age	groups	for	each	country	are	not	available.	This	was	mitigated	for	by	adding	in	‘Percent	Population	Above	65	Years’	as	a	variable	within	the	analysis.	
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	Lack	of	regional	data	for	platelet	and	plasma	usage	precluded	a	regional	analysis	of	their	use.	Such	an	analysis	would	have	given	further	insight	into	the	extent	of	regional	variation	in	blood	product	usage.		Though,	as	pointed	out	on	page	102,	Hofstede’s	theory	of	cultural	dimensions	is	one	of	the	most	frequently	cited	models	in	terms	of	cultural	theories,	it	is	not	without	its	critics	and	of	course	has	limitations.	The	main	limitation	stems	from	the	fact	that	the	original	study	was	performed	in	the	international	subsidiaries	of	one	company,	and	the	number	of	respondents	may	not	have	been	large	enough	to	make	it	completely	representative	and	generalizable	for	all	the	nations	studied.		The	main	statistical	tools	used	within	this	thesis	are	the	Pearson	correlation	and	regression	analysis.	It	is	well	known	that	when	testing	multiple	relationships	using	these	methods,	strong	relationships	between	the	variables	being	examined	could	occasionally	also	arise	from	the	influence	of	other	unmeasured	variables	and	the	results	do	not	guarantee	causal	relationships	between	the	independent	and	dependent	variables.		A	further	limitation	was	the	issue	of	missing	data	in	the	databases	from	which	data	for	this	thesis	was	extracted.	Though	countries	participate	in	the	various	initiatives	for	data	collection,	some	do	not	provide	all	the	data	requested.	Countries	with	multiple	missing	data	points	were,	in	some	analysis,	left	out	altogether.	Pairwise	deletion	was	used	in	the	Pearson	correlation	analysis	rather	than	listwise	deletion	to	maintain	as	many	datapoints	as	possible	for	the	analysis.		
	130	
6.5	Future	Work	There	is	scope	for	continuing	to	validate	the	blood	product	usage	as	a	tool	for	measurement	of	change	by	re-analysing	the	data	when	the	figures	for	markers	in	different	years	become	available	in	the	specific	databases.		There	is	also	scope	for	further	collaboration	with	colleagues	to	identify	ways	of	collecting	regional	data	for	usage	of	blood	products	-	in	the	case	of	red	cells,	in	countries	where	this	is	not	yet	available,	and	in	the	case	of	platelets	and	plasma,	in	most	countries.	This	would	provide	an	additional	tool,	this	time	to	measure	change	in	regions.			Similarly	collaborative	studies	on	using	blood	product	usage	as	a	quality	performance	indicator	to	measure	the	effect	of	interventions	applied	to	reduce	unwarranted	variation	in	standards	of	health	care	will	be	an	ongoing	project.		 	
	131	
	
	
	
References	
	 	
	132	
Abraham,	I.	&	Sun,	D.	(2012)	The	cost	of	blood	transfusion	in	Western	Europe	as	estimated	from	six	studies.	Transfusion,	52	(9):	1983-1988.		Ades,	F.,	Senterre,	C.,	de	Azambuja,	E.,	Sullivan,	R.,	Popescu,	R.,	Parent,	F.	&	Piccart,	M.	(2013)	Discrepancies	in	cancer	incidence	and	mortality	and	its	relationship	to	health	expenditure	in	the	27	European	Union	member	states.	
Annals	of	Oncology,	24	(11):	2897-2902.		Agencia	Nacional	de	Vigilancia	Sanitaria	(2010)	Relatorio	de	Hemovigilancia	
2007-2008.	Available	from:	http://portal.anvisa.gov.br/documents/33868/405222/Relat%C3%B3rio+de+Hemovigil%C3%A2ncia+-+2007+e+2008/68356d60-a415-44ec-a528-53e9f6d3123c				Ali,	A.,	Auvinen,	M.	K.	&	Rautonen,	J.	(2010)	The	aging	population	poses	a	global	challenge	for	blood	services.	Transfusion,	50	584-588.		Anderson,	S.	A.,	Menis,	M.,	O'Connell,	K.	&	Burwen,	D.	R.	(2007)	Blood	use	by	inpatient	elderly	population	in	the	United	States.	Transfusion,	47	582-592.		Andreasen,	J.	J.,	Westen,	M.,	Pallesen,	P.	A.,	Jensen,	S.,	Gorst-Rasmussen,	A.	&	Johnsen,	S.	P.	(2007)	Transfusion	practice	in	coronary	artery	bypass	surgery	in	Denmark:	a	multicenter	audit.	Interactive	CardioVascular	and	Thoracic	
Surgery,	6	623-627.		Andreu,	G.	(2002)	Haemovigilance	network	in	France:	organisation	and	analysis	of	immediate	transfusion	incident	reports	from	1994	to	1998.	
Transfusion,	42	1356-1364.		Aubuchon,	J.	P.,	Custer,	B.	&	Cher,	G.	(2010)	A	comparison	of	healthcare	and	blood	supply	system	structures.	Vox	Sanguinis,	100	22-35.		Australasian	Society	of	Blood	Transfusion	(2001)	Clinical	practice	guidelines	
on	the	use	of	blood	components	(red	blood	cells,	platelets,	fresh	frozen	plasma,	
cryoprecipitate).	Available	from:	https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp78_cp_blood_components.pdf				Australian	Bureau	of	Statistics	(2015)	3218.0	regional	population	growth,	
Australia.	Table	10:	estimated	resident	population,	States	and	territory	
summary.	[online]	Available	from:	http://www.abs.gov.au/ausstats/subscriber.nsf/log?openagent&32180ds0001_2005-15.xls&3218.0&DataCubes&69EA5EDF01684278CA257F8500171164&0&2014-15&30.03.2016&Latest	(Accessed	8	Sep	2016).		
	133	
Australian	Commission	on	Safety	and	Quality	in	Health	Care	(2015)	
Australian	atlas	of	healthcare	variation.	Available	from:	http://www.safetyandquality.gov.au				Barr,	P.	J.,	Donnelly,	M.,	Morris,	K.,	Parker,	M.,	Cardwell,	C.	&	Bailie,	K.	E.	M.	(2010)	The	epidemiology	of	red	cell	transfusion.	Vox	Sanguinis,	99	239-250.		Beguin,	C.,	Closon,	M.	C.,	Vandekerckhove,	P.	&	Baele,	P.	(2007)	Concentration	of	transfusion	resources	on	a	few	pathologies	and	a	few	patients:	analysis	of	the	comprehensive	in-hospital	patient	database.	Transfusion,	47	217-227.		Benjamin,	R.	J.	&	Whitaker,	B.	I.	(2011)	Boom	or	bust?	Estimating	blood	demand	and	supply	as	the	baby	boomers	age.	Transfusion,	51	670-673.		Bennett,	S.	&	Peters,	D.	H.	(2015)	Assessing	National	Health	Systems:	Why	and	How.	Health	Systems	&	Reform,	1	(1):	9-17.		Bennett-Guerrero,	E.,	Zhao,	Y.,	O'Brien,	S.	M.,	Ferguson,	T.	B.,	Peterson,	E.	D.,	Gammie,	J.	S.	&	Song,	H.	K.	(2010)	Variation	in	use	of	blood	transfusion	in	coronary	artery	bypass	graft	surgery.	Journal	of	the	American	Medical	
Association,	304	(14):	1568-1575.		Bero,	L.	A.,	Grilli,	R.,	Grimshaw,	J.	M.,	Harvey,	E.,	D,	O.	A.	&	Thomson,	M.	A.	(1998)	Closing	the	gap	between	researching	practice:	an	overview	of	systematic	reviews	of	interventions	to	promote	the	implementation	of	research	findings.	British	Medical	Journal,	317	465-468.		Birkmeyer,	J.	D.,	Reames,	B.	N.,	McCulloch,	P.,	Carr,	A.	J.,	Campbell,	W.	B.	&	Wennberg,	J.	E.	(2013)	Variation	in	Surgery	1:	understanding	of	regional	variation	in	the	use	of	surgery.	Lancet,	382	1121-1129.		Borg,	M.	A.	(2012)	National	cultural	dimensions	as	drivers	of	inappropriate	ambulatory	care	consumption	of	antibiotics	in	Europe	and	their	relevance	to	awareness	campaigns.	Journal	of	Antimicrobial	Chemotherapy,	67	763-767.		Borg,	M.	A.	(2014)	Cultural	determinants	of	infection	control	behaviour:	understanding	drivers	and	implementing	effective	change.	Journal	of	Hospital	
Infection,	86	161-168.		Borg,	M.	A.,	Camilleri,	L.	&	Waisfisz,	B.	(2012)	Understanding	the	epidemiology	of	MRSA	in	Europe:	do	we	need	to	think	outside	the	box?	
Journal	of	Hospital	Infection,	81	251-256.		Borkent-Raven,	B.	A.,	Janssen,	M.	P.	&	van	der	Poel,	C.	L.	(2010)	Demographic	changes	and	predicting	blood	supply	and	demand	in	the	Netherlands.	
Transfusion,	50	2455-2460.		
	134	
Bracey,	A.	W.	(2008)	Blood	Transfusion	in	cardiac	surgery:	a	highly	varied	practice.	Transfusion,	48	1271-1273.		Brinkhous,	K.	M.,	Shanbrom,	E.,	Roberts,	H.	R.,	Webster,	W.	P.,	Fekete,	L.	&	Wagner,	R.	H.	(1968)	A	new	high-potency	glycine-precipitated	antihemophilic	factor	(AHF)	concentrate:	treatment	of	classical	hemophilia	and	hemophilia	with	inhibitors.	Journal	of	the	American	Medical	Association,	205	613-617.		Brown,	J.	R.,	Birkmeyer,	N.	J.	&	O'Connor,	G.	T.	(2007)	Meta-analysis	comparing	the	effectiveness	and	adverse	outcomes	of	anti-fibrinolytic	agents	in	cardiac	surgery.	Circulation,	115	2801-2813.		Canadian	Blood	Services	(2010)	Annual	Checkup:	A	report	to	Canadians	
2009/2010.	Available	from:	http://itsinyoutogive.ca/Annual/2010/pdfs/cbsltc_report_en.pdf		Ontario,	Canada			Carson,	J.	L.,	Terrin,	M.	L.,	Noveck,	H.,	Sanders,	D.	W.,	Chairman,	B.	R.,	Rhoads,	g.	g.,	Nemo,	G.,	Dragert,	K.,	Beaupre,	L.,	Hildebrand,	K.,	Macaulay,	W.,	Lewis,	C.,	Cook,	D.	R.,	Dobbin,	G.,	Zakriya,	K.	J.,	Apple,	F.	S.,	Horney,	R.	A.	&	Magaziner,	J.	(2011)	Liberal	or	restrictive	transfusion	in	high-risk	patients	after	hip	surgery.	New	England	Journal	of	Medicine,	365	2453-2462.		Carter,	S.	M.,	Rogers,	W.,	Heath,	I.,	Degeling,	C.,	Doust,	J.	&	Barratt,	A.	(2015)	The	challenge	of	overdiagnosis	begins	with	its	definition.	British	Medical	
Journal,	350	h869.		Centers	for	Disease	Control	and	Prevention	(1982)	Epidemiologic	notes	and	
reports	Pneumocystis	carinii	pneumonia	among	persons	with	hemophilia	A.	Available	from:	https://www.cdc.gov/mmwr/preview/mmwrhtml/00001126.htm				Centers	for	Disease	Control	and	Prevention	(1983)	Current	trends	prevention	
of	acquired	immune	deficiency	syndrome	(AIDS):	Report	of	inter-agency	
recommendations.	Available	from:	https://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm				Centers	for	Disease	Control	and	Prevention	(1986)	Current	trends	Human	T-
Lymphotrophic	Virus	type	III	/	Lymphadenopathy-Associated	Virus	antibody	
testing	at	alternate	sites.	Available	from:	https://www.cdc.gov/mmwr/preview/mmwrhtml/00000728.htm				Centers	for	Medicare	and	Medicaid	Services	(2009)	National	Health	
Expenditure	Projections	2010-2020.	Available	from:	https://www.cms.gov/NationalHealthExpendData/downloads/proj2010.pdf				
	135	
Cobain,	T.	J.,	Vamvakas,	E.	C.,	Wells,	A.	&	Titlestad,	K.	(2006)	A	survey	of	the	demographics	of	blood	use.	Transfusion	Medicine,	17	1-15.		Comer,	P.	J.	&	Huntly,	P.	J.	(2003)	TSE	risk	assessment:	a	decision	support	tool.	Statistical	Methods	in	Medical	research,	12	279-291.		Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance	(2013)	Rapport	d'hemovigilance	des	coordonateurs	régionaux	d'hemovigilance	
et	de	sécurité	transfusionnelle.	Année	2012.	Available	from:	http://www.hemovigilance-cncrh.fr/www2/lu_pour_vous/rapports_hemovigilance.html				Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance	(2014)	Rapport	d'hemovigilance	des	coordonnateur	régionaux	
d'hemovigilance	et	du	sécurité	transfusionnelle.	Année	2013.	Available	from:	http://www.hemovigilance-cncrh.fr/www2/lu_pour_vous/rapports_hemovigilance.html				Conference	Nationale	des	Co-ordonnateurs	Régionaux	d'Hemovigilance	(2015)	Rapport	d'hemovigilance	des	coordonnateurs	régionaux	
d'hemovigilance	et	de	sécurité	transfusionnelle.	Année	2014.	Available	from:	http://www.hemovigilance-cncrh.fr/www2/lu_pour_vous/rapports_hemovigilance.html				Cooper,	H.	A.,	Rao,	S.	V.,	Greenberg,	M.	D.,	Ramsey,	M.	P.,	McKenzie,	M.,	Alcorn,	K.	W.	&	Panza,	J.	A.	(2011)	Conservative	versus	liberal	red	cell	transfusion	in	acute	myocardial	infarction	(the	CRIT	Randomised	Pilot	Study).	American	
Journal	of	Cardiology,	108	1108-1111.		Corallo,	A.	N.,	Croxford,	R.,	Goodman,	D.	C.,	Bryan,	E.	L.,	Srivastava,	D.	&	Stukel,	T.	A.	(2014)	A	systematic	review	of	medical	practice	variation	in	OECD	countries.	Health	Policy,	114	5-14.		Coyne,	J.	S.	&	Hilsenrath,	P.	(2002)	The	World	Health	Report	2000:	can	health	care	systems	be	compared	using	a	single	measure	of	performance?	American	
Journal	of	Public	Health,	92	(1):	30-33.		Crosby,	E.,	Ferguson,	D.,	Hume,	H.	A.,	Kronick,	J.	B.,	Larke,	B.,	LeBlond,	P.,	McLellan,	B.	&	Warkentin,	T.	E.	(1997)	Guidelines	for	red	blood	cell	and	plasma	transfusion	for	adults	and	children.	Canadian	Medical	Association	
Journal,	156	(11	suppl):	S1-S24.		Currie,	C.	J.,	Patel,	T.	C.,	McEwan,	P.	&	Dixon,	S.	(2004)	Evaluation	of	the	future	supply	and	demand	for	blood	products	in	the	United	Kingdom	National	Health	Service.	Transfusion	Medicine,	14	19-24.		
	136	
Danish	Transfusion	Database	(2009)	Danish	Transfusion	Database.	Annual	
Report	2009.	The	most	blood	consuming	diagnoses	and	surgical	procedures:	
using	red	cells.	Available	from:	http://www.dtdb.dk/download/DTDB_Rapport_2009_43.pdf				Dartmouth	Atlas	Project	(2007a)	A	Dartmouth	atlas	project	brief:	effective	
care.	Available	from:	http://www.dartmouthatlas.org/downloads/reports/effective_care.pdf				Dartmouth	Atlas	Project	(2007b)	A	Dartmouth	atlas	project	topic	brief:	
preference-sensitive	care.	Available	from:	http://www.dartmouthatlas.org/downloads/reports/preference_sensitive.pdf				Dartmouth	Atlas	Project	(2007c)	A	Dartmouth	atlas	project	topic	brief:	supply-
sensitive	care.	Available	from:	http://www.dartmouthatlas.org/downloads/reports/supply_sensitive.pdf				Davidson,	T.,	Ekermo,	B.,	Gaines,	H.,	Lesko,	B.	&	Akerlind,	B.	(2011)	The	cost	effectiveness	of	introducing	nucleic	acid	testing	to	test	for	hepatitis	B,	hepatitis	C	and	human	immunodeficiency	virus	among	blood	donors	in	Sweden.	Transfusion,	51	421-429.		de	Kort,	W.,	Wagenmans,	E.,	van	Dongen,	A.,	Slotboom,	Y.,	Hofstede,	G.	&	Veldhuizen,	I.	(2010)	Blood	product	collection	and	supply:	a	matter	of	money?	Vox	Sanguinis,	98	201-208.		Department	of	Health	and	Human	Services	(2011)	The	2009	National	Blood	
Collection	and	Utilization	Survey	Report.	Available	from:	https://wayback.archive-it.org/3919/20140402175927/https:/www.hhs.gov/ash/bloodsafety/2009nbcus.pdf		Washington,	DC			Department	of	Health	and	Human	Services	(2013)	The	2011	Nationwide	
Blood	Collection	and	Utilization	survey	Report.	Available	from:	https://www.hhs.gov/sites/default/files/ash/bloodsafety/2011-nbcus.pdf		Washington,	DC			Djulbegovic,	B.	&	Paul,	A.	(2011)	From	efficacy	to	effectiveness	in	the	face	of	uncertainty:	indication	creep	and	prevention	creep.	Journal	of	the	American	
Medical	Association,	305	(19):	2005-2006.		Duguid,	J.,	O'Shaughnessy,	D.	F.,	Atterbury,	C.,	Bolton	Maggs,	P.,	Murphy,	M.,	Thomas,	D.,	Yates,	S.	&	Williamson,	L.	M.	(2004)	Guidelines	for	the	use	of	fresh-frozen	plasma,	cryoprecipitate	and	cryosupernatant.	British	Journal	of	
Haematology,	126	11-28.		
	137	
Emanuel,	E.	J.	&	Fuchs,	V.	R.	(2008)	The	perfect	storm	of	overutilization.	
Journal	of	the	American	Medical	Association,	299	(23):	2789-2791.		Emery,	D.	J.,	Shojania,	K.	G.,	Forster,	A.	J.,	Mojaverian,	N.	&	Feasby,	T.	E.	(2013)	Overuse	of	magnetic	resonance	imaging.	Journal	of	the	American	Medical	
Association,	173	(9):	823-825.		Eskander,	A.,	Irish,	J.	C.,	Urbach,	D.	R.	&	Goldstein,	D.	P.	(2015)	Head	and	neck	
cancer	surgery	in	Ontario,	2003	-	2010.	Available	from:	http://www.ices.on.ca/~/media/Files/Atlases-Reports/2015/Head-Neck-Cancer-Surgery-Atlas/Full-Report.ashx		Toronto,	ON			European	Union	(2003)	Directive	2002/98/EC	of	the	European	Parliament	
and	the	Council	as	regards	setting	standards	of	quality	and	safety	for	the	
collection,	testing,	processing,	storage	and	distribution	of	human	blood	and	
blood	components	and	amending	Directive	2001/83/EC.	Available	from:	http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2002_98/dir_2002_98_en.pdf		Official	Journal	of	the	EU			European	Union	(2004)	Commission	Directive	2004/33/EC	of	22	March	2004	
implementing	Directive	2002/98/EC	of	the	European	Parliament	and	of	the	
Council	as	regards	certain	technical	requirements	for	blood	and	blood	
components.	Available	from:	http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004484.pdf		Official	Journal	of	the	EU			European	Union	(2005a)	Directive	2005/61/EC	implementing	Directive	
2002/98/EC	of	the	European	Parliament	and	of	the	Council	as	regards	
traceability	requirements	and	notification	of	serious	adverse	reactions	and	
events.	Available	from:	http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004485.pdf		Official	Journal	of	the	EU			European	Union	(2005b)	Commission	Directive	2005/62/EC	of	30	September	
2005	implementing	Directive	2002/98/EC	of	the	European	Parliament	and	of	
the	Council	as	regards	community	standards	and	specifications	relating	to	a	
quality	system	for	blood	establishments.	Available	from:	http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32005L0062&from=EN		Official	Journal	of	the	EU			Eurostat	(2011)	Proportion	of	population	aged	65	and	over	(%	of	total	
population).	Available	from:	http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&language=en&pcode=tps00028&plugin=1		Eurostat	Website			
	138	
Evatt,	B.	L.	(2006)	The	tragic	history	of	AIDS	in	the	hemophilia	population,	1982-1984.	Journal	of	Thrombosis	and	Hemostasis,	4	2295-2301.		Faber,	J.	C.	(2002)	Haemovigilance	around	the	world.	Vox	Sanguinis,	83	(S1):	71-76.		Fajadet,	J.	&	Chieffo,	A.	(2012)	Current	management	of	left	main	coronary	artery	disease.	European	Heart	Journal,	33	36-50.		Finish	Red	Cross	Blood	Service	(2010)	Finnish	Red	Cross	Blood	Service	in	
2009;	Living	life	together	every	day.	Available	from:	https://www.redcross.fi/materiaali/finnish-red-cross-annual-reports				Freedman,	J.,	Luke,	K.,	Escobar,	M.,	Veronica,	L.	&	Chiavetta,	J.	A.	(2008)	Experience	of	a	network	of	transfusion	coordinators	for	blood	conservation	(Ontario	Transfusion	Coordinators	[ONTraC]).	Transfusion,	48	237-250.		Garcia	Armesto,	S.,	Martinez	Lizaga,	N.,	Angulo	Pueyo,	E.,	Bloor,	K.	&	Cookson,	R.	(2014)	ECHO	atlas	on	lower	value	care	in	England.	Available	from:	http://echo-health.eu/wp-content/uploads/2015/03/report_LVC_ENG_final_owen_logos_5.pdf					GBD	2015	SDG	Collaborators	(2016)	Measuring	the	health-related	sustainable	development	goals	in	188	countries:	a	baseline	analysis	from	the	Global	Burden	of	Disease	Study	2015.	Lancet,	388	(10053):	1813-1850.		Ghani,	A.	C.,	Ferguson,	N.	M.,	Donnelly,	C.	A.	&	Anderson,	R.	M.	(2000)	Predicted	vCJD	mortality	in	Great	Britain.	Nature,	406	583-584.		Glover,	J.	A.	(1938)	The	incidence	of	tonsillectomy	in	school	children.	
Proceedings	of	the	Royal	Society	of	Medicine,	31	1219-1236.		Gombotz,	H.,	Rehab,	P.	H.,	Shander,	A.	&	Hofmann,	A.	(2014)	The	second	Austrian	benchmark	study	for	blood	use	in	elective	surgery:	results	and	practice	change.	Transfusion,	54	2646-2657.		Gombotz,	H.,	Rehak,	P.	H.,	Shander,	A.	&	Hofmann,	A.	(2007)	Blood	use	in	elective	surgery:	the	Austrian	benchmark	study.	Transfusion,	47	1468-1479.		Goodnough,	L.	T.,	Johnston,	M.	F.	M.	&	Toy,	P.	T.	C.	Y.	(1991)	The	variability	of	transfusion	practice	in	coronary	artery	bypass	surgery.	Journal	of	the	
American	Medical	Association,	265	86-90.		Greenwalt,	T.	J.	(1997)	A	short	history	of	transfusion	medicine.	Transfusion,	37	(5):	550-563.		
	139	
Greinacher,	A.,	Fendrich,	K.,	Alpen,	U.	&	Hoffmann,	W.	(2007)	Impact	of	demographic	changes	on	the	blood	supply:	Mecklenburg	West	Pomerania	as	a	model	region	for	Europe.	Transfusion,	47	395-401.		Greinacher,	A.,	Fendrich,	K.	&	Hoffmann,	W.	(2010)	Demographic	change:	the	impact	on	safe	blood	supply.	ISBT	Science	Series,	5	239-243.		Greinacher,	A.,	Weitmann,	K.,	Lebsa,	A.,	Gloger,	D.,	Stangenberg,	W.,	Kiefel,	V.	&	Hoffmann,	W.	(2016)	A	population-based	longitudinal	study	on	the	implications	of	demographics	on	future	blood	supply.	Transfusion,	56	2986-2994.		Groene,	O.,	Klazinga,	N.,	Kazandjian,	V.,	Lombrail,	P.	&	Bartels,	P.	(2008)	The	World	Health	Organisation	performance	assessment	tool	for	quality	improvement	in	hospitals	(PATH):	an	analysis	of	the	pilot	implementation	in	37	hospitals.	International	Journal	of	Quality	in	Health	Care,	20	(3):	155-161.		Grytten,	J.	&	Sorensen,	R.	(2003)	Practice	variation	and	physician-specific	effects.	Journal	of	Health	Economics,	22	403-418.		Hajjar,	L.	A.,	Vinvent,	J.	L.,	Galas,	F.	R.,	Nakamura,	R.	E.,	Silva,	C.	M.,	Santos,	M.	H.,	Fukushima,	J.,	Kalil	Filho,	R.,	Sierra,	D.	B.,	Lopes,	N.	H.,	Mauad,	T.,	Roquim,	A.	C.,	Sundin,	M.	R.,	Leao,	W.	C.,	Almeida,	J.	P.,	Pomerantzeff,	P.	M.,	Dallan,	L.	O.,	Jatene,	F.	B.,	Stolf,	N.	A.	&	Auler,	J.	O.	J.	(2010)	Transfusion	requirements	after	cardiac	surgery.	The	TRACS	randomised	controlled	trial.	Journal	of	the	
American	Medical	association,	304	1559-1567.		Ham,	C.	(2010)	The	coalition	government's	plans	for	the	NHS	in	England:	Much	more	work	is	needed	to	ensure	they	can	deliver	improvements	in	care.	
British	Medical	Journal,	341	c3790.		Heal	The	World	Foundation	(2012)	Population	density	per	square	kilometre	
by	country.	[online]	Available	from:	http://www.nationmaster.com/graph/geo_pop_den-geography-population-density	(Accessed	12	April	2012).		Hebert,	P.	C.,	Wells,	G.,	Blajchman,	M.	A.,	Marshall,	J.,	Martin,	C.,	Pagliarello,	G.,	Tweeddale,	M.,	Schweitzer,	I.	&	Yetisir,	E.	(1999)	A	multi-center	randomized	controlled	clinical	trial	of	transfusion	requirements	in	critical	care.	New	
England	Journal	of	Medicine,	340	409-417.		Heijink,	R.,	Engelfriet,	P.,	Rehnberg,	C.,	Kittelsen,	S.	A.	C.	&	Hakkinen,	U.	(2015)	A	window	on	geographic	variation	in	health	care:	insights	from	Europe.	Health	Economics,	24	164-177.		Hema-Quebec	(2010)	Annual	Report	2009-2010.	Available	from:	https://www.hema-
	140	
quebec.qc.ca/userfiles/file/media/anglais/publications/RA2010_HemaQuebec_ang_web.pdf		Quebec,	Canada:			Hicks,	L.	K.	(2015)	Reframing	overuse	in	health	care:	Time	to	focus	on	the	harms.	Journal	of	Oncology	Practice,	11	(3):	168-170.		Hoffman,	J.	R.	&	Kanzaria,	H.	K.	(2014)	Intolerance	of	error	and	culture	of	blame	driven	medical	excess.	British	Medical	Journal,	349	g5702.		Hofstede,	G.	(2001)	Culture's	consequences:	comparing	values,	behaviours,	
institutions,	and	organisations	across	nations.	Thousand	Oaks,	CA:	Sage	Publications.		Hofstede,	G.,	Hofstede,	G.	J.	&	Minkov,	M.	(2010)	Cultures	and	organisations:	
software	of	the	mind:	intercultural	cooperation	and	its	importance	for	survival.	3rd	edn.	McGraw-Hill.		Hurley,	R.	(2014)	Can	doctors	reduce	harmful	medical	overuse	worldwide.	
British	Medical	Journal,	349	g4289.		I.Stat	(2016)	Popolazione	residente	al	1	gennaio	I.Stat	export.	[online]	Available	from:	http://dati5b.istat.it/OECDstat_Metadata/ShowMetadata.ashx?Dataset=DCIS_POPRES1&amp;amp;ShowOnWeb=true&amp;amp;Lang=fr	(Accessed	12	Sep	2016).		Institut	Nationale	de	la	Statistique	et	des	Etudes	Economiques	(2015)	
Estimations	de	population	au	1er	janvier,	par	region,	sexe	et	grande	class	
d'ageEstimations	de	population	au	1er	janvier,	par	region,	sexe	et	grande	class	
d'age.	[online]	Available	from:	http://www.insee.fr	(Accessed	20	Sep	2016).		Institute	of	Medicine	(2001)	Crossing	the	quality	chasm:	a	new	health	system	
for	the	21st	century.	Available	from:	http://www.nationalacademies.org/hmd/~/media/Files/Report	Files/2001/Crossing-the-Quality-Chasm/Quality	Chasm	2001		report	brief.pdf		Washington			Institute	of	Medicine	(2012)	Best	care	at	lower	cost:	the	path	to	continuously	
learning	health	care	in	America.	Available	from:	http://www.nationalacademies.org/hmd/~/media/Files/Report	Files/2012/Best-Care/BestCareReportBrief.pdf				International	Agency	for	Research	on	Cancer	(2008)	Cancer	-	crude	and	age	
standardized	rates	per	100,000.	[online]	Available	from:	http://globocan.iarc.fr/Pages/summary_table_pop_sel.aspx	(Accessed	28	Feb	2012).		
	141	
Irish	Blood	Transfusion	Service	(2010)	Irish	Blood	Transfusion	Service	Annual	
Report	2009.	Available	from:	http://www.giveblood.ie/About_Us/Publications_Guidelines/Annual_Reports/2000-to-2010/				Janssen,	M.	P.,	van	der	Poel,	C.	&	Behr-Gross,	M.	E.	(2011)	The	collection	
testing	and	use	of	blood	and	blood	products	in	Europe	2009.	Available	from:	https://www.edqm.eu/medias/fichiers/the_collection_testing_and_use_of_blood_and_blood_components_in_europe_2009_report.pdf				Janssen,	M.	P.,	van	der	Poel,	C.	&	Behr-Gross,	M.	E.	(2014)	The	collection,	
testing	and	use	of	blood	and	blood	components	in	Europe	2010	Report.	Available	from:	https://www.edqm.eu/medias/fichiers/the_collection_testing_and_use_of_blood_and_blood_components_in_europe_2010_report.pdf				Japanese	Red	Cross	Society	(2010)	Haemovigilance	by	JRCS	2008.	Available	from:	http://www.jrc.or.jp/vcms_lf/anzen_HVreport2008_en.pdf				Jin,	R.,	Zelinka,	E.	S.,	McDonald,	J.,	Byrnes,	T.,	Grunkemeier,	G.	L.	&	Brevig,	J.	(2013)	Effect	of	hospital	culture	on	blood	transfusion	in	cardiac	procedures.	
Annals	of	Thoracic	Surgery,	95	1269-1275.		Kassirer,	J.	P.	(1989)	Our	stubborn	quest	for	diagnostic	certainty.	A	cause	of	excessive	testing.	New	England	Journal	of	Medicine,	320	1489-1491.		Kendrick,	D.	B.	(1964)	Blood	program	in	world	war	II.	Office	of	the	Surgeon	General,	Dept	of	the	Army.		Kirkman,	B.	L.,	Lowe,	K.	B.	&	Gibson,	C.	B.	(2006)	A	quarter	century	of	
Culture's	Consequences:	a	review	of	empirical	research	incorporating	Hofstede's	cultural	values	framework.	Journal	of	International	Business	
Studies,	37	285-320.		Kontopantelis,	E.,	Springate,	D.	A.,	Ashworth,	M.,	Webb,	R.	T.,	Buchan,	I.	E.	&	Doran,	T.	(2015)	Investigating	the	relationship	between	quality	of	primary	care	and	premature	mortality	in	England:	a	spatial	whole-population	study.	
British	Medical	Journal,	350	h904.		Lafortune,	G.	&	de	Looper,	M.	(2011)	Health	at	a	Glance.	Available	from:	https://www.oecd.org/els/health-systems/49105858.pdf				Landsteiner,	K.	&	van	der	Scheer,	J.	(1924)	On	the	specificity	of	agglutinins	and	precipitins.	The	Journal	of	Experimental	Medicine,	40	(1):	91-107.		
	142	
Lasmezas,	C.	I.,	Deslys,	J.	P.,	Demaimay,	R.,	Adjou,	K.	T.,	Lamoury,	F.,	Dormont,	D.,	Robain,	O.,	Ironside,	J.	&	Hauw,	J.	J.	(1996)	BSE	transmission	to	macaques.	
Nature,	381	743-744.		Lewisohn,	R.	(1916)	The	importance	of	the	proper	dosage	of	sodium	citrate	in	blood	transfusion.	Annals	of	Surgery,	64	(5):	618-623.		Likosky,	D.	S.,	Al-Attar,	P.	M.,	Malenka,	D.	J.,	Furnary,	A.	P.,	Lehr,	E.	J.,	Paone,	G.,	Kommareddi,	M.,	Helm,	R.,	Jin,	R.,	Maynaud,	C.,	Hanson,	E.	C.,	Olmstead,	E.	M.,	Mackenzie,	T.	A.,	Ross,	C.	S.	&	Zhang,	M.	(2014)	Geographic	variability	in	potentially	discretionary	red	blood	cell	transfusions	after	coronary	artery	bypass	graft	surgery.	The	Journal	of	Thoracic	and	Cardiovascular	Surgery,	148	3084-3089.		Llewellyn,	C.	A.,	Hewitt,	P.	A.,	Knight,	R.	S.	G.,	Amar,	K.,	Cousens,	S.,	Mackenzie,	J.	&	Will,	R.	G.	(2004)	Possible	transmission	of	variant	Creudzfeldt-Jakob	disease	by	blood	transfusion.	Lancet,	363	417-421.		Ludlam,	C.	A.	&	Turner,	M.	L.	(2005)	Managing	the	risk	of	transmission	of	variant	Creutzfeldt-Jakob	disease	by	blood	products.	British	Journal	of	
Haematology,	132	13-24.		Maddux,	F.	W.,	Dickinson,	T.	A.,	Rilla,	D.,	Kamienski,	R.	W.,	Saha,	S.	P.,	Eales,	F.,	Rego,	A.,	Donias,	H.	W.,	Crutchfield,	S.	L.	&	Hardin,	R.	A.	(2009)	Institutional	variability	of	intraoperative	red	blood	cell	utilization	in	coronary	artery	bypass	graft	surgery.	American	Journal	of	Medical	Quality,	24	403-411.		Magruder,	J.	T.,	Blasco-Colmenares,	E.,	Crawford,	T.,	Alejo,	D.,	Conte,	J.	V.,	Selenger,	R.,	Fonner,	C.	E.,	Kwon,	C.	C.,	Bobbitt,	J.,	Brown,	J.	M.,	Nelson,	M.	G.,	Horvath,	K.	A.	&	Whitman,	G.	R.	(2017)	Variation	in	red	blood	cell	transfusion	practices	during	cardiac	operations	among	centres	in	Maryland:	Results	from	a	state	quality-improvement	collaborative.	Annals	of	Thoracic	Surgery,	103	152-161.		Malhotra,	A.,	Maughan,	D.,	Ansell,	J.,	Lehman,	R.,	Henderson,	A.,	Gray,	M.,	Stephenson,	T.	&	Bailey,	S.	(2015)	Choosing	wisely	in	the	UK:	the	Academy	of	Medical	Colleges'	initiative	to	reduce	the	harms	of	too	much	medicine.	British	
Medical	Journal,	350	h2308.		Marshall,	D.	A.,	Kleinman,	S.	H.,	Wong,	J.	B.,	AuBuchon,	J.	P.,	Grima,	D.	T.,	Kulin,	N.	A.	&	Weinstein,	M.	C.	(2004)	Cost	effectiveness	of	nucleic	acid	test	screening	of	volunteer	blood	donations	for	hepatitis	B,	hepatitis	C	and	human	immunodeficiency	virus	in	the	United	States.	Vox	Sanguinis,	86	28-40.		Maycock,	W.	d'A.	(1940)	Blood	Transfusion	in	the	B.E.F.	British	Medical	
Journal,	2	467.		
	143	
McClelland,	D.	B.	L.,	Pirie,	E.	&	Franklin,	I.	M.	(2010)	Manual	of	optimal	blood	
use.	Available	from:	http://www.optimalblooduse.eu				McHenry,	L.	&	Khoshnood,	M.	(2014)	Blood	money:Bayer's	inventory	of	HIV-contaminated	blood	products	and	third	world	haemophiliacs.	Accountability	
in	Research,	21	(6):	389-400.		McMahon,	L.	F.	&	Chopra,	V.	(2012)	Health	care	cost	and	value:	the	way	forward.	Journal	of	the	American	Medical	Association,	307	(7):	671-672.		McQuilten,	Z.	K.,	Andrianopoulos,	N.,	Wood,	E.	M.,	Cole-Sinclair,	M.	F.,	McNeil,	J.	J.,	Cameron,	P.	A.,	Reid,	C.	M.,	Newcomb,	A.	E.,	Smith,	J.	A.	&	Phillips,	L.	E.	(2014)	Transfusion	practice	varies	widely	in	cardiac	surgery:	results	from	a	national	registry.	The	Journal	of	Thoracic	and	Cardiovascular	Surgery,	147	1684-1690.		Meeuwesen,	L.,	van	den	Brink-Muinen,	A.	&	Hofstede,	G.	(2009)	Can	dimensions	of	national	culture	predict	cross-national	differences	in	medical	communication?	Patient	and	Education	and	Counseling,	75	58-66.		Ministero	della	Salute	(2014)	Programma	di	autosufficienza	nazionale	del	
sangue	e	dei	suoi	prodotti	Anno	2014.	Available	from:	http://www.gazzettaufficiale.it/gazzetta/serie_generale/caricaDettaglio?dataPubblicazioneGazzetta=2014-11-14&numeroGazzetta=265		Roma,	Italia			Ministero	della	Salute	(2015)	Programma	di	autosufficienza	nazionale	del	
sangue	e	i	suoi	prodotti	Anno	2015.	Available	from:	http://www.centronazionalesangue.it/MC-API/Risorse/StreamAttributoMediaOriginale.aspx?guid=2C82EE43-290E-462F-BEC0-FCF5391568BD		Roma,	Italia			Ministero	della	Salute	(2016)	Programma	nazionale	del	autosufficienza	del	
sangue	e	dei	suoi	prodotti	Anno	2016.	Available	from:	http://www.centronazionalesangue.it/MC-API/Risorse/StreamAttributoMediaOriginale.aspx?guid=A72AF36D-FDE3-417A-9C0B-B119F52FF9CD		Roma,	Italia			Mitra,	B.,	Nash,	J.	L.,	Cameron,	P.	A.,	Fitzgerald,	M.	C.,	Moloney,	J.	&	Velmahos,	G.	C.	(2015)	Potentially	avoidable	blood	transfusion	during	trauma	resuscitation.	Injury	International	Journal	of	the	Care	of	the	Injured,	46	10-14.		Murphy,	M.	F.	(2012a)	End-to-end	electronic	transfusion	management	in	hospital	practice.	ISBT	Science	Series,	7	192-196.		Murphy,	M.	F.	(2015)	The	Choosing	Wisely	campaign	to	reduce	harmful	medical	overuse:	its	close	association	with	Patient	Blood	Management	initiatives.	Transfusion	Medicine,	25	287-292.	
	144	
	Murphy,	M.	F.,	Stanworth,	S.	J.	&	Yazer,	M.	(2011)	Transfusion	practice	and	safety:	current	status	and	possibilities	for	improvement.	Vox	Sanguinis,	100	46-59.		Murphy,	M.	F.,	Wallington,	T.	B.,	Kelsey,	P.,	Boulton,	F.,	Bruce,	M.,	Cohen,	H.,	Duguid,	J.,	Knowles,	S.	M.,	Poole,	G.	&	Williamson,	L.	M.	(2001)	British	Committee	for	Standards	in	Haematology	guidelines	for	the	clinical	use	of	red	cell	transfusions.	British	Journal	of	Haematology,	113	24-31.		Murphy,	W.	G.,	(2012b)	Personal	communication.			Murphy,	W.	G.	(2012c)	Of	mad	cows	and	bolted	horses:	the	economics	of	blood	safety.	Transfusion,	52	(11):	2278-2281.		Murphy,	W.	G.	(2013)	Lessons	from	the	response	to	the	threat	of	transfusion-transmitted	vCJD	in	Ireland.	Transfusion	Clinique	et	Biologique,	20	416-421.		Murray,	C.	J.	L.,	Frenk,	J.,	Piot,	P.	&	Mundel,	T.	(2013)	GBD	2.0:	a	continuously	updated	global	resource.	Lancet,	382	9-11.		Musgrove,	P.	(2010)	Health	care	systems	ranking.	New	England	Journal	of	
Medicine,	362	(16):	1546-1547.		Myers,	R.	W.	(1945)	Life-saving	blood	flows	on	Iwo,	thanks	to	last	month's	
donors.	Available	from:	http://spiderbites.nytimes.com/pay_1945/articles_1945_03_00002.html				National	Blood	Authority	(2011)	Australian	Haemovigilance	Report	2010.	Available	from:	https://www.blood.gov.au/system/files/documents/australian-haemovigilance-report-2010_0.pdf				National	Blood	Authority	(2015)	The	Australian	Haemvigilance	Report	2015.	Available	from:	https://www.blood.gov.au/pubs/2015-haemovigilance/index/part-05-fresh-blood-product-use-and-haemovigilance-systems.html				Navarro,	V.	(2002)	Can	health	care	systems	be	compared	using	a	single	measure	of	performance?	American	Journal	of	Public	Health,	92	(1):	31-34.		Nelson,	E.	C.,	Batalden,	P.	B.,	Huber,	T.	P.,	Mohr,	J.	J.,	Godfrey,	M.	M.,	Headrick,	L.	A.	&	Wasson,	J.	H.	(2002)	Microsystems	in	health	care:	Part	1.	Learning	from	high	performing	front-line	clinical	units.	The	Joint	Commission	Journal	
on	Quality	Improvement,	28	(9):	472-493.		
	145	
NHS	Blood	and	Transplant	(2010)	NHS	Blood	and	Transplant	Annual	Report	
and	Accounts	2009/10.	Available	from:	http://www.nhsbt.nhs.uk/download/trust_fund_accounts_2010.pdf				NHS	Blood	and	Transplant	(2016)	NHS	Blood	and	Components	Price	List	
2016/17.	Available	from:	http://hospital.blood.co.uk/media/28230/component-price-list-2016-2017.pdf				Niranjan,	G.,	Asimakopoulos,	G.,	Karagounis,	A.,	Cockerill,	G.,	Thompson,	M.	&	Chandrasekaran,	V.	(2006)	Effects	of	cell-saver	autologous	blood	transfusion	blood	loss	and	homologous	blood	transfusion	requirements	in	patients	undergoing	cardiac	surgery	on-	versus	off-cardiopulmonary	bypass:	a	randomised	trial.	European	Journal	of	Cardiothoracic	Surgery,	30	271-277.		Norgaard,	A.,	de	Lichtenberg,	T.	H.,	Nielsen,	J.	&	Johansson,	P.	I.	(2014)	Monitoring	compliance	with	transfusion	guidelines	in	hospital	departments	by	electronic	data	capture.	Blood	Transfusion,	12	509-519.		NZBLOOD	(2010)	National	Haemovigilance	Programme:	Annual	Report	2009.	Available	from:	http://www.nzblood.co.nz/assets/Haemovigilance/Haemovigilance-Annual-Report-2009.pdf				Organisation	for	Economic	Co-operation	and	Development	(2009a)	Data	set:	
Health	care	utilisation;	surgical	procedure	by	ICD-9-CM	per	100,000	
population:	coronary	bypass,	hip	replacement.	[online]	Available	from:	http://stats.oecd.org/	(Accessed	10	April	2012).		Organisation	for	Economic	Co-operation	and	Development	(2009b)	Annual	
Labour	Force	Statistics:	Population	over	65	as	a	percent	of	population.	[online]	Available	from:	http://stats.oecd.org/	(Accessed	15	Jun	2012).		Organisation	for	Economic	Co-operation	and	Development	(2014)	
Geographic	variations	in	health	care:	what	do	we	know	and	what	can	be	done	
to	improve	health	system	performance?	Available	from:	http://www.oecd.org/health/geographic-variations-in-health-care-9789264216594-en.htm		OECD	publishing			Organisation	for	Economic	Co-operation	and	Development	(2016a)	OECD	
Data	-	Health.	Available	from:	https://data.oecd.org/health.htm				Organisation	for	Economic	Co-operation	and	Development	(2016b)	"Health	
Status",	OECD	Health	Statistics	(database).	Available	from:	http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_STAT				
	146	
Otsubo,	T.,	Imanaka,	Y.,	Morishima,	T.,	Sasaki,	N.,	Park,	S.	&	Lee,	J.	(2016)	Variations	in	healthcare	spending	and	quality	among	institutions.	In:	Johnson,	A.	&	Stukel,	T.	A.,	eds.	Medical	Practice	Variations.	1	edn.	New	York:	Springer	US:	383-406.		Oxman,	A.	D.,	Thomson,	M.	A.,	Davis,	D.	A.	&	Haynes,	R.	B.	(1995)	No	magic	bullets:	a	systematic	review	of	102	trials	of	interventions	to	improve	professional	practice.	Canadian	Medical	Association	Journal,	153	(10):	1423-1431.		Pair,	C.	Q.	(1929)	Intravenous	Therapy.	Journal	of	the	National	Medical	
Association,	22	(1):	21-24.		Pena,	J.	R.	A.	&	Dzik,	W.	(2014)	Utilization	management	in	the	blood	transfusion	service.	Clinica	Chimica	Acta,	427	178-182.		Perel,	P.,	Roberts,	I.	&	Ker,	K.	(2013)	Colloids	vs	crystalloids	for	fluid	resuscitation	in	critically	ill	patients.	Cochrane	Database	of	Systematic	
Reviews,	(2):	CD000567.		Pfunter,	A.	W.	L.	&	Stocks,	C.	(2010)	Most	frequent	procedures	performed	in	US	
hospitals.	Available	from:	http://hcup-us.ahrq.gov/reports/statbriefs/sb149.pdf				Picker,	S.	M.,	Kaleta,	T.,	Hekmat,	K.,	S,	K.	&	Gathof,	B.	S.	(2007)	Anti-platelet	therapy	preceding	coronary	artery	surgery:	implications	for	bleeding,	transfusion	requirements	and	outcome.	European	Journal	of	Anaesthesiology,	24	332-339.		Pool,	J.	G.	&	Shannon,	A.	E.	(1965)	Production	of	high-potency	concentrates	of	antihemophilic	globulin	in	a	closed-bag	system	—	assay	in	vitro	and	in	vivo.	
New	England	Journal	of	Medicine,	273	1443-1447.		Public	Health	England	(2015)	The	NHS	atlas	of	variation	in	healthcare:	
reducing	unwarranted	variation	to	increase	value	and	improve	quality.	Available	from:	https://www.england.nhs.uk/rightcare/intel/cfv/atlas/		London,	UK			Ralston,	S.	L.	&	Schroeder,	A.	R.	(2015)	Doing	more	vs	doing	good:Aligning	our	ethical	principles	from	the	personal	to	the	societal.	JAMA	Pediatrics,	169	(12):	1085-1086.		Rehm,	J.	P.,	Otto,	P.	S.,	West,	W.	W.,	Grange,	J.	J.,	Halloran,	B.	G.,	Lynch,	T.	G.	&	Baxter,	B.	T.	(1998)	Hospital-wide	education	program	decreases	red	blood	cell	transfusions.	Journal	of	Surgical	Research,	75	183-186.		
	147	
Rogers,	M.	A.	M.,	Blumberg,	N.,	Saint,	S.,	Langa,	K.	M.	&	Nallamothu,	B.	K.	(2009)	Hospital	variation	in	transfusion	and	infection	after	cardiac	surgery:	a	cohort	study.	BMC	Medicine,	7	37-45.		Rothberg,	M.	B.,	Cohen,	J.,	Lindenauer,	P.,	Maselli,	J.	&	Auerbach,	A.	(2010)	Little	evidence	of	correlation	between	growth	in	health	care	spending	and	reduced	mortality.	Health	Affairs,	29	(8):	1523-1531.		Rubin,	B.	B.,	Drenth,	B.	&	Beanlands,	R.	S.	B.	(2015)	Appropriate	quality	imaging	tests	through	linkage	of	payment	to	guidelines,	accreditation	and	training.	Canadian	Medical	Association	Journal,	187	(4):	E126-E127.		Sanquin	(2010)	Sanquin	Annual	Report;	Close	to	'09.	Available	from:	http://www.sanquin.nl/repository/documenten/en/about-sanquin/sanquin/45297/45308/ENG_Sanquin_jaarverslag_2009_binnenwerk_def.pdf				Seeff,	L.	B.	(1988)	Transfusion-associated	hepatitis	B:	past	and	present.	
Transfusion	Medicine	Reviews,	2	(4):	201-214.		Seifried,	E.,	Klueter,	H.	&	Weidmann,	C.	(2011)	How	much	blood	is	needed?	
Vox	Sanguinis,	100	10-21.		Shander,	A.,	Hofmann,	S.,	Ozawa,	S.	&	Javidroozi,	M.	(2009)	The	true	cost	of	red	blood	cell	transfusion	in	the	surgical	patient.	Blood,	112	1147.		Slichter,	S.	J.,	Kaufman,	R.	M.,	Assmann,	S.	F.,	McCullough,	J.,	Triulzi,	D.	J.,	Strauss,	R.	G.,	Gemsheimer,	T.	B.,	Ness,	P.	M.,	Brecher,	M.	E.,	Josephson,	C.	D.,	Konkle,	B.	A.,	Woodson,	R.	D.,	Ortel,	T.	L.,	Hilyer,	C.	D.,	Skerrett,	D.	L.,	McCrae,	K.	R.,	Sloan,	S.	R.,	Uhl,	L.,	George,	J.	N.,	Aquino,	V.	M.,	Manno,	C.	S.,	McFarland,	J.	G.,	Hess,	J.	R.,	Lessinger,	C.	&	Granger,	S.	(2010)	Dose	of	prophylactic	platelet	transfusions	and	prevention	of	hemorrhage.	New	England	Journal	of	Medicine,	362	600-613.		Slight,	R.	D.,	Alston,	R.	P.,	McClelland,	D.	B.	&	Mankad,	P.	S.	(2009)	What	factors	should	we	consider	in	deciding	when	to	transfuse	patients	undergoing	elective	cardiac	surgery?	Transfusion	Medicine	Reviews,	23	42-54.		Slight,	R.	D.,	Bappu,	N.	J.,	Nzewi,	O.	C.,	B,	M.	D.	&	Mankad,	P.	S.	(2006)	Perioperative	red	cell,	plasma	and	blood	volume	change	in	patients	undergoing	cardiac	surgery.	Transfusion,	46	392-397.		Snyder-Ramos,	S.	A.,	Mohnle,	P.,	Weng,	Y.	S.,	Bottiger,	B.	W.,	Kulier,	A.,	Levin,	J.	&	Mangano,	D.	T.	(2008)	The	on-going	variability	in	blood	transfusion	practices	in	cardiac	surgery.	Transfusion,	48	1284-1299.		
	148	
Starr,	D.	(1998)	Blood:	An	epic	history	of	medicine	and	commerce.	New	York,	USA:	Alfred	A	Knopf.		Statistics	Denmark	(2009)	RASU11:	Population	by	region,	education,	
socioeconomic	status,	age	and	sex.	[online]	Available	from:	http://www.statistikbanken.dk/statbank55/SelectVarVal/define.asp?MainTable=RASU11&amp;amp;PLanguage=1&amp;amp;Tabstrip=&amp;amp;PXSId=0&amp;amp;SessID=182700766&amp;amp;FF=20&amp;amp;grouping5=200611149542922218592&amp;amp;tfrequency=1	(Accessed	14	Dec	2016).		Stetler,	C.	B.	(2003)	Role	of	the	organisation	in	translating	research	into	evidence-based	practice.	Outcomes	Management,	7	(3):	97-103.		Stover,	E.	P.,	Siegel,	L.	C.,	Parks,	R.,	Levin,	J.,	Body,	S.	C.,	Maddi,	R.,	D'Ambra,	M.	N.,	Mangano,	D.	T.	&	Spiess,	B.	D.	(1998)	Variability	in	transfusion	practice	for	coronary	artery	bypass	surgery	persists	despite	national	consensus	guidelines.	Anesthesiology,	88	327-333.		Surgenor,	D.	M.,	Churchill,	W.	H.,	Wallace,	E.	L.,	Rizzo,	R.	J.,	McGurk,	S.,	Goodnough,	L.	T.,	Kao,	K.	J.,	Koerner,	T.	A.	W.,	Olson,	J.	D.	&	Woodson,	R.	D.	(1998)	The	specific	hospital	significantly	affects	red	cell	and	component	transfusion	practice	in	coronary	artery	bypass	graft	surgery:	a	study	of	five	hospitals.	Transfusion,	38	122-134.		Tasian,	G.	E.,	Pulido,	J.	E.,	Keren,	R.,	Dick,	A.	W.,	Setodji,	C.	M.,	Hanley,	J.	M.,	Madison,	R.	&	Saigal,	C.	S.	(2014)	Use	of	regional	variation	in	initial	CT	imaging	for	kidney	stones.	Pediatrics,	134	(5):	909-915.		Tchouaket,	E.	N.,	Lamarche,	P.	A.,	Goulet,	L.	&	Contandriopoulos,	A.	P.	(2012)	Health	care	system	performance	of	27	OECD	countries.	The	International	
Journal	of	Health	Planning	and	Management,	27	(2):	104-129.		Tebe,	C.,	Abilleira,	S.,	Ridao,	M.,	Espallargues,	M.,	Salas,	T.	&	Bernal-Delgado,	E.	(2013)	VPM	Atlas	de	variaciones	en	la	pratica	medica	en	el	sistema	nacional	de	
salud:	atlas	de	variaciones	en	el	manejo	de	la	enfermedad	cerebrovascular	
isquemica.	Available	from:	http://www.atlasvpm.org				The	National	CJD	Research	&	Surveillance	Unit	(2017)	Variant	CJD	cases	
worldwide.	[online]	Available	from:	http://www.cjd.ed.ac.uk/sites/default/files/worldfigs_1.pdf	(Accessed	23	February	2017).		Thomas,	S.,	Turner,	M.	L.	&	Williamson,	L.	(2013)	UK	approach	to	assessing	assays	and	filters	designed	to	reduce	the	risk	of	transfusion-transmitted	vCJD.	Transfusion	Clinique	et	Biologique,	20	405-411.		
	149	
Toner,	R.	W.,	Pizzi,	L.,	Leas,	B.,	Ballas,	S.	K.,	Quigley,	A.	&	Goldfarb,	N.	I.	(2011)	Costs	to	hospitals	of	acquiring	and	processing	blood	in	the	US:	a	survey	of	hospital-based	blood	banks	and	transfusion	services.	Applied	Health	
Economics	and	Health	Policy,	9	(1):	29-37.		UK	Department	of	Health	(2007)	Better	blood	transfusion	-	safe	and	
appropriate	use	of	blood.	Available	from:	http://www.transfusionguidelines.org/document-library/documents/hsc-2007-001-better-blood-transfusion-safe-and-appropriate-use-of-blood		London,	UK			United	Nations	Development	Programme	(2011)	Human	Development	Report	
2011	Statistical	Tables.	[online]	Available	from:	http://hdr.undp.org/en/statistics/hdi/	(Accessed	22	March	2012).		Vamvakas,	E.	C.	&	Taswell,	H.	F.	(1994)	Epidemiology	of	Blood	Transfusion.	
Transfusion,	34	464-470.		Vogel,	L.	(2015)	Choosing	wisely	around	the	world.	Canadian	Medical	
Association	Journal,	187	(11):	E341-E342.		Wallace,	E.,	Smith,	S.	M.	&	Fahey,	T.	(2012)	Variation	in	medical	practice:	getting	the	balance	right.	Family	Practice,	29	501-502.		Weeks,	W.	B.,	Paraponaris,	A.	&	Ventelou,	B.	(2014)	Geographic	variation	in	rates	of	common	surgical	procedures	in	France	in	2008-2010,	and	comparison	to	the	US	and	Britain.	Health	Policy,	118	215-221.		Welch,	H.	G.	&	Frankel,	B.	A.	(2011)	Likelihood	that	a	woman	with	screen-detected	breast	cancer	has	had	her	"life	saved"	by	that	screening.	Archives	of	
Internal	Medicine,	171	(22):	2043-2046.		Wells,	A.	W.,	Llewelyn,	C.	A.,	Casbard,	A.,	Johnson,	A.	J.,	Amin,	M.,	Ballard,	S.,	Buck,	J.,	Malfroy,	M.,	Murphy,	M.	F.	&	Williamson,	L.	M.	(2009)	The	EASTR	Study:	Indications	for	transfusion	and	estimates	of	transfusion	recipient	numbers	in	hospitals	supplied	by	the	National	Blood	Service.	Transfusion	
Medicine,	19	315-328.		Wennberg,	J.	&	Gittelsohn,	A.	(1973)	Small	area	variations	in	health	care	delivery:	A	population-based	health	information	system	can	guide	planning	and	regulatory	decision-making.	Science,	182	1102-1108.		Wennberg,	J.,	McPherson,	K.	&	Goodman,	D.	(2015)	Small	area	analysis	and	the	challenge	of	practice	variation.	In:	Johnson,	A.	&	Stukel,	T.,	eds.	Medical	
Practice	Variations.	New	York,	USA:	Springer	Science	&	Business	Media:			
	150	
Wennberg,	J.	E.	(2010)	Tracking	Medicine;	A	researcher's	quest	to	understand	
health	care.	Oxford	University	Press,	Inc.		Wennberg,	J.	E.,	Barnes,	B.	A.	&	Zubkoff,	M.	(1982)	Professional	uncertainty	and	the	problem	of	supplier	induced	demand.	Social	Science	&	Medicine,	16	811-824.		Wensing,	M.,	Wollersheim,	H.	&	Grol,	R.	(2006)	Organisational	interventions	to	implement	improvements	in	patient	care:	a	structured	review	of	reviews.	
Implementation	Science,	1	2.		Westert,	G.	P.,	Nieboer,	A.	P.	&	Groenewegen,	P.	P.	(1993)	Variation	in	duration	of	hospital	stay	between	hospitals	and	between	doctors	within	hospitals.	Social	Science	and	Medicine,	37	(6):	833-839.		Will,	R.	G.,	Ironside,	J.	W.,	Ziedler,	M.,	Estibeiro,	K.,	Cousens,	S.	N.,	Smith,	P.	G.,	Alperovitch,	A.,	Poser,	S.,	Pocchiari,	M.	&	Hofman,	A.	(1996)	A	new	variant	of	Creutzfeldt-Jakob	disease	in	the	UK.	Lancet,	347	921-925.		Williamson,	L.	M.	(1998)	Serious	hazards	of	transfusion	annual	report	1996-
1997.	Available	from:	https://www.shotuk.org/wp-content/uploads/2010/03/SHOT-Report-96-97.pdf				Williamson,	L.	M.,	Llewelyn,	C.	A.,	F,	F.	N.,	Allain,	J.-P.,	Bellamy,	M.	C.,	Ballin,	T.	P.,	Freeman,	J.,	Klinck,	J.	K.,	Ala,	F.	A.,	Smith,	N.,	Neuberger,	J.	&	Wreghitt,	T.	(1999)	A	randomised	trial	of	solvent/detergent	and	standard	fresh	frozen	plasma	in	the	coagulopathy	of	liver	disease	and	transplantation.	Transfusion,	39	1227-1234.		World	Bank	(2009a)	Maternal	mortality	ratio	per	100,000	population.	[online]	Available	from:	http://data.worldbank.org/indicator/SH.STA.MMRT	(Accessed	11	April	2012).		World	Bank	(2009b)	Health	care	expenditure	per	capita	(current	US$	
purchasing	power	parity).	[online]	Available	from:	http://data.worldbank.org/indicator/SH.XPD.PCAP?view=chart	(Accessed	10	April	2012).		World	Bank	(2009c)	Gross	domestic	product	per	capita	(current	US$).	[online]	Available	from:	http://data.worldbank.org/indicator/NY.GDP.PCAP.CD?year_high_desc=true	(Accessed	15	June	2012).		World	Health	Organisation	(2003)	World	Cancer	Report.	Available	from:	http://www.iarc.fr/en/publications/pdfs-online/wcr/2003/WorldCancerReport.pdf		Geneva,	Switzerland			
	151	
World	Health	Organisation	(2010)	Clinical	transfusion	process	and	patient	
safety	-	Aide	memoire	for	national	health	authorities	and	hospital	
management.	Available	from:	http://www.who.int/bloodsafety/clinical_use/who_eht_10_05_en.pdf?ua=1				World	Health	Organisation	(2016)	World	health	statistics	2016:	monitoring	
health	for	the	SDGs.	Available	from:	http://www.who.int/gho/publications/world_health_statistics/2016/en/		Geneva,	Switzerland					 	
	152	
	
	
	
Appendices	
	 	
	153	
Correspondence	to	individual	medical	directors	of	national	
transfusion	services	in	Europe	Dear	XXXXXXX,		I	hope	you	are	keeping	well.	I	would	be	grateful	if	you	could	have	a	look	at	the	attachment	to	this	mail.	As	I	explained,	I	have	put	together	a	model	that	shows	correlation	of	the	variation	in	red	cell	use	with	a	number	of	factors.	However,	I	am	also	interested	in	looking	at	the	regional	differences	within	individual	countries.	My	theory	is	that	the	variation	in	red	cell	use,	though	trackable	to	some	national	demographic	differences,	is	also	a	result	of	practice	differences	within	institutions.	I	also	believe	that	demonstration	of	variation	in	red	cell	use	across	regions	within	the	same	country	will	continue	to	strengthen	this	hypothesis.	The	ultimate	aim	is	to	make	the	case	that	one	requires	local	leadership	to	implement	appropriate	red	cell	use	and	just	writing	national	guidelines	and	leaving	it	up	to	the	individual	medics	to	follow	them	does	not	work	in	the	same	way	across	different	countries.	Additionally	I	think	it	is	important	to	highlight	that	the	implementation	of	PBM	cannot	be	a	case	of	one-size	fits	all	-	it	really	depends	upon	the	culture	of	the	organisation	and	the	tools	to	put	PBM	in	place	should	be	adapted	to	the	specific	institution.		I	am	writing	to	you	in	the	hope	that	you	may	be	able	to	supply	me	with	the	data	for	your	country	or	to	put	me	in	contact	with	anyone	within	your	organization	who	may	have	access	to	these	figures.	Of	course,	I	would	gladly	share	what	I've	done	to	date	and	what	I	hope	to	continue	to	do,	and	would	be	only	too	happy	to	collaborate	on	this	with	individuals	who	may	be	interested.		I	look	forward	to	your	thoughts	and	comments.		Warm	regards,		Dr	Stefan	Laspina	Consultant,	Transfusion	Medicine	Mater	Dei	Hospital	Blood	Bank	Clinical	Chairperson,	Haematology	&	Oncology	Mater	Dei	Hospital	Malta		 	
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Attachment	to	correspondence		Subsequent	Council	of	Europe	documents	have	shown	that	blood	usage	across	different	countries	varies.	It	has	been	posited	that	this	variance	may	be	a	result	of	demographic	differences	rather	than	an	actual	difference	in	specific	medical	practice.	A	performance	of	statistical	correlations	does	indicate	that	this	variance	may	indeed	be	partially	explained	by	demographics.	But	not	all	of	it	is.	I	have	attempted	to	build	a	model	showing	the	association	of	the	variance	with	a	number	of	factors.	It	appears	that	as	one	would	intuitively	expect,	the	variance	is	associated	with	indices	such	as	‘Per	Cent	Population	over	65	Years’	(as	has	been	shown	in	a	couple	of	publications)	and	the	‘Prevalence	of	Coronary	Artery	Bypass	Surgery	per	100,000	Population’.	It	does	however	also	seem	likely	that	blood	use	varies	with	the	‘Health	Care	Expenditure	per	Capita	US$	Purchasing	Power	Parity’,	and	also	that	part	of	the	variance	cannot	be	explained	except	perhaps	by	real	differences	in	practice.	This	latter	point	is	also	evident	from	the	publications	showing	differences	in	practice	across	countries	and	even	across	institutions	within	the	same	country	with	regards	to	the	use	of	red	cells	in	specific	procedures	such	as	hip	replacement	and	cardiac	surgery.		Up	until	now,	I	have	used	only	National	statistics	available	from	various	public	reports	and	various	publically	available	databases.	At	this	stage	I	would	like	to	look	at	the	differences	across	regions	within	the	same	country.	I	would	like	to	examine	the	hypothesis	that	the	patterns	of	usage	are	consistent	across	the	country	(i.e.	very	similar	in	a	majority	of	regions)	as	opposed	to	the	hypothesis	that	every	region	has	a	different	pattern	of	usage	and	the	national	figure	is	only	a	composite	of	what	occurs	in	the	regions.		I	would	be	sincerely	grateful	if	you	could	help	me	out	with	this.	In	order	to	examine	the	hypothesis,	I	would	need	figures	for	red	cell	use	(or	red	cell	distribution)	in	the	regions	and,	if	available,	the	population	of	the	individual	regions.	If	possible,	the	data	should	be	for	either	of	2012,	2013	or	2014.		I	am	attaching	a	template	for	ease	of	compilation:		Country:	 XXXXXXXXXXX	(Insert	Name	of	Country)		 Region	Name	 Red	Cells	Used	Within	Region	2012	/	2013	/	2014	(Circle	as	appropriate)	
Population	of	Region	
Region	1	 	 	 	Region	2	 	 	 	Region	3	 	 	 	Region	4	 	 	 	Region	5	 	 	 	Etc…	 	 	 		
